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ABSTRACT 
Introduction  
The increasing intake of traditional medicines among HIV/AIDS patients in sub-Saharan Africa 
needs urgent consideration by clinicians and other healthcare providers since the safety of such 
medications are unknown. The pharmacokinetic parameters - Absorption, Distribution, 
Metabolism and Elimination (ADME) play important role in the safety evaluation of drugs, thus 
implicating drug metabolizing enzymes and transporters as critical indicators for herb-drug 
interactions. The objective of this study was to evaluate the risk potential of seven herbal 
medicines commonly consumed by HIV/AIDS patients for drug interactions applying in vitro 
models. In this study, inhibition and induction effects of the herbal medicines on cytochrome 
P450s (CYPs) 1A2, 2C9, 2C19, 2D6 and 3A4 as well as P-glycoprotein (P-gp) were 
investigated.  
Methods 
Herbal medicines – Lessertia frutescens, Hypoxis hemerocallidea, Kalanchoe integra and 
Taraxacum officinale were sourced from Medico Herbs, South Africa were identified by experts 
from Compton Herbarium, South African National Biodiversity Institute, Cape Town. Moringa 
oleifera, Echinacea purpurea and Kalanchoe crenata were obtained from the repository of the 
National Centre for Natural Product Research (NCNPR), University of Mississippi, USA. 
Reversible inhibitory effect of aqueous and methanol herbal extracts were evaluated in 
recombinant CYPs applying the fluorescent metabolites at specified excitation/emission 
wavelengths; CYP1A2 (3-cyano-7-hydroxycoumarin (CHC); 405/460 nm), CYP2C9, CYP2C19 
and CYP3A4 (7-hydroxy-4-(trifluoromethyl)-coumarin (HFC); 405/535 nm) and CYP2D6 (7-
hydroxy-4-(aminomethyl)-coumarin (HAMC); 390/460 nm). Comparative studies in human liver 
microsomes (HLM) and recombinant CYPs were conducted to investigate the inhibitory effect of 
methanol herbal extracts and fractions on 6β testosterone hydroxylation activity. Time dependent 
inhibitory (TDI) effect of the herbal extracts were evaluated applying the IC50 shift fold, 
normalized ratio and the NADPH-, time- and concentration-dependent approaches. Influence of 
herbal extracts on metabolic clearance of testosterone was assessed in both HLM and human 
hepatocytes. The effects of each herbal extract on expression of CYP1A2, CYP3A4 and MDR1 
genes were evaluated in activated human pregnane X receptor (PXR) co-transfected HepG2 
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cells. Finally, the inhibitory effect of herbal extracts on P-gp was assessed using the calcein-
acetoxymethyl ester (calcein-AM) uptake and the digoxin radiolabelled substrates in MDCKII-
MDRI cells. 
Results 
The aqueous extracts of Moringa oleifera, Kalanchoe integra, Kalanchoe crenata, Echinacea 
purpurea and Lessertia frutescens demonstrated high risk of in vivo inhibition on CYPs 3A4 and 
1A2 with Cmax/Ki >1.0. Methanol extracts of these herbal medicines also indicated potential risk 
of reversible drug interaction. The methanol extracts of M. oleifera, K. crenata and L. frutescens 
showed strong TDI effect on CYP3A4 with IC50 shift fold >1.5 and normalised ratio <0.7. 
Moringa oleifera intermediately reduced intrinsic clearance of testosterone in human hepatocytes 
(2 ≤ AUC ratio ≤ 5) when scaled up to humans. Methanol extracts of Echinacea purpurea up-
regulated the expression of CYP1A2, CYP3A4 and MDR1 genes in activated PXR. Kalanchoe 
crenata and Echinacea purpurea indicated strong inhibition on P-gp by reducing transport of 
digoxin across hMDR1-MDCKII cell monolayer from basolateral to apical with IC50 values of 
18.24 ± 2.52 µg/mL and 24.47 ± 4.97 µg/mL, respectively.  
Conclusion 
The herbal medicines especially M. oleifera, K. integra and E. purpurea have the potential to 
cause herb-drug interaction in vivo if sufficient hepatic concentration is achieved in humans. 
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ABSTRAK 
Inleiding  
Die verhoogde inname van tradisionele medisynes onder MIV/VIGS-pasiënte in 
sub-Sahara-Afrika verg dringend oorweging deur klinici en ander gesondheidsorgverskaffers, 
aangesien die veiligheid van sodanige medikasies onbekend is. Die farmakokinetiese parameters 
– Absorpsie, Distribusie, Metabolisme en Eliminasie (ADME) – speel ’n belangrike rol by die 
veiligheidsevaluering van geneesmiddels, en impliseer gevolglik geneesmiddel-metaboliserende 
ensieme en vervoerders as kritiese indikators vir krui-geneesmiddel-interaksies (HDI). Die 
oogmerk van hierdie studie is om die risikopotensiaal van sewe kruiemedisynes wat algemeen 
deur MIV/VIGS-pasiënte geneem word, vir geneesmiddel-interaksies te evalueer deur in 
vitro-modelle te gebruik. In hierdie studie is die inhiberings- en induseringsuitwerkings van die 
kruiemedisynes op sitochroom P450’s (verkort na CYP’s) 1A2, 2C9, 2C19, 2D6 en 3A4, sowel 
as P-glikoproteïen (P-gp), ondersoek.  
Metodes 
Kruiemedisynes – Lessertia frutescens, Hypoxis hemerocallidea, Kalanchoe integra en 
Taraxacum officinale – is van Medico Herbs, Suid-Afrika, bekom en deur kundiges van die 
Compton-herbarium, by die Suid-Afrikaanse Nasionale Biodiversiteitsinstituut, Kaapstad, 
geïdentifiseer. Moringa oleifera, Echinacea purpurea en Kalanchoe crenata is van die 
bewaarplek van die Nasionale Sentrum vir Natuurlike Produknavorsing (NCNPR) aan die 
Universiteit van Mississippi in die VSA verkry. Die omkeerbare inhiberende uitwerking van 
kruie-ekstrakte in water en metanol is in rekombinante CYP’s geëvalueer deur die gebruik van 
die fluoresserende metaboliete op gespesifiseerde opwekkings-/emissiegolflengtes; CYP1A2 (3-
siaan-7-hidroksikumarien (CHC); 405/460 nm), CYP2C9, CYP2C19 en CYP3A4 (7-hidroksi-4-
(trifluoormetiel)-kumarien (HFC); 405/535 nm) en CYP2D6 (7-hidroksi-4-(aminometiel)-
kumarien (HAMC); 390/460 nm). Vergelykende studies van menslikelewermikrosome (HLM) 
en rekombinante CYP’s is uitgevoer om die inhiberende uitwerking van metanolkruie-ekstrakte 
en -fraksies op 6β-testosteroonhidroksileringsaktiwiteit te ondersoek. Die tydafhanklike 
inhiberende uitwerking (TDI) van die kruie-ekstrakte is geëvalueer deur gebruikmaking van die 
IC50-verskuiwingsvou-, die genormaliseerdeverhoudings- en die NADPH-, tyd- en 
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konsentrasieafhanklike benaderings. Die invloed van kruie-ekstrakte op metaboliese 
testosteroonverheldering is in beide HLM en menslike hepatosiete geëvalueer. Die uitwerkings 
van elke kruie-ekstrak op die uitdrukking van CYP1A2-, CYP3A4- en MDR1-gene is in 
geaktiveerde menslike pregnaan-X-reseptor(PXR)-, ko-getransfekteerde HepG2-selle 
geëvalueer. Laastens is die inhiberende uitwerking van kruie-ekstrakte op P-gp geëvalueer, met 
gebruikmaking van die kalsien-asetoksimetiel-ester (kalsien-AM)-opname en die digoksien- 
radiogemerkte substrate in MDCKII-MDRI-selle. 
Resultate 
Die ekstrakte in water van M. oleifera, K. integra, K. crenata, E. purpurea en L. frutescens het ’n 
hoë risiko van in vivo-inhibering op CYP’s 3A4 en 1A2 met Cmaks/Ki >1.0 getoon. Ekstrakte van 
hierdie kruiemedisynes in metanol het verder potensiële risiko van omkeerbare 
geneesmiddelinteraksie getoon. Die ekstrakte van M. oleifera, K. crenata en L. frutescens in 
metanol het sterk TDI-uitwerking op CYP3A4 met IC50-verskuiwingsvou >1.5 en 
genormaliseerde verhouding <0.7 getoon. M. oleifera het intermediêre vermindering van 
intrinsieke testosteroonverheldering in menslike hepatosiete (2 ≤ AUC verhouding ≤ 5) tot 
gevolg wanneer die skaal na mense verhoog word. Ekstrakte van E. purpurea in metanol het die 
uitdrukking van CYP1A2-, CYP3A4- en MDR1-gene in geaktiveerde PXR opgereguleer. K. 
crenata en E. purpurea het sterk inhibering van P-gp getoon deur die vervoer van digoksien deur 
die hMDR1-MDCKII-selmonolaag van basolateraal tot apikaal met IC50-waardes van 
onderskeidelik 18.24 ± 2.52 µg/mL en 24.47 ± 4.97 µg/mL te verminder.  
Gevolgtrekking 
Kruiemedisynes, veral M. oleifera, K. integra en E. purpurea, het die potensiaal om HDI in vivo 
te veroorsaak indien voldoende hepatiese konsentrasie by mense bereik word. 
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CHAPTER ONE 
 
1. INTRODUCTION  
Traditional medicines and products are used globally for treatment of diverse pathological 
conditions. The World Health Organisation (WHO) defines traditional medicine as herbal 
medicines, animal parts and minerals used in the maintenance of health as well as in the 
prevention, diagnosis, improvement or treatment of physical and mental illness (WHO, 2002). 
Herbal medicines include herbs, herbal materials, herbal preparations and finished herbal 
products, which contain active ingredients from parts of plants or other plants materials or 
combinations. According to a UNAIDS estimate, one-third of the adults in developed countries 
and over 80% of Africans depend on herbal medicines for treatment of common ailments such as 
cold, inflammatory disorders, heart disease, diabetes, and central nervous system diseases 
(UNAIDS, 2006). In developed countries, people access these medicines/health supplements 
through the mushrooming natural products/food supplements outlets in major cities of the world 
(Verma and Singh, 2008). In developing countries, people consult traditional health practitioners 
(THPs) who live within the communities, have been trusted over years, share identical cultural 
and spiritual beliefs and are ever willing to assist patients with their knowledge and skills 
sometimes at a reduced cost  (Peltzer 2000; UNAIDS, 2006; Peltzer 2008). Other preparations of 
herbal medicines are available at chemical and pharmacy shops as over-the-counter (OTC), 
which can be consumed without the recommendation or advice of a physician (Obach, 2000). 
They are usually sold as nutritional supplements with implied benefits in the various disease 
conditions or maintenance of health without specific medicinal claims (Mathes et al., 2010; 
Serafini et al., 2012). 
In recent years, with increased burden of HIV/AIDS especially in Africa, an overwhelming 
proportion of infected individuals patronize herbal medicines.  Tshibangu et al (2004) reported 
that, in South Africa, herbal medicines are good supplements to antiretroviral therapies because 
of their immune boosting properties. Herbal medicines are used in HIV-infected patients 
primarily for the perceived additional anti-viral and immune boosting effects, improvement of 
general well-being, and feeling of control over the pathological condition. Most clinicians are 
unaware of the concurrent use of herbal medicines with the conventional antiretroviral drugs 
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(ARVs) or other treatments by their patients. Such practise has raised concern of the possible risk 
of adverse drug reactions (ADRs) due to the herbs alone or possible unfavorable effect on the 
safety and efficacy of the ARVs as a consequence of herb-drug interactions (HDIs) (Hussain, 
2011).  
The major pathways for HDI are via the cytochrome P450 enzymes (CYPs) and the drug 
transporters. Herb-induced inhibition or induction of CYPs can alter the metabolism of ARVs, 
leading to lack of efficacy or toxicity which could be lethal. For example, a case study in two 
HIV-infected patients on ritonavir indicated severe gastrointestinal toxicity after co-
administration with garlic supplement for over two weeks. The symptoms however, re-occurred 
when the patients were given low-dose of ritonavir, suggesting possible interaction between 
garlic and ritonavir, through inhibition of CYP3A4 and induction of P-gp (Gallicano et al., 
2003). Another case study in five HIV-infected patients on both nevirapine (NVP) and St. John’s 
wort (SJW), reported reduced bioavailability of the NVP (de Maat et al., 2001). SJW was also 
demonstrated to significantly reduce exposure levels and increase the clearance of the protease 
inhibitor, indinavir with high risks for failed treatment in such patients (Piscitelli et al., 2001). 
These findings have led to revisions of the ARV labels where the use of SJW is not 
recommended in patients on ARVs (Clauson et al., 2008). Further pharmacokinetic and 
enzymological investigations indicated that SJW induces CYP3A4 (Izzo and Ernst, 2009), an 
enzyme responsible for metabolism of NVP and protease inhibitor.  
For conventional drug discovery and development, the mechanism of many drug-drug 
interactions (DDI) has been shown to be through the inhibition or induction of major drug 
metabolising enzymes, in particular CYPs, or transporters such as P-glycoprotein. The United 
States Food and Drug Administration (US FDA) has therefore published guidelines on the 
evaluation of new chemical entities for risk of metabolism-based DDI (Zhang et al., 2009). With 
the increased use of herbal medicines in developed countries and reports of in vivo HDIs on 
mechanism similar to those of conventional DDI, research started to adopt the FDA guidelines 
for the in vitro evaluation of herbal medicines for risks of HDI (Modarai et al., 2007). Whilst 
there is a large panel of CYPs and drug transporters important for drug metabolism and potential 
DDI, most studies currently conduct the first screen on the 5 major CYPs (CYP1A2, 2C9, 2C19, 
2D6 and 3A4) and P-glycoprotein responsible for the metabolism of over 90% of the drugs in the 
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market (Yang et al., 2004;  Paine et al., 2006). This study is thus designed to evaluate the risk 
potential of selected herbal medicines (n=7) used by HIV/AIDS patients for treatment of related 
infections and other comorbidity to cause HDIs in vitro, focusing on the five major drug 
metabolizing enzymes and P-gp.   
 
1.1. Overview of drug metabolism 
The human body is constantly exposed to wide ranges of chemicals found in foods, air, and 
drugs used for treatments of diseases. The majority of these chemicals are not required for 
normal physiological function and may be deleterious. The body has an array of enzyme-
catalyzed processes to eradicate these invading foreign substances known as xenobiotics.  
There are basically two major chemical pathways for the metabolism of xenobiotics: phase I and 
phase II. Phase I reactions involve functionalization of lipid-soluble drug via addition of a polar 
group. Oxidative metabolism is considered the most important aspect of phase I although other 
processes such as reduction and hydrolysis do occur. The cytochrome P450 monooxygenases 
(CYPs) group of enzymes is principally responsible for drug oxidation which forms the crux of 
this study. Phase II reactions involve conjugation of endogenous substances such as glucuronic 
acid to the phase I generated polar compound forming water-soluble product suitable for 
excretion.  
1.2 Cytochrome P450 enzymes (CYPs) 
The capacity of mammalian tissues to oxidise lipid-soluble xenobiotics was widely recognized in 
the early 1950s. Nevertheless, the specific enzymes responsible for the catalysis of such 
reactions were unknown at that time. The main evidence of the enzyme likely to oxidize 
xenobiotics originated from spectroscopic studies of microsomal heme proteins. In 1955, 
Axelrod and Brodie et al., identified an enzyme in the endoplasmic reticulum of the liver capable 
of oxidizing xenobiotic compounds. Garfinkel and Klingenberg in 1958 detected a carbon 
monoxide (CO) binding pigment in the liver microsomes which had an absorption maximum at 
450 nm. Later in 1964, the pigment was demonstrated to be a hemeprotein of the b-type class 
which was named Cytochrome P450 (CYP) after a strong feature in its absorption spectrum 
(Omura and Sato, 1964a and 1964b). Further investigation employing an electron spin resonance 
spectroscopy revealed that CYP is a low spin ferric hemeprotein with a thiol residue as an axial 
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heme ligand. This led to the explanation of the unusual Soret peak position and related 
perturbation after substrate complex formation and other chemicals in terms of charge transfer 
modulated by Fe-S bond (Bayer et al., 1969; Hill et al., 1970a; Hill et al., 1970b).  
CYP enzymes are now known as a family of heme containing proteins with an iron 
protoporphyrin IX non-covalently bound to the apoprotein as the prosthetic group. The prosthetic 
group is confined between the distal and proximal helix and bound to the adjacent Cysteine-
heme ligand loop. The proximal Cysteine forms double hydrogen bounds with the neighboring 
backbone amides. Variations in the protein components of the enzyme among members of the 
superfamily account for the different properties such as substrates and products specificity 
(Ricoux et al., 2007).  
 
Figure 1.1 Prosthetic of cysteinato-heme enzymes: an iron (III) protoporphyrin-IX linked with a 
proximal cysteine ligand (adapted from Hu et al., 2011). 
 
The mammalian CYPs are chiefly located in the endoplasmic reticulum and to a lesser extent in 
the mitochrondria, nuclei and lysosomes. It is predominantly found in the liver, but present in all 
mammalian cells except matured red blood cells and skeletal muscles. Unlike mammalian cells, 
bacteria CYPs are non-membrane bound and are located in the soluble fraction of the cytoplasm.  
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1.2.1 Cytochrome P450 nomenclature 
A standardized system of CYPs nomenclature was established to name and assign individual 
genes into families and subfamilies (Danielson, 2002). The system of CYPs nomenclature was 
determined by the P450 Nomenclature Committee based on the level of amino acid sequence 
identity, phylogenetic association and gene organization 
(http://drnelson.utmem.edu/CytochromeP450). The root for all CYP genomic and cDNA 
sequence names is represented as CYP. The individual family is then designated by an Arabic 
numeral (1, 2, 3, …), the subfamily with a letter (A, B, C, …) and another Arabic numeral (1, 2, 
3, …) for the respective protein. CYP sequences in the same family must display greater than 
40% identical amino acid.  Those belonging to the same subfamily exhibit greater than 55% 
identical amino acids and more than 97% identical amino acids represent the same allele except 
there are proof to contrary (Nebert et al., 1991; Nelson et al., 1993). An example of CYP 
nomenclature is illustrated in Figure 1.2. 
                                      CYP       2        D    6 *          4 
 
 
Abbreviation of mammalian     Family      Iso-enzyme 
Cytochrome P450 enzyme                   Subfamily       Allele  
Figure 1.2 Nomenclature of CYPs (adapted from Wijnen et al., 2007). The asterisk (*) refers to 
a polymorphic gene. 
 
1.2.2 Enteric and hepatic distribution of CYPs 
The principal organ for elimination of xenobiotics, the liver, has the highest concentration of the 
CYPs (Lin and Lu, 2001).  A systematic characterization of the five major CYPs in 60 human 
donor livers and anti-CYP antibodies reported the CYP3A subfamily (i.e. CYP3A4+CYP3A5) as 
the most abundant with 30% of the total CYP content. The CYP2C subfamily (i.e. 
CYP2C8+CYP2C9+CYP2C18+CYP2C19) is ranked second (18%), followed by CYP1A2 
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(15%), CYP2E1 (10%), CYP2A6 (5%), CYP2D6 (5%), and CYP2B6 (5%) (Paine et al., 2006) 
as depicted in Figure 1.3.  
 
 
Figure 1.3 Major hepatic CYPs involved in drug metabolism. 
 
Additionally, the CYPs are well expressed in small intestinal mucosa, lung, kidney, brain, 
olfactory mucosa, and skin. Nevertheless, the intestinal mucosa remains the most relevant 
extrahepatic site of drug biotransformation. Consequently, the presystemic biotransformation and 
subsequent reduction in bioavailability may occur as drugs pass sequentially through the small 
intestine and liver.  
In the small intestine, the CYP3A4 is the most abundant CYP subfamily with 50 – 70% average 
specific content (Watkins, 1987; Paine, 1997). The enteric CYP3A4 is localized within the 
enterocytes which form the major part of the mucosa lining (Kolars, 1994). The content of 
enteric microsomal CYP3A and its catalytic activity decline from the proximal region towards 
the distal ileum (Zhang et al., 1999). Unlike CYP3A, the abundance and importance of other 
CYPs in the small intestine remain unclear. Systematic characterization of the inter-individual 
variation in the specific contents of CYPs in microsomal preparation from 31 human donors 
small intestines showed that CYP2C9 represent the second largest proportion followed, by 
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CYP2C19, CYP2J2 and CYP2D6 (Paine et al., 2006). Therapeutic effects of orally administered 
drugs metabolized via the major hepatic and enteric CYPs; CYP3A and CYP2C9 pathways are 
likely to be reduced due to presystemic biotransformation. Hence proper dose adjustment of such 
drugs must be done to avoid inefficacy and presystemic toxicity.  
 
1.2.3 Role of CYPs in xenobiotic metabolism 
Plants and animals are constantly engaged in biological warfare. Each develops a unique 
approach to defend itself against possible invasion from the opponent. Plants use three major 
defensive strategies including physical protection, toxic secondary metabolites and metabolic 
defenses. Most plant secondary metabolites act as pro-drugs in animals which need to be 
metabolized by CYPs to deploy their toxic effects in the body.  Some plants reduce 
detoxification of secondary metabolites through inhibition of efflux pumps (phase III proteins) 
(Stermitz et al., 2000). Conversely, animals have developed protective mechanisms against 
chemical toxins produced by plants (McLean and Duncan, 2006).  The metabolism of 
xenobiotics via CYPs to increase detoxification represent the most single effective approach used 
by animals to cope with toxic influences from their environment. The warfare between possum 
and Eucalyptus plants is a classic example of an effective animal detoxification system. Possums 
ingest doses of about 10 grams of 1, 8-cineole per day which could be quite poisonous in human 
beings. Compared with humans, cineole is rapidly metabolised by possum liver microsomes to 
less toxic compounds especially after induction through prior terpene exposure (Pass et al., 
2001)  
Human beings use a similar defensive mechanism to detoxify xenobiotics. It is estimated that 
approximately 66% of marketed drugs are metabolized by the CYP enzyme system (Rendic and 
Di Carlo, 1997; Guengerich, 2003; Williams et al., 2004). Five of the human genes coding for 
CYPs (1A2, 2C9, 2C19, 2D6 and 3A4) account for 95% metabolic clearance of drug and 
xenobiotics. This account however varies from the liver to the intestine and other extrahepatic 
metabolism as summarized in Table 1.1.  
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Table 1.1 Hepatic and enteric abundances of CYP isoforms. Table obtained from (Rostami-
Hodjegan and Tucker, 2007; Pain, 2006). 
 
P450 isoform Mean abundance in 
liver (pmol/mg) 
Mean abundance in 
human intestine 
(pmol/mg) (%) 
Contribution to 
metabolism in 
marketed drug (%) 
CYP1A1 ND 5.6 (7.43%)  
CYP1A2 37 (10.63%)  9 
CYP2A6 29 (8.33%)   
CYP2B6 7 (2.01%)  2 
CYP2C8 19 (5.46%)   
CYP2C9
*
 60 (17.248%) 8.4 (11.14%) 16 
CYP2C19
*
 9 (2.59%) 1.0 (1.33%) 12 
CYP2D6
*
 7 (2.01%) 0.5 (0.66%) 12 
CYP2E1 49 (14.085%)  2 
CYP2J2  0.9 (1.19%)  
CYP3A4 131 (37.64%) 43 (57.03%) 46 
CYP3A5  16 (21.22%)  
 
CYPs with asterisk (*) are polymorphic genes and ND refers to not determined. 
 
 
1.2.3.1 Role of CYP1A2 in drug metabolism  
 
Catalytic activities of CYP1A enzymes include hydroxylation and oxidative biotransformation of 
polycyclic aromatic hydrocarbons and other aromatic substances. CYP1A1 prefers planar 
aromatic hydrocarbons whilst CYP1A2 favours metabolic clearance of aromatic amines and 
heterocyclic compounds. The classical biotransformation reactions catalysed by CYP1A2 
include 7-ethoxyresorufin O-deethylation, phenacetin O-deethylation, and caffeine N3-
demethylation (Fuhr et al., 2007; Zhou et al., 2009).  The relatively high expression of CYP1A2 
shows the importance of its metabolic clearance of clinically important drugs. Therapeutic agents 
metabolised by CYP1A2 include; analgesics and antipyretics (acetaminophen, phenacetin, 
lidocaine), antipsychotics (olanzapine, clozapine), antidepressants (duloxetine; Lobo et al., 
2008), anti-inflammatory drugs (nabumetone; Turpeinen et al., 2009), cardiovascular drugs 
(propranolol, guanabenz, triamterene), the cholinesterase inhibitor tacrine used for the treatment 
of Alzheimer's disease, the muscle relaxant - tizanidine (Granfors et al., 2004), the hypnotic -
zolpidem used in the short term treatment of insomnia, the drug riluzole used to treat 
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amyotrophic lateral sclerosis, the 5-lipoxygenase inhibitor - zileuton. Endogenous substrates of 
CYP1A2 comprise arachidonic acid, prostaglandins, oestrogens, melatonin and retinoic acid 
(Nebert & Dalton, 2006). Additionally, CYP1A2 is responsible for the bioactivation of 
procarcinogens like arylarenes, nitroarenes, and arylamines, found in charbroiled food and 
industrial combustion products. The reactive and carcinogenic products intercalates with DNA to 
cause permanent damage which may lead to generation of cancerous cells. Substrates of 
CYP1A2 are prone to drug interactions by small molecules that reversibly or irreversibly fit the 
active site or through the Aryl hydrocarbon receptor (AhR)-mediated gene induction.  Examples 
of potent inhibitors are α-naphtoflavone (Ki<50 nM) and the selective serotonin reuptake 
inhibitor (SSRI), fluvoxamine (Ki~0.2 μM; Hiemke & Härtter, 2000). 
 
1.2.3.2 Role of CYP2C9 and CYP2C19 in drug metabolism 
 
CYP2C9, the major isoform of CYP2C accepts weakly acidic drugs including the anticoagulant 
warfarin, the anticonvulsants phenytoin and valproic acid, the angiotensin receptor blockers 
candesartan and losartan, oral antidiabetics like glibenclamide and tolbutamide, and nonsteroidal 
anti-inflammatory drugs (NSAIDs) (Lee et al., 2002). Diclofenac and tolbutamide are common 
substrates employed in CYP2C9 phenotyping. CYP2C9 is inhibited by several xenobiotics which 
can clinically influence warfarin treatment (Lu et al., 2008).  
 
The discovery of CYP2C19 as genetic polymorphic CYP enzymes has led to the classification of 
S-mephenytoin phenotype into poor and extensive metabolizers (Küpfer and Preisig, 1984). It is 
the primary enzyme for the metabolic inactivation of proton pump inhibitors including 
omeprazole and pantoprazole, and for the metabolic activation of the anticoagulant clopidogrel 
to the active 2-oxo metabolite (Hulot et al., 2006; Kazui et al., 2010; Dansette et al., 2011; 
Boulenc et al., 2012). CYP2C19 also plays an important role in the metabolism of several 
antidepressants of the first and second generation (Brøsen, 2004). 
1.2.3.3 Role of CYP2D6 in drug metabolism 
 
Although CYP2D6 has a low relative abundance in the liver, it is responsible for the metabolism 
of large number of drugs including approximately 15-25% of clinically used drugs. Therapeutic 
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classes of drugs metabolised by CYP2D6 include; antiarrhythmics (e.g. propafenone, mexiletine, 
flecainide), tricyclic and second generation antidepressants (e.g. amitriptyline, paroxetine, 
venlafaxin), antipsychotics (aripiprazole, risperidone), β-blockers (bufuralol, metroprolol), anti-
cancer drugs (selective estrogen receptor modifier (SERM) tamoxifen), opioid analgesics 
(codeine and tramadol) (Zanger et al., 2008; Stingl et al., 2012). Clinically, the phenotype of 
CYP2D6 is determined using selective test drugs such as debrisoquine, dextromethorphan, 
metoprolol, sparteine, and tramadol (Frank et al., 2007).  
 
Two independent scientists Eichelbaum et al., (1979) and Smith, (1986) discovered the genetic 
deficiency of debrisoquine and spartein metabolism. The study on debrisoquine, a sympatholytic 
antihypertensive drug observed a pronounced hypotensive response in one group compared to 
others. This was found to be due to impaired 4-hydroxylation of debrisoquine (Smith, 1986). An 
independent research conducted by a team of physicians in Bonn around the same time observed 
increased side effects associated with decreased oxidative metabolism of sparteine, an oxytocic 
and antiarrythmic alkaloid (Eichelbaum et al., 1979; Smith, 1986). Population studies were 
conducted for both debrisoquine and spartein with determination of the urinary metabolic ratio 
(MR). Individuals with MR greater than 12.6 and 20 were categorised as poor metabolisers of 
debrisoquine and spartein, respectively for ratio of debrisoquine to 4-OH-debrisoquine and of 
sparteine to 2- and 5-dehydrospartein (Evans et al., 1980; Eichelbaum et al., 1986).  
 
These two studies gave recognition to CYP2D6 as a polymorphic enzyme with different 
phenotypes in a given population. The frequency of phenotype of poor metabolisers differs 
among the various ethnic groups. Less than 1% of Asians, 2-5% of African-Americans, and 6-
10% of Caucasians are poor metabolisers of CYP2D6 (Kalow et al., 1980). The CYP2D6*3, *4, 
*5 and *6 are the common variant alleles found in Caucasians which accounts for about 98% of 
poor metabolisers.  
The Asian and African-American populations tend to have reduced CYP2D6 activity compared 
with Caucasians due to a lower occurrence of non-functional alleles (e.g., *3, *4, *5,*6), but a 
higher frequency of alleles associated with reduced activity (e.g., *10, *17) (Wang et al., 1993). 
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In in vitro assays, bufuralol is commonly used as probe substrates of CYP2D6. Quinidine and 
methadone with high affinity for CYP2D6 inhibit the enzyme even though they are not substrates 
(Gelston et al., 2012). 
 
1.2.3.4 Role of CYP3A in drug metabolism 
 
The CYP3A subfamily enzymes metabolize ~30% of clinically used therapeutic drugs (Bu, 
2006; Liu et al., 2007; Zanger et al., 2008). This is attributed to the large and flexible active site 
of CYP3A4 capable of accommodating and metabolizing many lipophilic compounds with 
comparatively large structures (Scott and Halpert, 2005; Hendrychová et al., 2011). Typical large 
substrates are immunosuppressants like cyclosporine A and tacrolimus, macrolide antibiotics like 
erythromycin, and anticancer drugs including taxol. However, smaller molecules including 
ifosfamide, tamoxifen, benzodiazepines, several statins, antidepressants, opioids are also 
substrates. CYP3A4 is also known as an efficient steroid hydroxylase which catabolizes several 
endogenous steroids namely testosterone, progesterone, androstenedione, cortisol and bile acids. 
Typical probe drugs used to measure general CYP3A activity include; midazolam, testosterone, 
erythromycin, alprazolam, and dextromethorphan (Fuhr et al., 2007; Liu et al., 2007).  
 
Because CYP3A4 and CYP3A5 share > 85% identical primary amino acid sequence, there is 
high similarity in substrate selectivity between the isoforms (Williams et al., 2002). However, 
few substrate variations have been reported. Aflatoxin B1 (AFB1) 3α- hydroxylation to AFQ1 is 
solely catalyzed by CYP3A4 and results in detoxification and subsequent elimination of AFB1, 
whereas CYP3A5 converts it to the genotoxic aflatoxin B(1)-8, 9-epoxide (AFBO) (Kamdem et 
al., 2006). 
 
1.2.4 CYP catalytic cycle 
The CYP cycle usually starts with P450 iron in the ferric state. Although the catalytic cycle has 
been presented here in stages, it is noteworthy to mention that these reactions do not necessarily 
occur in the order discussed. In some cases, substrate binding and dissociation can occur with 
some ferrous P450. Also, some CYPs assume the ferrous resting state in the highly reducing 
Stellenbosch University  https://scholar.sun.ac.za
12 
 
environment in cells with low oxygen tension. The general stepwise catalytic cycle for the CYP 
reactions are presented from step 1-9: 
Step 1: Substrates bind to the active or peripheral site of the CYPs. The rate of substrate binding 
is considered to be a relatively rapid, univalent process especially for CYPs with relatively small 
binding sites such as CYP2A6 in humans. For such enzymes, the CYP protein undergoes rapid 
conformational changes allowing for substrate binding. The CYP2A6 substrate imbeds deeply 
into the active site, therefore the protein must be opening and closing rapidly.  The rate of 
substrate binding to CYPs with large active sites like CYP3A4 and CYP1A2 is comparatively 
slow. Here, the substrate binds to the peripheral sites of the CYP followed by a conformational 
change that moves the substrate closer to the heme. The substrate displaces axial water molecule 
upon binding to the CYP active site. Consequently, the displacement of the iron from the plane 
of porphyrin ring at the resting state increases. This makes the heme better electron sink and 
activates an electron transfer from the reductase protein.   
Step 2: After substrate binding, the iron (III) reduces to the ferrous state via electron transfer. 
NADPH donates electron to CYP through the accessory flavoprotein NADPH-P450 reductase, 
and progressive electron flow from the reductase prosthetic group FAD to FMN to the CYP. 
 
Step 3: Triplet dioxygen reacts with ferrous CYP to produce a stable dioxygen adduct. Iron (III)-
oxygen bond formation occurs via donation of an electron each from the iron (III) center and the 
triplet oxygen, respectively. Although the iron (III)-oxygen complex is relatively stable, it can 
dissociate to an iron (III) and superoxide anion at room temperature. The release of superoxide 
within the enzyme is accompanied by decoupling (uncoupling) reaction characterized by 
disproportionation and generation of a harmful radical, hydrogen peroxide. 
   
Step 4: It is a relatively slow step which generates negative charge iron (III)-peroxo complex 
which undergoes rapid deprotonation to generate iron (III)-hydroperoxo complex. The 
unprotonated iron (III)-peroxo complex is a stronger nucleophile than the corresponding iron 
(III)-hydroperoxo complex. However, both entities participate in CYP-catalysed reactions 
involving generation of nucleophilic oxidant intermediates. Oxidative decarbonylation of 
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aldehydes and the final stage of the aromatization of the cycle A of androstenedione in the 
biosynthesis of estrone are classical examples of such intermediate nucleophilic oxidants.  
 
Step 5: Iron (III)-peroxo is protonated to produce P450-Fe
III
-OOH intermediate which behaves as 
nucleophile.  
 
Step 6: The terminal oxygen atom of Fe
III
-OOH entity is further protonated to produce iron (V)-
oxo species and water molecule. The O-O bond in Fe
III
-OOH undergoes heterolytic cleavage by 
protonation to generate compound I or iron (V)-oxo which is considered as the main reactive 
species of the catalytic cycle. 
 
Step 7-9: Abstraction of hydrogen or electron occurs. Oxygen is inserted to generate 
hydroxylated species through the oxygen rebound mechanism takes place. The substrate is 
finally released. The catalytic cycle for CYP activity is summarized in Figure 1.4. 
 
 
 
Figure 1.4 The general scheme for CYP catalysis (adapted from Guengerich 2001). Where the 
numbers refer to steps 1-9 of the catalytic cycle. 
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1.2.5 Enzyme kinetics of CYP-mediated reactions 
The use of multiple drugs for the treatment of chronic diseases such as HIV/AIDS, diabetes and 
hypertension is routine in clinical practice. However, multiple administrations of drugs in 
patients have the tendency to cause DDI with significant clinical consequences ranging from 
drug toxicity to inefficacy. In DDI, one drug (inhibitor or inducer) influences the activity of the 
CYP on the metabolism of the second drug (substrate). Inhibition and induction are the main 
mechanisms responsible for such interactions. The apoprotein structures in different CYPs 
determine the variations in the substrates specificity and kinetic properties for each isoform.  
Generally, most CYP-mediated reactions follow simple Michaelis-Menten (M-M) kinetics. The 
kinetic parameters derived from M-M kinetics based on in vitro data can be employed to predict 
in vivo pharmacokinetic DDI. The M-M kinetic assumes that only a single binding site is 
available at the active site of the enzyme where catalytic activity occurs and the reaction velocity 
can be characterized as a hyperbolic saturating profile as illustrated in Scheme 1.1 and Figure 
1.5, respectively (Segel, 1975). The reaction velocity is plotted against the range of substrate 
concentrations used.  
              
Scheme 1.1: The classical enzyme catalytic process. 
E, S, ES and P are the concentrations of the enzymes, substrates, enzyme-substrate complex and 
the products (metabolites), respectively, K1 is the association rate constant; K-1 and Kp are the 
dissociation rate constant from ES to E and S, and E and P, respectively.  
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Figure 1.5  Michaelis-Menten relationship for substrate metabolism. 
 
v = Vmax. [S]/Km + [S]                                                Equation 1.1 
The M-M constant (Km) is defined as;  
Km = (kp +k-1) /K1 and V = (kp/Km)*E*[S]                 Equation 1.2 
Where v is the reaction velocity; Vmax, maximum velocity; [S], substrate concentration; Km, 
Michaelis constant; kp, rate of dissociation and E, free enzyme concentration. 
Hence the reaction velocity (V) depends on the concentration of both free enzyme and the 
substrate in the steady state.  
The enzyme catalytic rate reaches its maximum (Vmax) when the substrate saturates the active 
site. At this point, the rate of catalytic activity becomes substrate concentration-independent. The 
dissociation rate constant Kp becomes the maximum catalytic rate constant (Kcat). To predict 
CYP-mediated DDI in clinic, the intrinsic clearance of specific drug is determined as CLint = 
Vmax/Km (equation 1.3), an important parameter which bridges enzyme kinetics and 
pharmacokinetics (Shou et al., 2001).  
 
1.3 Inhibition of CYP enzymes 
CYP inhibition has been implicated in most clinically relevant DDI. The mechanism of CYP 
inhibition is broadly classified into: (I) reversible inhibition and (II) irreversible inhibition also 
referred as time-dependent inhibition (TDI).  
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1.3.1 Reversible inhibition 
Reversible inhibition involves rapid association and dissociation between drugs and enzymes. It 
can further be divided into competitive, uncompetitive, noncompetitive and mixed inhibition as 
demonstrated in Scheme 1.2. Competitive inhibition is the most common and uncompetitive 
inhibition the rarest event. 
 
 
Scheme 1.2: Reversible enzyme inhibition. Figure adapted from (Shou et al., 2001) 
Pathway 1 (competitive inhibition), pathway 2 (uncompetitive inhibition), pathway 1 and 2 
(noncompetitive inhibition) and pathways 1, 2 and 3 (mixed inhibition). 
It is noteworthy to mention that reversible inhibition follows M-M kinetics. 
1.3.1.1 Competitive inhibition 
It occurs when the inhibitor (I) competes with the substrate (S) for the same binding site within 
the enzyme apoprotein. For competitive inhibition, the metabolic rate (v) can be expressed as: 
v = Vmax.[S]/Km (1+[I]/Ki)+[S]                                                          Equation 1.4  
Vmax is the maximum metabolic rate and Ki, inhibition constant for an inhibitor (I). Based on the 
equation above, the substrate concentration [S] determines the strength of inhibition. The 
inhibition by a specific concentration of an inhibitor is more pronounced when the substrate 
concentration is low and less when the substrate concentration is high (Nelson and Cox, 2008).  
1.3.1.2 Noncompetitive inhibition 
The inhibitor binds to both free and substrate-bound enzyme at site(s) different from the 
substrate-binding site resulting in a conformational change in the protein.  In noncompetitive 
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inhibition, it is assumed that inhibitor binds to the unbound enzyme and ES complex with similar 
affinity. Metabolic rate for noncompetitive inhibition is expressed as: 
v = {Vmax/(1+[I]/Ki)}.[S]/Km + [S]                                                           Equation 1.5  
Thus, the substrate concentration does not determine the degree of inhibition. 
1.3.1.3 Uncompetitive inhibition 
The inhibitor binds to the enzyme only when it has formed a complex with the substrate. 
However, unlike competitive and noncompetitive inhibition, the inhibitor cannot bind to the 
unbound enzyme. The metabolic rate of uncompetitive inhibition can be expressed as: 
v = {Vmax/(1 +[I]/Ki)} . [S]/ Km/(1 +[I]/Ki) +[S]                                         Equation 1.6 
In this case, the strength of inhibition depends on the substrate concentration.  
1.3.1.4 Mixed inhibition 
The inhibitor binds identical at site(s) that overlap with substrate-binding site, the free and the 
substrate-bound enzyme with different affinities.  The metabolic rate for mixed inhibition is 
expressed as: 
v = Vmax/(1 +[I]/Ki) +(1 + Ks/[S]) x (1 + [I]/Ki)                                        Equation 1.7  
Ks is the dissociation constant of the enzyme-substrate complex. It is approximately equivalent 
to Km (K3 <<K2). 
 
1.3.2 Prediction of in vivo DDI based on in vitro reversible inhibition 
The influence of a test drug (inhibitor) on a specific CYP probe substrate in a test system (HLMs 
or recombinant CYP) can be assessed by monitoring different concentrations of the inhibitor. 
The IC50 or Ki values determined are used to rank the risk of inhibition in vivo. Before the 
conduct of in vitro DDI studies, the concentrations of the probe substrate (Km, Vmax) and the 
inhibitor (IC50 or Ki) must be established. IC50 is the inhibitor concentration at which the reaction 
rate is reduced by 50%. The Km value is determined by nonlinear regression plot of enzyme 
activity against substrate concentration. Optimization of substrate turnover by a given test system 
remains key procedure for determination of the kinetic parameters for specific probe substrate. It 
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is important to aim a turnover which is linearly dependent on time and less than 20% substrate 
consumption. Preferably, the lowest amount of protein that yields quantifiable metabolite 
concentrations in the incubation mixture should be utilized. The relationship between IC50 and Ki 
(inhibition constant) can be established for the various categories of reversible inhibition as 
illustrated in equation 1.8. 
Competitive: IC50 = Ki*(1 + [S]/Km) 
Uncompetitive: IC50 = K*(1 =Km/[S]) 
Noncompetitive: IC50 = Ki 
Mixed: IC50 = K*(1 + [S]/Km)/(1 + (Ki/K’)*([S]/Km)) 
 If the concentration of probe substrate is equivalent to the Km, inhibitor concentration capable of 
decreasing the enzyme activity by 50% (IC50) will be the same as the Ki value when the type of 
inhibition is noncompetitive (IC50 = Ki) or almost twice the Ki for competitive inhibitor or an 
uncompetitive inhibitor (IC50 = 2Ki).  
The criteria for ranking the potential risk of an inhibitor to cause DDI according to FDA draft 
guidance for drug interaction (2012) is based on [I]/Ki ratio where [I] is the concentration of the 
inhibitor an individual is exposed to and the Ki, the inhibition constant for a pure compound. For 
[I]/Ki ratio to be meaningful in the estimation of HDI for herbal supplements consisting of 
multiple constituents, certain assumptions must be established. First, the amount of an inhibitor  
[I] used is based on the assumption that the aqueous or methanol soluble extracts of the herbs to 
be absorbed from the GIT and to interact with intestinal CYPs and P-glycoprotein was 
completely soluble in the 250 mL GIT fluid (Fasinu et al., 2012). Secondly, for an herbal 
medicines consisting of multiple phytochemical constituents, it is unlikely to determine the Ki 
since most of the constituents are unknown. It is therefore assumed that at least one 
phytochemical constituent of the herb is responsible for the inhibitory effect observed on CYPs. 
Furthermore, based on the design of the in vitro assay, substrate concentration at Km was used to 
determine the IC50 value. It is therefore assumed from the experimental design that the speculated 
phytochemical constituent exhibits competitive inhibition which will result to a higher inhibition 
index. The herbal extracts were subsequently risk ranked based on FDA guidelines where, [I]/Ki 
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>1.0 is associated with high risk for DDI, [I]/Ki = 0.1-1 is associated with intermediate risk for 
DDI and [I]/Ki<0.1 is unlikely to result in DDI (Zhou et al., 2005; Huang et al., 2008; 
Prueksaritanont et al., 2013). 
Furthermore, to estimate the phytochemical constituents of the herb interacting with the hepatic 
CYPs and transporters, the maximum hepatic input amount of the extract entering the portal vein 
from the GIT and systemic circulation was determined using the equation: [I]in = [I]gut + 
KaFaD/Qh. where, Ka (absorption rate constant), Fa (fraction absorbed from the gut into the portal 
vein), D (dose of herb used in humans) and Qh (hepatic blood flow rate). To make the above 
equation useful, it was assumed that there is complete absorption of the soluble herbal extract 
from the GIT into the portal vein (Fa = 1.0). The values of Ka and Qh were also assumed to be 0.1 
min
-1
 and 1610 mL/min, respectively (Kanamitsu et al., 2000) 
 
1.3.3 Time dependent inhibition 
Time dependent inhibition (TDI) is a kinetically defined phenomenon whereby inhibitors display 
an increased intensity of enzyme inhibition upon prolonged duration of pre-incubation with the 
enzyme and NADPH. Mechanism-based inhibition (MBI) is a subset of TDI which involves 
inactivation of the enzyme via the formation of metabolic intermediates that bind tightly and 
irreversibly to the enzyme.  Hence TDI is also referred as irreversible inhibition. MBI is 
characterized by NADPH-, time- and concentration-dependent enzyme inactivation and substrate 
protection. Often, MBI results in unfavourable DDI as the inactivated enzyme has to be replaced 
by de novo synthesis to recover its in vivo activity. MBI can be broadly classified into two major 
subdivisions, namely (i) quasi-irreversible and (ii) true irreversible inactivation (Lin and Lu, 
1998).  
 
1.3.3.1 Quasi-irreversible inactivation 
During quasi-irreversible inactivation, the inhibitors undergo metabolic activation by the CYP 
enzyme to generate reactive intermediates which coordinate with the ferrous form of the CYP 
heme in a tight noncovalent complex resulting to the formation of metabolic intermediate 
complex (MIC).  The MIC is catalytically inactive and cannot bind to carbon monoxide which is 
used as a diagnostic test to assess whether the CYP TDI happens through MIC formation. Many 
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of heme-ligand complexes are reversible in vitro after dialysis, hence the term ‘quasi-
irreversible’. In vitro treatment of microsomes or recombinant CYPs with K3Fe(CN)6 oxidizes 
the iron to the ferric states Fe(III) and displaces the metabolic intermediate from the active site 
leading to reactivation of the CYP activity. However, in in vivo MIC are very stable to the extent 
that the inactivated CYP is generally unavailable for drug metabolism. Consequently, DDIs due 
to quasi-irreversible inhibitors are prominent after multiple dosing compared to the reversible 
inhibitors (Lin and Lu, 1998).   
Common quasi-irreversible CYP inactivators include primary amines and 1, 3-benzodioxole 
(methylenedioxyphenyl) derivatives. Primary amines are oxidized to nitroso metabolites via the 
intermediate hydroxylamine metabolites capable of forming MIC with the ferrous form of the 
heme iron atom. The nitroso-heme complexes can be decoupled in vitro by treating the 
inactivated CYP with potassium ferricyanide.   The potassium ferricyanide oxidizes iron (II) to 
ferric state (III) and liberates the active carbon monoxide binding CYP enzyme. The transition 
from ferrous to ferric weakens the complex, an indication that the metabolic intermediate only 
strongly coordinates to the ferrous iron (Murray, 2000).  
 
1.3.3.2 True irreversible inactivation of CYP 
True irreversible inactivation of CYP involves formation of covalent bond between the 
metabolite and the CYP. At times, irreversible inactivation of CYP can generate hapten 
formation which triggers an autoimmune-response leading to acute hepatotoxicity (Li, 2002).  
Such an immune toxicity depends on a number of factors such as competing detoxification 
pathways, daily dose, dose regime, genetic factors and the intended target population. Reactive 
metabolite formed within the CYP active site can cause true irreversible inhibition via two 
different mechanisms: (i) covalent modification of heme prosthetic group and/or apoprotein in 
CYP enzymes and (ii) covalent modification of CYP by heme fragments. 
 
1.3.3.2 Prediction of in vivo DDI based on in vitro TDI 
The effect of a mechanism based inactivator in vivo is a combined function of its ability to 
inactivate the CYP and the synthesis rate of the enzyme (Mayhew et al., 2000). Hence, to assess 
the potential impact of MBI in vivo, it is important to determine the inactivation parameters of 
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the inactivator in vitro. The critical characteristics of mechanism-based enzyme inactivation are 
illustrated in the scheme below: 
 
 
Scheme 1.3: Kinetic for mechanism-based inactivation.  
Upon binding to an enzyme, an inactivator has three possible fates: (i) release from the enzyme 
through reversible binding, (ii) conversion to a product (P) through productive catalytic cycle or 
(iii) inactivation of enzyme by forming an irreversible complex (EI). E* is the concentration of 
free enzyme at equilibrium.  
Based on the scheme, the rate of enzyme inactivation can be defined by: 
d/dt[E]t = -Kinact x [I] x [E]t/[I] + KI                                                           Equation 1.9 
[E]t is the active enzyme concentration at time t, [I] is the inactivator concentration, and KI and 
Kinact are estimated by the nonlinear regression. For the Kinact and KI parameters to be 
meaningful, two assumptions are made: (i) the binding of inactivator to the enzyme is in a rapid 
equilibrium and (ii) the catalytic steps common to both productive catalysis and irreversible 
inactivation are rapid and non-rate limiting hence can be ignored. The rate of enzyme 
inactivation at a given inactivator concentration is termed as the apparent inactivation rate 
constant, which is commonly denoted by kobs or λ (Tudela et al., 1987) (Figure 1.6A): 
λ = [I] x Kinact/[I] + KI                                                                                 Equation 1.10 
Linear and nonlinear methods are used to obtain Kinact and KI values. Taking reciprocal of each 
sides of the above equation gives 
1/λ = 1/Kinact + KI/Kinact.1/[I]                                                                       Equation 1.11 
A plot of 1/λ against 1/[I] generates a trend of line which has y-intercept of 1/Kinact and an x-
intercept of -1/KI. This is also referred to as double reciprocal or Kitz-Wilson plot (Kitz and 
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Wilson 1962) (Figure 1.6B).  For a nonlinear regression, the hyperbolic relationship between λ 
and the [I] are fitted to derive estimated Kinact and KI (Figure 1.6C). 
 
 
 
Figure 1.6 Graphical representations relevant to conventional experimental procedure for 
chracterising MBI. (A) time- and concentration-dependent inactivation of enzyme by MBI. (B) 
The Kitz-Wilson plot, a double reciprocal plot of the observed inactivation constant (kobs) as 
function of MBI concentration [I]. (C) Relationship between the observed inactivation rate 
constant (Kobs) and the MBI constant [I].  Figure adapted from (Yang et al., 2005). 
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1.4 Induction of CYPs 
Induction of CYPs occurs as a consequence of a drug or xenobiotic triggering an increase in gene 
transcription to generate protein activity above the normal biological range. Increase hepatic 
clearance of drugs metabolized by the induced CYPs is an indicative of elevated levels of 
enzyme gene expression. Pharmacokinetically, the AUC of the co-administered drug are reduced 
in the presence of an inducer. Interaction between midazolam (CYP3A4 substrate) and 
antidepressant herbal product, St. John’s wort (CYP3A4 inducer) is an example where the AUC 
of midazolam declined by 79% when the two products were administered in healthy subjects 
(Mueller et al., 2006). Additionally, certain drugs, for example carbamazepine and artemisinin 
which are known substrates for CYP3A4 and CYP2B6, respectively cause autoinduction by both 
acting as inducer and thus reduce plasma levels of the affected drugs (Bertilsson et al., 1980; 
Simonsoun et al., 2003) (Table 1.2). Study conducted in healthy volunteers indicated that 
concomitant administration of rifampicin and oral contraceptives could lead to failure of the 
antifertility effects of the latter (Reimers and Jezek, 1971). Such effect was attributed to the 
induction of estrogen-2-hydroxylation pathway which is catalyzed primarily by CYP3A4 in the 
presence of rifampicin (Lee et al., 2003).  
Induction of CYPs can have serious consequences: 1) reduction in the intrinsic pharmacological 
activity of the target drug or a coadministered drug due to rapid hepatic clearance, and 2) 
increased toxicity of primary drug due to elevated levels of metabolites in plasma as the 
expression of CYP increases in the presence of the co-administered drug.  
 
1.4.1 Mechanism of induction 
There are two primary mechanisms of enzyme induction: 1) stabilization of the mRNA or 
enzyme and 2) increased gene transcription. Transcriptional gene activation is however regarded 
as the common mechanism for induction. Transcriptional gene activation of drug metabolizing 
CYPs is mediated by nuclear receptors which function as transcription factors. These 
transcription factors include aromatic hydrocarbon receptor (AhR), constitutive androstane 
receptor (CAR), and pregnane X receptor (PXR).  This portion of the review will however focus 
on detailed mechanism of PXR mediated induction which is the most extensively studied nuclear 
receptor. 
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Table 1.2 Commonly used in vivo probes for clinical studies and CYP inducers. Table adapted 
from (FDA, 2012 and Tucker et al., 2001).  
P450 Substrates/Probes Inducers  
CYP1A2 Theophylline, caffeine, acetaminophen, 
aromatic amines, phenacetin 
Cigarette smoke, omeprazole 
charbroiled meats, cruciferous 
vegetables 
CYP2A6 Coumarin, butadiene, nicotine Barbiturates 
CYP2B6 Efavirenz Rifampin 
CYP2C8 Repaglinide, rosiglitazone Rifampin 
CYP2C9 S-warfarin, tolbutamide, phenytoin, 
NSAIDs 
Rifampin, barbiturates 
CYP2C19 Omeprazole, esoprazole, lansoprazole, 
pantoprazole, citalopram, diazepam, 
hexobarbital, imipramine, proguanil, 
propanolol 
Rifampin, barbiturates 
CYP2D6 Antidepressants, neuroleptics, beta-
blockers, antiarrhytmics, codeine, 
etylmorphine, desipramine, 
dextromethorphan, atomoxetine, 
nicotine 
Not identified 
CYP2E1 Chlorzoxazone, acetaminophen, 
alcohols, caffeine, dapsone, enflurane, 
theophylline 
Ethanol, isoniazid 
CYP3A4 Midazolam, buspirone, felodipine, 
lovastatin, eletriptan, sildenafil, 
simavastatin, triazolam, 
acetaminophen, carbamezapine, 
cyclosporin, digitoxin, diazepam, 
erythromycin, fluoxetine, nifedipine, 
quinidine, saquinavir, terfenadine, 
verapamil, warfarin 
Rifampin, carbamazepine, 
dexamethasone, phenytoin, 
troleandomycin 
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1.4.2 PXR mediated induction of CYP3A 
This nuclear receptor is closely related to the vitamin D receptor (VDR) and complex with VDR 
DNA elements as a heterodimer with a retinoid X receptor alpha (RXRα).  PXR element has 
been identified in human CYP3A4 and rat CYP3A23 promoter sites. X-ray crystallography 
showed that PXR has the largest ligand-binding pocket compared to other nuclear receptors, 
enabling it to be more promiscuous (Watkins et al., 2001). Upon activation by ligand binding, 
PXR translocates into the nucleus to form heterodimer with RXR. The PXR/RXR dimer binds to 
response elements upstream of the target gene causing chromatin remolding and transcriptional 
activation (Meijerman et al., 2006). Once the transcription of target genes is activated, CYP3A4 
expression level increases as depicted in Figure 1.7. 
 
 
 
Figure 1.7 Mechanism of PXR activation via luciferase reporter gene assay (adapted from 
Meijerman et al., 2006). 
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1.4.3 Clinical relevance of CYP induction 
Unlike enzyme inhibition which is rapid and reproducible in vitro, induction is time-dependent. 
There is therefore the probability of ignoring enzyme induction by compounds which has 
resulted in serious implications. For example, some protease inhibitors have been found to 
interact with SJW. A study showed that intake of 900 mg/day of SJW standardized to 0.3% 
hypericin for two weeks led to a decrease in plasma concentration of indinavir (Piscitelli et al., 
2000). SJW is reported to cause induction of hepatic CYP3A4 responsible for metabolism of 
indinavir. Low plasma concentration of the protease inhibitor leads to development of drug 
resistance and treatment failure in HIV-infected patients. The immunosuppressive agent, 
cyclosporine is a substrate for P-gp and CYP3A4 and is widely used after transplantation with 
cases of allograft rejection reported when the plasma concentration decline below the effective 
level in patients taking SJW (Akhlaghi and Trull, 2002). Case reports of patients receiving 
transplantation of heart, liver, kidney and pancreas have shown that a decline in blood trough 
concentration of cyclosporine resulted in transplant graft rejection within 3-4 weeks of using 
SJW (Barone et al., 2000; Ruschitzka et al., 2000).  
 
1.4.4 In vitro models for CYP inhibition and induction studies 
1.4.4.1 Recombinant CYPs 
These are cDNA CYPs expressed in baculovirus-insect cell or an Escherichia coli (E. coli) based 
expression system. Only single enzyme is expressed in such systems, hence resulting to higher 
activity when a specific substrate is applied (Foti et al., 2010). Recombinant enzymes are usually 
employed in high throughput screening (HTS) of new candidate drugs at early stages of drug 
development. The absence of contribution of other metabolic enzyme in recombinant CYP 
assays is a major setback associated with this system (Kramer and Tracy, 2008). 
1.4.4.2 Human liver microsomes 
It is regarded as the gold standard enzyme source for most in vitro inhibition studies. Human 
liver microsomes (HLM) are very convenient, easy to use and affordable. HLM contains 
multiple phase I hepatic drug metabolizing enzymes compared to the recombinant CYPs. 
Microsomes obtained from liver has vesicles of the hepatocytes endoplasmic reticulum collected 
from liver preparation such as fresh human liver, liver slices, liver cell lines and primary 
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hepatocytes at specific  differential centrifugation. HLMs do not represent complete in vivo 
situation since only CYP and UGT enzymes are present in HLM (Brendon et al., 2003). 
1.4.4.2 Human liver S9 fractions 
These are subcellular fractions containing drug metabolism enzymes such as CYPs, flavin 
monooxygenases and UDP-glucuronyltransferases. S9 fractions depict a complete representation 
of metabolic profile compare to HLM since they contain both phase I and phase II drug-
metabolism enzymes. However, the enzyme activity is relatively lower than that of HLM 
(Brendon et al., 2003). 
1.4.4.3 Liver slices 
The liver slices have been developed as an in vitro model for assessment of hepatic drug 
metabolism. The tissue slices maintain the cytoarchitecture of the liver which can be easily 
examined when needed. Phase II enzymes, albumin production, and gluconeogenesis have been 
shown to decrease slightly but remain fairly stable for up to 20-96 hours in cultured liver slices 
(Toutain et al., 1998). Major challenges with liver slices include erratic supply of the liver, 
maintenance of slice cultures with quality viability over the study period and the high 
interindividual variability (Thohan and Rosen, 2002).    
1.4.4.4 Primary hepatocytes 
Cultured human hepatocyte is currently the gold standard for studying CYP induction (Lecluyse, 
2001). Availability of tissue is a major concern and restricts the use of human hepatocytes for in 
vitro applications. Furthermore, there is time-dependent decline in the expression of mRNA for 
the major CYPs resulting in reduced enzyme activities. To overcome this flaw, dishes and plates 
for human hepatocytes assays are coated with an extracellular matrix such as Matrigel or 
collagen which is termed as sandwich culturing to mimic physiological condition. Human 
hepatocytes in sandwich culture have cytoarchitecture similar to that found in vivo. 
 
1.4.4.5 Cell lines 
Fa2N-4, a non-tumorigenic hepatic cell line, is the most utilized cell system by the 
pharmaceutical industry (Sinz et al., 2008). It shows inducible CYP1A1/2, CYP3A4, CYP2C9, 
UGT1A and MDR1 mRNA expression, as well as increased enzymatic activity of CYP1A2, 
CYP2C9 and CYP3A4 when treated with prototypical inducers. Fa2N-4 is however flawed with 
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low basal enzyme activity; hence sensitive analytical methods are required to measure enzyme 
activity. Because of the low basal enzyme activity, mRNA detection is often used as an end point 
when using this cell line. 
Human hepatoma cell lines such as HepG2, HepaRG and BC2 have been employed for induction 
studies. HepaRG and HepG2 cells have been shown to respond differently to CYP1A1/2 and 
3A4 inducers whilst BC2 cells have been reported to respond to CYP1A inducers (Aninat et al., 
2006; Guillouzo et al., 2007). These cell lines however do not maintain the complete phenotypic 
characteristics of human hepatocytes including enzyme, receptor function or expression. 
1.4.4.6 Reporter gene 
 In the reporter gene assay, plasmids containing elements of the target gene promoter of interest 
fused into the reporter gene expression vector is transiently or stably transfected into cell lines. 
HepG2 cell line transfected with two plasmids containing 5’-regulatory elements (PCR5) of 
CYP3A4 linked to a gene expressing luciferase and PXR expression vector is used for the 
assessment of PXR activation or CYP3A4 induction in most research laboratories (Sinz et al., 
2006). The cells are treated with the test samples and PXR activation or CYP3A4 induction 
measure using luciferase activity as depicted in Figure 1.7 above. Cells used in reporter gene 
assays are easy to maintain, and the luciferase measurement applicably for high throughput 
screenings. However, the levels of target genes and receptor expression are not at physiological 
levels and the cell lines may not contain all the regulatory factors present in hepatocytes. Hence 
reporter gene assays are used only for screening purposes to flag compounds as potential 
inducers. 
1.4.4.7 Transgenic/Chimeric animals 
Humanized nuclear receptor transgenic mice, knock out mice and chimeric mice with human 
transplanted hepatocytes have emerged as useful models for investigating the regulation of drug 
metabolizing enzymes by potential drug candidates. These in vivo models provide an advantage 
over the above-mentioned in vitro models. Transgenic animals have dynamic systems where 
drug absorption, distribution, metabolism, and elimination occur simultaneously. Animals can be 
administered with drug candidates at doses equivalent to those expected in human plasma to 
improve assessment of induction or inhibition potential of such drugs. The major flaw with the 
transgenic/knock out systems are that only single or double genes are “humanized” and the 
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cross-talk between nuclear receptors/enzymes/transporters may be compromised as the human 
and mouse systems may or may not be working in a similar fashion (Sinz et al., 2008).  
 
1.5 Drug transporters 
Drug transporters play key part in drug disposition, efficacy and adverse effects. Studies 
resulting to clinically significant DDIs and HDIs have suggested that transporters work together 
with drug metabolizing enzymes in drug disposition and elimination. Uptake and efflux 
transporters are localized at both the apical side and basolateral membranes of the intestinal 
enterocytes. Efflux transporters commonly expressed in the intestinal membranes include P-
glycoprotein (P-gp), multidrug resistance proteins (MRP 1–6), and breast cancer resistance 
protein (BCRP). These are members of the ATP-binding cassette (ABC) transport proteins which 
utilise ATP as energy source to transport substrates against a concentration gradient 
 
from the 
cytoplasm of intestinal cells back to the intestinal lumen or to the blood (Ho and Kim, 2005; 
Oostendorp et al., 2009; Shugarts et al., 2009).  
Primary active efflux transporters notably P-gp, MRP2, and BCRP are well expressed on 
brushborder apical membrane of the enterocytes and reported to form major hindrance to 
intestinal absorption of drugs (Chan et al., 2004; Yu et al., 2007). These have the tendency to 
reduce oral bioavailability of specific drugs by expulsion from the enterocytes into intestinal 
lumen.  P-gp is a well-recognized efflux transporter which influences absorption and excretion of 
several drugs due to its wider range of substrate specificity (Troutman et al., 2001). BCRP is 
capable to extrude glucuronides and sulphate conjugates formed in the enterocytes into the 
lumen, although its main function relates to excretion of drugs and xenobiotics into breast milk 
and a defensive role at the placental barrier (Adachi et al., 2005). MRP2 plays an important role 
in detoxification of drug and xenobiotics which have undergone phase II metabolism to facilitate 
excretion (Russel et al., 2002). Unlike efflux transporters, apical membrane uptake transporters 
increase absorption of drugs from the lumen into the enterocytes (Kullak-Ublick et al., 2001). 
Finally, receptor mediated endocytosis can also play a role in drug absorption. 
 
Uptake transporters e.g., peptide transporter (PEPT), organic anion transporter (OAT), organic 
anion transporting polypeptide (OATP), organic cation transporter (OCT) are members of solute 
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carrier (SLC and SLCO) superfamilies and function independent of ATP but rather transport 
drugs according to their concentration gradient (Figure 1.8).  
 
 
Figure 1.8 Localization of ABC and SLC transporters in human small intestine (adapted from 
Artursson, 1991; Awortwe et al., 2014a).  
The various abbreviations represent: BCRP (breast cancer reistance protein); Pgp (p-
glycoprotein); MRP (multi-drug resistance associated proteins); MCT (monocarboxylate 
transporters); PEPT (peptide transporters); OATP (organic anion-transporting polypeptide); OCT 
(organic cation transporter); OCTN (organic zwitterions/cation transporters); CNT (concentrative 
nucleoside transporter); ENT (equilibrative nucleoside transporter); and ASBT (apical sodium 
dependent bile acid transporters). 
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1.5.1 In vitro models for evaluation of P-glycoprotein  
1.5.1.1 Caco - 2 cell line 
The Caco - 2 cell line is the most common and extensively characterized cell-based model for the 
assessment of absorption of drugs via the intestinal membrane enterocytes (Artursson, 1991; 
Artursson and Karlsson, 1991; Rubas et al., 1996). It is derived from heterogenous human 
epithelial colorectal adenocarcinoma cells, developed through research by Jorgen Fogh (1975) at 
Sloan-Kettering Institute for Cancer Research (Fogh and Trempe, 1975). The Caco - 2 cells have 
the intrinsic ability to initiate spontaneous differentiation on reaching confluence in the presence 
of normal culture conditions. At confluence, there is progressive development of brush border. 
The surface occupied by each cell gradually reduces from 5 to 20 days post-confluence and 
intimate intercellular junctions are developed. During the same period, the length and density of 
microvilli increase. The Caco - 2 cells form well - developed tight junctions after 21 days of 
culturing. At day - 30 post-confluence, the cell surface reaches minimum with typical 
enterocytes-like morphology. Most cells develop complete brush borders with tall and regular 
microvilli when the full structural polarization is achieved after 30 days (Vachon and Beaulieu, 
1992). The complete polarized Caco - 2 cells resemble human small intestinal mucosa cells 
expressing brush borders, tight junctions and, efflux and uptake transporters at both apical and 
basolateral compartments.  
The Caco - 2 cell lines is considered as a good model which mimics the intestinal biochemical 
barrier due to expression of membrane efflux proteins (P-gp, MRP 1-3), CYP isoenzymes and 
phase II conjugating enzymes such as sulfotransferase, UDP-glucuronyltransferase, glutathione 
S-transferase (Prueksaritanont et al., 1996; Hunter and Hirst, 1997). Table 1.3 summarizes the 
characteristics of a parental Caco - 2 cell line. Permeability of substrate via the Caco - 2 cell 
monolayer has proven to correlate closely with oral absorption in humans compared with other 
parental cell-based models. Currently, Caco - 2 monolayers are applied for screening the 
potential effects of herbs and new chemical entities (NCE) on absorption of drugs. 
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Table 1.3 Characteristics of Caco-2 cell line 
Parameter  Description  
Origin Human colorectal adenocarcinoma 
Growth in culture Monolayer epithelial cells 
Differentiation 14-21 days after confluence in standard culture 
medium 
Morphology Polarized cells, with tight junctions, apical 
brush border 
Electrical resistance High transepithelial electrical resistance 
(TEER) 
Digestive enzymes Typical membranous peptidases and 
disaccharidases of the small intestine 
 
 
1.5.1.2 MDCK 
The Madin-Darby canine kidney (MDCK) is considered as an alternative to Caco - 2 cells for 
permeability studies. The MDCK cell line is derived from the normal dog kidney. When cultured 
in an appropriate media, MDCK differentiate into columnar epithelial cells with clear tight 
junctions similar to Caco - 2 formed within on a semi-permeable membrane. The differentiated 
MDCK cell maintains characteristics of kidney epithelial cells such as asymmetric distribution of 
enzymes and vectorial transport of sodium and water from the apical to the basolateral 
membrane 
 
(Balcarova-Stander et al., 1984). The MDCK has a shorter cultivation period (3 - 5 
days) compared to 21 days of Caco - 2 cell lines. Furthermore, the transepithelial electrical 
resistance (TEER) of MDCK cells is lower and closer to that of small intestine compared to Caco 
- 2 cells. This often results in a higher permeability coefficient of hydrophilic compounds in 
MDCK cells than Caco - 2 cells. The shorter culture duration is advantageous since it reduces 
cost, time, and enhances high throughput. The MDCK cell line appears to be more robust and 
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need less rigorous nutritional schedule over a short incubation period relative to Caco - 2 cells. 
However, these cells are derived from dog kidney and therefore there is a high propensity of 
differences in the expression levels of some transporters and metabolic activity as compared to 
Caco - 2 cells 
 
(Braun et al., 2000).  
1.5.1.3 LLC-PK1 
LLC-PK1 cells derived from pig kidney epithelial have been employed as an alternative model to 
Caco - 2 cells for assessing permeability of test compounds. Studies have reported the use of 
LLC-PK1 for characterization of passive absorption of test compounds (Thwaites et al., 1993; Li 
et al., 2002; Adachi et al., 2003). LLC-PK1 stably transfected with P-gp/MDR1 has been 
reported as an important model for studying bidirectional transport of compounds.  
 
1.6 Evidence of herbal medicines interactions with antiretrovirals drugs 
Several pharmacokinetic ARV-herb interactions and case studies have been reported. These have 
been summarised in Tables 1.4a and 1.4b.  
St. Johns wort (SJW) is widely used for the management of clinical depression, which is a 
common co-morbidity associated with HIV/AIDS. Clinically pharmacokinetic drug interaction 
study between indinavir and SJW was conducted to determine the effect of 2-week regimen of 
SJW on the AUC0-8 and the concentration 8 h post-dose (C8) of indinavir, at steady state using 
crossover study design involving eight healthy subjects (Piscitelli et al., 2000). The result 
showed significant reduction in the systemic exposure of indinavir in the presence of SJW. 
However, since this was a crossover study, it is unknown what influence duration had on the 
effect observed.  Additionally, in vitro studies indicated that SJW or its major component, 
hyperforin, has a dual effect on CYP3A4 as a potent inducer and inhibitor which is the primary 
enzyme for the metabolism of indinavir (Krusekopf et al., 2003; Lee et al., 2006). In 2001, a 
case study in five HIV/AIDs patients who were concurrently taken nevirapine and SJW was 
reported. The study showed that plasma concentrations of nevirapine in patients taking SJW 
were lower than those who took only nevirapine (de Maat et al., 2001).  
Garlic (Allium sativum) supplements are ranked among top ten best patronized herbal products 
worldwide with confounding reported incidence of garlic-drug interactions (Bianchini and 
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Vainio, 2001). Extracts from garlic are commonly used in HIV-infected patients to fight 
opportunistic infections and improve health due to its antihyperlipidemic, antioxidant and 
antimicrobial activities (Standish et al., 2001). A case study in two HIV-infected patients on 
ritonavir showed severe gastrointestinal toxicity after administration of garlic supplement for 
over two weeks (Tattelman, 2005). The symptoms re-occurred when patients were given low-
dose of ritonavir. This result suggested dose independent interaction between garlic and 
ritonavir, through inhibition of CYP3A4 and induction of P-gp.  In another study, 2 × 5 mg daily 
intake of garlic showed reduction in plasma concentration of ritonavir after day-4 (Foster et al., 
2001).  
A population pharmacokinetic study using allicin, an isolated phytochemical compound from 
garlic also showed a reduction in plasma levels of saquinavir (Piscitelli et al., 2002a). 
Interestingly, an in vitro study of saquinavir as a probe substrate induced expression of P-gp 
(Dupuis et al., 2003). Therefore, the reduced plasma levels of saquinavir reported previously was 
attributed to auto-induction of P-gp by saquinavir.  Other HDI studies on garlic oil using 
midazolam and alprazolam as probe substrates for CYP3A4/5, showed no changes in the 
metabolism of either probe substrates (Gurley et al., 2005).   
The hepatoprotective effect of Silybum marianum renders its useful in HIV-infected patients for 
management of possible hepatotoxicity associated with some ARVs (Cohen et al., 2001). 
Independent studies conducted in human subjects on indinavir and milk thistle showed non-
significant effects of the herb on pharmacokinetic parameters of the PI (Dicenzo et al., 2003). 
This result agreed with an earlier in vitro study which showed that; therapeutic dose of milk 
thistle has no effect on inhibition or induction of both CYP3A4 and P-gp (Doehmer et al., 2005). 
However, caution must be exercised towards the use of such herbal products with non-significant 
interactions on monotherapeutic ARVs since the current treatment of HIV-infected patients 
employs combination therapy.  
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Table 1.4a Case reports on ARVs and herb drug interactions  
Medicinal plants Concomitant ARV  Sample size  Possible Mode 
 of interactions 
Clinical outcome  References  
Cat’s claw 
Uncaria tomentosa 
atazanavir, ritonavir 
and saquinavir 
45 year old woman 
with cirrhosis 
Inhibition of CYP3A4 ↑ Cmin (serum 
trough 
concentration) 
 Lopez 
Galera et 
al., 2008 
St. John’s wort 
Hypericum 
perforatum 
Lamivudine 1 HIV-infected patient unknown Increased HIV RNA 
viral load 
Zhou et al., 
2007 
St. John’s wort 
Hypericum 
perforatum 
Nevirapine 5 HIV-infected patients Induction of CYP3A4 ↑CL/F De Maat et 
al., 2001  
Garlic 
Allium sativum 
Ritonavir 2 HIV-infected patients 
 
Inhibition of CYP3A4 
or Pgp 
 
Severe GI Toxicity 
 
Laroche et 
al., 1998 
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Garlic 
 
Ritonavir 10 HIV seronegative  Non-significant 
CYP3A4/P-gp 
inhibition 
 
↓AUC by 17%, 
↓ Cmax, by -1% 
Gallicano et 
al., 2003 
 Saquinavir 10 healthy volunteers Induction of CYP3A4 
& Pgp 
↓AUC by 51%, ↓C8h 
by 49%, ↓Cmax by 
54% 
 Piscitelli et 
al., 2002 
St. John’s wort 
 
Indinavir 8 HIV seronegative  CYP3A4 induction ↓ AUC by 57%, ↓C 
trough by 81% 
 Piscitelli et 
al., 2000 
Milk thistle Indinavir 10 HIV-infected patients Modulation of 
CYP3A4 and P-gp 
↓AUC by 9%, 
↓trough level (C8h) 
by 25% 
 Piscitelli et 
al., 2002 
 darunavir-
ritonavir 
15 HIV-infected patients NA ↓Cmax and AUC0-12 by 
15% 
Molto et al., 
2012 
Ginkgo  Lopinavir/ ritonavir 14 healthy volunteers NA Cmax and AUC0-12 Robertson 
et al., 2008 
Goldenseal  Indinavir 10 healthy volunteers,  CYP3A4 inhibition ↑Cmax by 7% , ↓ 
 CL/F by 7% 
Sandhu et 
al., 2003 
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Table 1.4b: In vitro screening of herbs for effect on CYP3A4, P-gp and PXR 
 
Medicinal plants Effect on CYPs  Effect on P-gp  Effect on PXR References  
Catharanthus 
roseus 
Inhibits of CYP2D6 and 
CYP3A4 in HLM 
Not determined Not determined  Usia et al., 2005 
Hypoxis 
hemerocallidea 
Inhibits CYP3A4, 3A5 and 
2C19 in CYP transfected 
microsomes 
Inducers in 
Caco-2 
Inducer in HepG2 Nair et al., 2007 
Lessertia frutescens Inhibits CYP3A4 in CYP-
transfected microsomes 
Inhibitor in P-
gp transfected 
membranes 
Inducer in HepG2 
transfected PXR 
Mills et al., 2005 
Hypoxis obtusa Inhibits CYP1A2, 2C9, 
2C19, 2D6 and 3A4 in 
recombinant CYPs 
No effect in 
Caco-2 
 
Not determined 
 
Gwaza et al., 2009 
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1.7 Selected herbal products use by HIV/AIDS patients  
 
The herb-drug interaction Unit of the Division of Clinical Pharmacology, Stellenbosch 
University in collaboration with HOPE Cape Town invited two traditional health practitioners 
(THPs) who practice in the Mfuleni and Delft communities in Cape Town, Western Cape 
Province. The two THPs identified Hypoxis hemerocallidea and Lessertia frutescens as popular 
herbs patronised by their clients. Exotic herbal products such as Moringa oleifera, Echinacea 
purpurea, Taraxacum officinale, Kalanchoe crenata and Kalanchoe integra were identified 
through the help of THPs who own herbal products shops in Bellville, Cape Town and Harare 
Zimbabwe. All the plants were purported to be taken orally for management of HIV/AIDS and 
its related co-morbidities. Fresh samples of Lessertia frutescens, Moringa oleifera, Echinacea 
purpurea and Kalanchoe crenata were obtained from the repository of the National Centre for 
Natural Products Research (NCNPR), University of Mississippi, Oxford, USA. Specimens of 
each sample with voucher numbers are available at the NCNPR.  Capsules and powdered roots 
of Hypoxis hemerocallidea, and roots of Taraxacum officinale with certificate of identification 
and batch numbers were sourced from Medico Herbs, Somerset West, Western Cape. Tablets of 
Lessertia frutescens were obtained from Pyto Nova Natural Medicines, Kwazulu Natal. The 
capsules of Echinacea purpurea were sourced from Herbal Soultions, Harare, Zimbabwe.  
 
1.7.1 Moringa oleifera 
It is the most cultivated species of the monogeneric family Moringaceae (Ramachandran et al., 
1980). Moringa oleifera is widely distributed in sub-Himalayan ranges of Arabia, India, 
Maadagascar, North East and South Western Africa and Sri Lanka (Fahey, 2005). The plant is 
known as the ‘drumstick tree’ or the ‘horse radish tree’ in some part of the world whilst others 
referred to it as the kelor tree (Anwar and Bhanger, 2003).  In the Nile valley M. oleifera is 
popular known as “Shagara al Rauwaq’ which means ‘tree for purifying’ (Anwar et al., 2007). In 
Ghana, M. oleifera is referred to as the ‘miraculous tree’. 
Moringa oleifera has had enormous attention as the natural nutrition of the tropics. Special 
websites and radio programs have been dedicated to promoting the sale of Moringa in certain 
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part of West Africa (http://www.africamoringa.co.za, http://www.moringasource.com, 
http://miracletrees.org). Many countries use the various parts of M. oleifera as a nutritional 
vegetable particularly in India, Pakistan, Philippines, Hawaii and several African countries 
(Anwar 2003). The leaves have been documented to be a rich source of β-carotene, protein, 
vitamin C, calcium and potassium which are purported to stimulate immune system in 
HIV/AIDS patients. It is also used as preservative to improve shelf-life of fat containing foods 
due to high contents of natural antioxidant such as ascorbic acid, flavonoids, phenolic acid and 
carotenoids (Siddhuraju and Becker, 2003).  A cross-sectional study conducted in HIV/AIDS 
patients attending a referral hospital in Harare, the capital city of Zimbabwe, indicated that 68% 
of the participants reported taken M. oleifera while on various ARVs (Monera et al., 2012).  The 
study participants attributed the use of M. oleifera to its immune boosting effect. In a similar 
study carried out at the Family Care Centre antiretroviral therapy clinic in Harare, Zimbabwe, M. 
Oleifera was reported as a common herbal medicine consumed by HIV-infected patients 
(Mudzviti et al., 2012). 
Each part of the plant has been used for treatment of many diseases in the folkloric medicine 
including cardiovascular, gastrointestinal, hematological and hepatorenal disorders. The leaf 
juice of M.oleifera is known to exhibit stabilizing effect on blood pressure (Dahot, 1988). 
Aqueous infusion of the roots, leaves, flowers, and seed have been documented to possess 
diuretic activity (Caceres et al., 1992). Experiments done in a rat model showed that methanolic 
extract of Moringa leaves has antiulcerogenic and hepatoprotective effects (Pal et al., 1995).   
Preliminary study on aqueous and methanolic extracts of M. oleifera leaves indicated a strong 
inhibitory effect on CYP3A4 (Menora et al., 2008). However, the study was based on reversible 
inhibition of CYP3A4 in HLM using testosterone as a probe substrate. HIV/AIDS patients often 
consume M. oleifera for chronic purposes; hence TDI investigation is required to ascertain the 
effect of prolonged use of the herb on CYP3A4 activity in both HLM and hepatocytes. 
Additionally, pharmacokinetic studies conducted in Swiss albino mice indicated that M. oleifera 
increased plasma concentration of rifampicin when administered concurrently (Pal et al., 2011).  
Therefore in vitro systems such as recombinant CYPs, HLM and human hepatocytes which are 
widely recommended for HDI studies will be employed to further investigate the effect 
inhibitory effect of M. oleifera on CYP3A4. 
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1.7.2 Kalanchoe crenata  
Kalanchoe crenata is a freshly herbaceous plant belonging to the family of Crassulaceae also 
known as the Bryophyllum. It is commonly known as “never die” or “dog’s liver”. Though K. 
crenata originated from Madagascar, it is now found in many tropical regions of Africa 
(Adjanohoun et al., 1996). Traditional health practitioners (THPs) extensively use K. crenata for 
treatment of several diseases. Juice from fresh leaves is employed to treat asthma, headache, 
convulsion, abdominal pain and smallpox.  In West Province of Cameroon, the juice is widely 
used by THPs to treat diabetes mellitus (Kamgang et al., 2008).  The use of K. crenata as 
antidiabetic herbal product in HIV/AIDS patients has been attributed to an increased in blood 
sugar levels reported as an adverse effect associated with the comsumption of some ARVs.  
Anecdotal cases of transient insulin-dependent diabetes mellitus have been reported in patients 
on didanosine (Garcia-Benayas et al., 2006). Thus, K. crenata may affect the metabolism of such 
ARVs when administered concurrently. However, no study has been reported on the potential of 
K. crenata to interact with drugs. 
 
1.7.3 Kalanchoe integra 
Kalanchoe integra belongs to the family "Crassulaceae" and is widely used in folklore medicine 
for cerebrovascular disorders, especially stroke (Dokosi, 1998). Species can be found in tropical 
and subtropical countries and is mostly referred to as the "life-plant" (Boyle, 1995). HIV 
infection can result to stroke through several mechanisms, including opportunistic infection, 
vasculopathy, cardioembolism, and coagulopathy (Benjamin et al., 2012). K.integra is also 
reported to be effective in the management of depression. Anecdoctal reports have indicated the 
use of K. integra in HIV/AIDS patients. This may be attributed to the benefits of K. integra in 
the management of cerebrovascular disorders and depression which are co-mordities associated 
with HIV/AIDS. However, no study on the potential of K. integra to cause HDI has been 
documented. 
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1.7.4 Lessertia frutescens 
Lessertia frutescens, popularly known as Cancer bush (Sutherlandia) has been used as part of 
traditional medicine system in South Africa for many years. It is widely consumed by HIV-
infected patients in South Africa as an immune booster and to improve well-being (Gericke 
2001). Concoctions of L. frutescens are used for the treatment of diseases such as diabetes, 
rheumatoid arthritis and gastrointestinal disorders (van Wyk et al., 2008). Tablets of L. 
frutescens are sold in several Pharmacy shops and Supermarkets in South Africa as an 
adaptogenic tonic to stimulate appetite and to counteract the muscular dystrophy in HIV/AIDS 
patients. A study on phytochemical constituents of L. frutescens showed that neither the plant nor 
its constituents inhibited atazanavir transport and metabolism in Caco-2 cell lines and HLM, 
respectively (Muller et al., 2012). However, this study failed to isolate individual triterpenoids 
(Sutherlandioside A-D) and quercetin glycoside (suthelandin A-D) constituents of L. frutescens.  
Extensive in vitro studies conducted to investigate the influence of crude methanol extract of L. 
frutescens on the 5 major CYPs activities also did not incorporate the isolated compounds 
(Fasinu et al., 2012). Another study conducted in rats indicated that chronic administration of L. 
frutescens reduced AUC and Cmax values of nevirapine significantly (Minocha et al., 2011). The 
current study, therefore takes into an account the reversible and irreversible inhibitory effects of 
sutherlandioside A-D and sutherlandin A-D on metabolic activities of the 5 major CYPs. 
 
1.7.5 Hypoxis hemerocallidea 
Hypoxis hemerocallidea is widely distributed in the southern Africa sub-region. The corm of the 
plant is commonly referred to as ‘African potato’ due to its potato-like shape. African potato 
extracts, powders, infusions and decoctions have been used for centuries as traditional medicine 
for treatment and management of cancer, immune-related diseases, urinary tract infections and 
heart weaknesses (Singh, 1999). In Swaziland, Hypoxis is popularly known as “zifozonke” 
referring to its application for treatment of diverse diseases (Amusan et al., 2007). Folkloric 
reports have documented the use of Hypoxis for treatment of prostate hyperplasia (Singh, 1999). 
Scientific investigations into immunostimulant properties of Hypoxis have gain attention in both 
academia and research laboratories in South Africa due to the purported benefit in HIV-infected 
patients. Hypoxis tablets and plant materials are available as supplements for immune-related 
illness such as cold, flu and arthritis in the pharmacy shops and mushroom stores (Mill et al., 
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2005). A prospective study to access HIV patients’ use of traditional, complementary and 
alternative medicines (TCAM) and its effect on ARV adherence at three public hospitals in 
Kwazulu-Natal, South Africa, implicated H. hemerocallidea as a major herb consumed by these 
patients prior to the introduction of ARV (Peltzer et al., 2011). However, there is no clinical or 
experimental evidence to support its immunostimulant claim.  
Substantial numbers of studies on the influence of H. hermerocallidea on in vitro metabolism of 
probe substrates of CYPs and antiretroviral drugs have been conducted (Brown et al., 2008; 
Mogatle et al., 2008). Study conducted by Fasinu et al., (2013) implicated H. hemerocallidea as 
mild inhibitor of major CYPs, OATP1B1 and OATP1B3. Also, investigation employing pure 
compounds of H. hemerocallidea implicated stigmasterol and norlignans as inhibitors of 
CYP3A4/5 and CYP2C19 mediated metabolism (Nair et al., 2007). However, with introduction 
of different formulations of this plant material into the market, there is likelihood of variations in 
the strength of inhibitory effect on the activities of the CYPs. Such effect may produce different 
levels of systemic toxicity or inefficacy when administered together with ARVs. Also, the effect 
of H. hemerocallidea in HIV/AIDS patients on both ARVs and anti-tuberculosis medications 
like rifampicin is unknown. Hence capsules and roots of H. hemerocallidea have been included 
in this study to investigate their effects on CYPs and HepG2 transfected PXR treated with 
rifampicin.  
 
1.7.6 Echinacea purpurea 
Echinacea species are examples of herbal products with an overwhelming popularity in both 
developed and developing countries. Echinacea preparations are ranked as one of the important 
herbal medications used globally for the management of upper respiratory infections, influenza 
and common cold. In the United States, the sale of Echinacea is ranked number 2 with its sale 
reaching above $36 million in the year 2006 (SPINS, 2007). Though there are nine different 
species of Echinacea, most preparations are made from three namely Echinacea purpurea, 
Echinacea angustifolia and Echnacea pallida. Liquid extracts, capsules, tablets, dried roots, 
creams, gels and teas are commercially available in both pharmacy shops and mushroom stores 
as over-the-counter preparations. It is however estimated that about 80% of Echinacea products 
currently in the markets are prepared from E. purpurea (Li, 1998). In HIV-infected patients, E. 
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purpurea preparations are predominantly consumed for its immunomodulatory and antiviral 
properties (Behm et al., 2004). The practice of E. purpurea consumption for its purported benefit 
is gaining popularity in HIV-patients resident in some sub-Saharan African countries. 
In vivo study in fifteen HIV-infected patients on boosted protease inhibitor darunavir-ritonavir 
showed that concurrent consumption of E. purpurea together with the ARV is safe (Moltó et al., 
2011). Another study on the inhibitory effect of E. purpurea employing fluorescent probe 
substrates implicated the plant material as mild inhibitor of CYP3A4 (Yale and Glurich, 2005). 
However, comparative in vitro studies on E. purpurea indicated lower inhibitory effect on 
CYP3A4 when testosterone was used as probe substrate compared to the fluorescent substrates 
benzyloxy-trifluoromethylcoumarin (BFC) and 7-benzyloxyquinoline (BQ) (Hansen and Nilsen, 
2008). Although E. purpurea demonstrated weak inhibitory effect on CYP3A4 activity, only 
human recombinant CYP3A4 was investigated. The metabolic clearance of testosterone might be 
affected by transcellular diffusion and presence of other drug metabolizing enzymes in human 
hepatoytes. This study therefore employs hepatocytes in addition to HLM to investigate the 
effect of E. purpurea on metabolic clearance of testosterone.  
E. purpurea has been reported in both in vitro and   in vivo studies as an inducer of CYP3A4 
(Gorski et al., 2004; Mrozikiewicz et al., 2010; Penzak et al., 2010; Modarai et al., 2011). 
However, the underlying mechanism for CYP3A4 induction remains unclear. The PXR has been 
implicated as the nuclear receptor gene responsible for induction of CYP3A4 (Meijerman et al., 
2006). The current study will attempt to investigate the underlying mechanism for CYP3A4-
mediated induction by E. purpurea in HepG2 transfected with human PXR.   
 
1.7.7 Taraxacum officinale 
 Taraxacum officinale is an herbaceous perennial plant. A first reference to its application is 
reflected in its name, which is derived from the Greek words “taraxis” for inflammation and 
“akeomai” for curative. In English speaking countries, T. officinale is commonly known as 
dandelion, from the French word - dent-de-lion. This refers to the serrated leaves of the plant 
(Schütz et al., 2005). The first evidence for its therapeutic use by Arabian physicians‘dates back 
10 and 11th centuries for treatment of liver and spleen ailments (Sweeney et al., 2005). The 
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German physician and botanist Leonhard Fuchs (1543) described its use, among others, to 
medicate gout, diarrhoea, blister, spleen and liver complaints. In North American aboriginal 
medicine, infusions and decoctions of the root and herb were applied to remedy kidney disease, 
dyspepsia and heart-burn (Sweeney et al., 2005). Other folklore uses of the plant include 
arthritis, eczema, diabetes mellitus and bronchitis. Drug-induced diabetes associated with 
didanosine in HIV/AIDS paitents might account for the use of T. officinale by these patients 
(Garcia-Benayas et al., 2006). Also, diarrhoea is a major opportunistic co-morbidity in 
HIV/AIDS patients due to increase availability of enteric parasites (Kulkarni et al., 2009). Thus, 
the use of T. officinale in such immunocompromised patients may be attributed to its potential to 
reduce diarrhoea. An in vitro investigation to determine the anti-viral property of T. officinale 
aqueous extract indicated potent inhibitory effect against HIV-1 replication and reverse 
transcriptase activity (Han et al., 2011). In traditional Chinese medicines, T. officinale extract is 
added to herbal preparations to boost immune system in immunocompromised patients. A study 
conducted in Wistar rats indicated that T. officinale inhibits CYP3A4 (Maliakal and 
Wanwimolruk, 2001). However, the effect of T. officinale on other intestinal CYPs and P-
glycoprotein is unknown.  
 
1.8 Justification of study 
The consumption of herbal medicines has become popular in most developed and developing 
countries. These medicines are well distributed throughout several outlets including pharmacy 
shops, chemical sellers and even at the local markets. Advertisement of herbal medicines 
frequently stream on the internet with attractive purported pharmacological effects convincing 
patients to patronize them. Majority of such medicines are used for the treatments and 
managements of chronic diseases such as diabetes, hypertension, migraine and sexual impotence. 
The use of herbal medicines among HIV/AIDS patients has received attention in the clinics and 
research institutions as their potential to cause inefficacy and/or systemic toxicity can be 
detrimental to the patient. Surveys and clinical studies have indicated that a significant 
proportion of HIV/AIDs patients acquire herbal medicines purported to have antiviral properties 
and to ameliorate idiosyncratic ADRs associated with some of the antiretrovirals. Such practice 
might lead to potential interactions between the antiretroviral drugs and the active ingredients of 
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the herbal medicines, further endangering the health of these patients. Unlike herbal medicines 
found in Westernized countries with extensive information on their potential to cause HDIs, 
safety information for most herbal medicines in sub-Saharan Africa is scanty.  
In most pharmaceutical companies, the in vitro methods employed in this study are routinely 
used at drug discovery and development processes to screen new chemical entities with the 
potential to cause drug interactions (Figure 1.9). Early screening process using this approach 
facilitates attrition of drugs and prevents postmarket withdrawal of medications with DDI 
potential. For herbal medications already being used by consumers, such in vitro investigations 
are conducted by pharmaceutical companies and other dedicated laboratories to highlight the 
likely risk associated with these medications once concurrently used with orthodox drugs. 
Studies of this nature offer the possibility of drug re-labeling or insertion of blackbox warning as 
reported in the case of SJW and indinavir and further serves as the basis for justification of 
studies in healthy subjects during ethics approval.  
This study aims to investigate the likely risk of drug interactions between popular herbal 
medicines used by HIV/AIDS patients and probe substrates of CYPs and P-glycoproteins using 
in vitro models, and to further make an in vivo-in vitro estimation. CYPs and P-gp play a critical 
role in the metabolism and absorption of antiretroviral drugs. The CYP3A4 and CYP2B6 are 
responsible for the metabolism of efavirenz and nevirapine. Efavirenz also inhibits CYP2C9 and 
2C19 to a less extent.  The protease inhibitors (PIs) are substrates primarily for CYP3A4. For 
example ritonavir is known as the most potent inhibitor whilst lopinavir and tipranavir are 
inducers of CYP3A4. A case study reported HIV RNA resistance to indinavir and lamivudine in 
a patient using SJW, a potential cause of therapeutic failure (Chiba et al., 1996). Also drugs such 
as amitriptyline, acetaminophen and diazepam metabolized by CYP1A2 are used for the 
management of peripheral neuropathy in HIV/AIDS patients. 
Most herbal medicines are consumed orally. The GIT conditions such as the low pH (pH 1-4), 
intestinal motility and the barrier influence the physico-chemical properties and absorption of an 
administered drug. The routine HDI studies in vitro introduce the herbal medicines or the active 
ingredients directly unto the CYPs. Such approach might lead to false positives and negatives 
predictions. Hence, introduction of absorption models in the prediction of HDI might increase 
the accuracy of such predictions. 
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Parallel artificial membrane permeability assay (PAMPA) is an absorption model employed in 
most pharmaceutical and research laboratories to monitor the passive permeability properties of 
new candidate drugs. Such parameters help medicinal chemist and the pharmacologist to make 
necessary modification to the functional groups of a drug candidate, improving its permeation 
through the intestinal membrane and also enhance the intrinsic activity. Herbal medicines 
contain several active ingredients with some likely to be impermeable via the intestinal 
membrane barrier. Though passive and active permeation regulate the absorption of herbal 
medicines through the intestinal membrane, the use of PAMPA as a passive permeability model 
to monitor the inhibitory effects of herbal medicines on CYPs activity will reduce the 
underestimation or overestimation of HDI observed in the conventional approach. Thus 
integration of PAMPA into CYPs screening assays in this study offers a paradigm shift in the 
conduct of HDI, reducing the tendency for false positive and negative predictions. 
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Figure 1.9 Timing of in vitro metabolism studies during drug discovery and development 
(adapted from Wienkers and Heath, 2005) 
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1.9 Aim of the thesis 
The primary aim of the thesis was to apply the in vitro models used in DDI studies to investigate 
interactions of selected herbal medicines with conventional probe substrates of the five major 
drug metabolizing enzymes and P-glycoproteins. 
The specific aims were to: 
1. investigate inhibition of CYPs and P-glycoprotein by herbal medicines namely; Moringa 
oleifera, Kalanchoe integra, Kalanchoe crenata, Echinacea purpurea, Lessertia 
frutescens, Hypoxis hemercallidea and Taraxacum officinale in recombinant CYPs, 
HLM, hepatocytes and MDCKII-MDR1 cells. 
2. rank the potential risk of each herb to cause HDI employing FDA draft guideline for DDI 
(2012)  
3. investigate the degree of inhibition of CYP by the above mentioned herbal medicines 
after permeation through PAMPA. 
4. investigate the modulation of PXR and regulation of CYP3A4, CYP1A2 and P-gp genes 
in activated PXR by the selected herbal medicines. 
 
1.10 Ethical consideration 
This study was approved by the University of Stellenbosch Health Research Ethics Committee 
with Ethics Reference number S12/09/249 (Apeendix 2). 
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CHAPTER TWO 
 
2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1 Chemicals 
3-Cyano- 7-ethoxycoumarin, sulfaphenazole, ketoconazole, quinidine, troleandomycin, caffeine 
and NADPH were obtained from Sigma-Aldrich (St. Louis, MO). 7-Benzyloxy-4-
trifluoromethylcoumarin, 7-methoxy-4-trifluoromethylcoumarin, and 7-methoxy-4-
aminomethylcoumarin and PAMPA were obtained from BD Gentest (Woburn, MA). Cimetidine 
was obtained from Research Institute of Smithkline and French Laboratories Ltd. 
Tranylcypromine, ketoconazole and 0.5M potassium phosphate buffer (pH 7.4) were from BD 
Gentest (Woburn, MA, USA). Troleandomycin was from Santa Cruz Biotechnology, Inc. 
(Dallas, TX, USA). Testosterone, 6β-hydroxytestosterone, magnesium chloride, and 
corticosterone were from Sigma-Aldrich (St Louis, MO, USA). NADPH regeneration solution A 
and B were purchased from Corning Discovery Labware (Woburn, MA, USA). HPLC grade 
acetonitrile, methanol and formic acid were from Fisher Scientific (Waltham, MA, USA). Solid 
Phase Extraction (SPE) cartridges (silica gel 10 g/60 mL, code 57134) were purchased from 
Supelco (Bellefonte, PA, USA). Organic solvents (chloroform and methanol) were purchased 
from Fisher Scientific (Fair Lawn, NJ, USA). CellTiter 96® AQueous One Solution Reagent 
containing tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS and an electron coupling reagent (phenazine 
ethosulfate; PES) were obtained from Promega, Wisconsin, USA. 
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2.1.2 Biologicals 
2.1.2.1 Drug metabolizing enzymes 
Bactosomes prepared from Escherichia coli cells coexpressing recombinant human NADPH- 
P450 reductase and individual human P450s (CYP1A2, 2C9, 2C19, 2D6 and 3A4) were 
purchased from BD Gentest (Woburn, MA, USA). Mixed gender pooled human liver 
microsomes prepared from 25 donors with protein concentration (20-26 mg/mL) and total P450 
concentration (≥0.320 nmol/mg) were obtained from BioreclamationIVT (Baltimore, USA). 
2.1.2.2 Cell cultures 
Pooled, mixed-gender cryopreserved hepatocytes prepared from 20 donors and Hepatozyme 
media were obtained from BD Gentest (Woburn, MA), stored in a liquid nitrogen tank (until 
use), and thawed according to supplier instructions before use. MDCK-II (parental) and hMDR1-
MDCK-II (transfected) cell lines were a gift from Dr. Gottesman (NIH, Bethesda, USA). The 
pSG5-hPXR expression vector was provided generously by Dr. Steven Kliewer (University of 
Texas Southwestern Medical Center, Dallas, TX, USA; Lehmann et al., 1998) and the reporter 
plasmid CYP3A4-PXR response element (PXRE)-LUC (containing the proximal 0/–362 and 
distal 7208/7797 PXRE regions fused upstream of luciferase; Goodwin et al., 1999) was a kind 
gift from Dr. Christopher Liddle (University of Sydney, Westmead, NSW, Australia). 
 
2.1.2.3 Other reagents 
Dulbecco’s Modified Eagle Medium (DMEM-F12), Minimal Essential Medium (MEM), Hanks 
Balanced Salt Solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin and Sodium 
Pyruvate were purchased from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA). Fetal 
bovine serum (FBS) was obtained from Hyclone Lab Inc. (Logan, UT, USA). All plastic-wares 
for mammalian cell culture were purchased from Corning Costar Corp. (Corning, NY, USA). 
Qiagen Rneasy® mini and micro kit were from Qiagen Ltd (Austin, TX, USA). TaqMan® 
Universal PCR Master Mix Reagents, SYBR® Green PCR Master Mix Reagents and TaqMan® 
probes were obtained from Bio-Rad laboratories (Hercules, CA, USA).  
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2.1.3 Herbal medicines and products 
The herbal medicines and products were obtained from traditional medicines suppliers and 
pharmacy shops. A total of seven (7) raw herbal medicines, two capsules and one tablet were 
obtained from different suppliers (Table 2.1).  Taraxacum officinale and Hypoxis hemerocallidea 
sourced from Medico Herbs, Somerset West, Western Cape, were identified and authenticated 
with the assistance of experts in the Compton Herbarium, South African National Biodiversity 
Institute, Cape Town and samples kept at the Division of Clinical Pharmacology, Stellenbosch 
University. The following voucher numbers were assigned to these plant materials: L. frutescens 
(#3222), E. purpurea (#13117), K. crenata (#2865) and M. oleifera (#11695) obtained from the 
repository of the National Centre for Natural Product Research (NCNPR), University of 
Mississippi, USA. Information on the mode of use, dose, and specific HIV/AIDS related 
indications were indicated on the various labels. 
 
2.1.4 Pure compounds of L. frutescens 
Pure compounds of Sutherlandioside B and D, and combination of Sutherlandin A &B, C &D 
from L. frutescens were obtained from Dr. Xing-con Li, National Center for Natural Products 
Research, the University of Mississippi, Mississippi, USA (Figure 2.1A and B).
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Table 2.1 Herbal medicines commonly used by HIV/AIDS patients in Africa. 
Preparation   Manufacturer Plant species   Voucher number Code for sample preparation 
Lessertia (herbal 
powder, tablets) 
Capsule - Phyto nova 
natural medicines 
[KwaZulu Natal, South 
Africa], Herbal powder 
- NCNPR 
Lessertia frutescens 
subspecies microphylla 
(SU1) 
NCNPR 3222 Aqueous: T50 (tablets), T79 
(tea cuts). Methanol: LFT 
(tablet), LFC (tea cut) 
Methanol: 39SF (whole plant), 
LFT (tablets) 
Hypoxis (capsules and 
powdered tubers) 
Medico Herbs [Cape 
Town, South Africa] 
Hypoxis 
hemerocallidea 
-
N
 Aqueous: T41 (capsule), T30 
(powdered leaves). Methanol: 
HHC (capsules), HHL (leaves) 
Dandelion (herbal 
roots) 
Medico Herbs [Cape 
Town, South Africa] 
Taraxacum officinale  -
N
 Aqueous (T66), methanol (TO) 
Echinacea (capsules) 
and whole plant 
Capsule - Herbal 
solutions [Harare, 
Zimbabwe] 
Whole plant - NCNPR 
Echinacea purpurea  
 
NCNPR 13117 
Aqueous: capsule (T60) 
Methanol: EP (whole plant 
material), 2660 (capsules) 
Moringa (powdered 
leaves) 
Herbal solutions 
[Harare, Zimbabwe] 
and NCNPR 
Moringa oleifera NCNPR 11695 Aqueous (2680), Methanol 
(MO) 
Kalanchoe (whole 
plant) 
Whole plant -NCNPR Kalanchoe integra 
Kalanchoe crenata 
-
N
 
NCNPR2865 
Aqueous (T61), Methanol 
(2600). Aqueous (T65), 
Methanol (39KC)  
-
N 
refers to no voucher number for herbs identified by the assistance of experts in the Compton Herbarium, South African National Biodiversity Institute, Cape 
Town. 
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Figure 2.1A Structures of flavonoids in L. frutescens used in this study (adapted from Bharathi 
et al., 2010). 
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Figure 2.1B Structures of saponins in L. frutescens used in this study (adapted from Bharathi et 
al., 2010). 
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2.2 Methods 
2.2.1 Preparation of herbal medicines 
2.2.1.1 Aqueous extraction of herbal medicines 
Powdered plant materials (10.0 g) were extracted with hot water in a round bottom flask. The 
flasks were placed in a water bath at 60 
o
C with constant shaking for 1 hour to mimic the indige-
nous mode of extraction. The mixture was removed from the water bath and allowed to extract 
for 72 hours at room temperature, decanted, and centrifuged at 13000 x g for 5 mins. The super-
natant was filtered (0.45 μm; Whatman International LTD, Maidstone, England) and freeze 
dried. The dried aqueous extracts were put into plastic bottles, labeled as H. hemerocallidea cap-
sule (T41) and powdered leaves (T30), L. frutescens tablets (T50) and tea cut (T79), T. officinale 
root (T66), E. purpurea capsules (T60), M. oleifera powdered leaves (T80) and stored at -20 
o
C 
for further use throughout the study. 
 
2.2.1.2 Methanol extracts and fractions of herbal medicines 
Each dried plant material (10.0 g) was extracted four times with 100 mL of methanol by 
sonication (30 min), centrifuged at 13000 x g for 5 minutes at 25
o
C and filtered. The solvent was 
evaporated under reduced pressure in a vacuum dryer at 37 °C to give a dried methanolic crude 
extract. The crude extract (820.0 mg) was then suspended in methanol (7.0 mL) and adsorbed on 
celite (1.0 g). The solvent was evaporated and the powdered residual material was loaded onto a 
10 g solid phase extraction (SPE) silica gel cartridge and fractionated using CHCl3 (100 mL), 
CHCl3:MeOH 9:1 (100 mL), CHCl3:MeOH:H2O 8:2:0.5 (150 mL), and methanol (150 mL). 
Fractions of 25 mL were collected and combined according to their TLC profile to give different 
fractions (Figure 2.2A-D). Samples of crude methanolic extract and fractions were dissolved in 
methanol (10.0 mg/mL) and stored at -20 
o
C for further use throughout the study.  
2.2.1.4 Extraction of herbal capsule 
200 mg capsule preparations of Echinacea, Lessertia, and Moringa were transferred into separate 
Eppendorf tubes and each extracted four times with 1.0 mL of water or methanol. The tubes 
containing appropriate solvent and capsules were first shaken by hand and sonicated for 30 mins. 
The extracts were centrifuged at 13000 x g for 5 minutes at 25 
o
C. The supernatants were 
transferred into clean Eppendorf tubes and re-centrifuged as described above. The final 
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supernatants were dried, dissolved in aqueous or methanol (10 mg/mL) and stored at -20
o
C for 
further use throughout the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2A Schematic representation of fractionation of methanolic crude extract of E. 
purpurea 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2B: Schematic representation of fractionation of methanolic crude extract of L. 
frutescens 
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Figure 2.2C: Schematic representation of fractionation of methanolic crude extract of K. crenata 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2D: Schematic representation of fractionation of methanolic crude extract of M. 
oleifera 
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2.2.1.5 Extraction of herbal tablets 
Tablets of Hypoxis were ground in a mortar before extraction. 200 mg of pulverized tablets were 
transferred into Eppendorf tubes and dissolved in water or methanol, hand shaken, sonicated for 
30 mins and centrifuged as described in sub-section 2.2.1.4. The final supernatant was dried, 
dissolved in appropriate solvent used for the extraction (10 mg/mL) and stored at -20
o
C for 
further use throughout the study. 
 
2.2.3 Inhibition of CYPs by herbal extracts and fractions 
2.2.3.1 Reversible inhibition assays 
2.2.3.1.1 Two point screening and IC50 determination 
The herbal extracts were evaluated for CYP inhibition in an assay set up based on recombinant 
CYPs metabolizing substrates which produce fluorescent metabolites. The assays for the 5 major 
CYPs were set up and run according to the method described by Crespi et al., (1997) with slight 
modifications as described by Bapiro et al., (2000). A two stage evaluation procedure was 
followed, the first one being a two concentration of herbal extract inhibition screening against 
each of the 5 CYPs. The second stage involves the determination of IC50 for each herbal extract 
for only CYPs in which over 20% enzyme inhibition was observed during the two point 
concentration screening. 
Each herbal extract was screened in black Costar 96-well plates (Corning Incorporated, Corning, 
NY) according to the protocol published by Crespi et al., (1997) under experimental conditions 
shown in Table 2.2. Each reaction mixture consisted of the appropriate concentration of enzyme, 
NADPH, substrate concentration equivalent to its Km, aqueous herbal extracts (0.2 and 2.0 
mg/mL) and methanol extracts (1.1 and 100 µg/mL) and potassium phosphate buffer (pH 7.4) as 
described by GENTEST (www.gentest.com). Phytochemical constituents of herbal medicines 
have the tendency to behave as fluorogenic compounds, hence auto-fluorescent readings were 
taken to avoid such errors. The mixtures of cofactors, NADPH, herbal extracts or positive 
control and buffer in the 96-well plates were pre-incubated for 10 min. An appropriate 
concentration of enzyme/substrate mixture was added to each well and incubated for 30 mins. 
The reaction was terminated by addition of ice-cold 20% Tris base/80% acetonitrile (ACN) after 
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incubation. Activity of the enzymes was monitored by measuring the formation of fluorescent 
metabolites at specific emission and excitation wavelengths as shown in Table 2.2. The 
experimental conditions in Table 2.2 were based on the protocol provided by the manufacturer. 
Fluorescence was measured on a Victor Wallace (1420 multi-plate reader). The per cent residual 
activity was determined using the equation:  
                      
               
                     
     
For IC50 determination, herbal extracts, fractions and pure compounds of final concentration 4 
mg/mL (aqueous preparations), 100 μg/mL (methanol preparations), 100 µM (pure compounds 
from L. frutescens) were serially diluted (1:3) in a 100 µL of cofactor/phosphate buffer/NADPH 
reaction mixture in each 96-well plates. The plates were pre-incubated for 10 mins. 100 µL of 
enzyme/substrate reaction mixture was added to each well and incubated for 30 mins. The 
reaction was terminated by addition of ice-cold 20% Tris base/80% acetonitrile (ACN) after 
incubation. Activity of the enzymes was monitored by measuring the formation of fluorescent 
metabolites at specific emission and excitation wavelengths for each enzyme. 
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Table 2.2 Experimental conditions for fluorescent CYPs assays 
CYP 1A2 2C9 2C19 2D6 3A4 
Enzyme 
concentration  
2.5 
pmol/mL 
25.0 
pmol/mL 
25.0 
pmol/mL 
30.0 
pmol/mL 
25.0 
pmol/mL 
NADPH 
concentration 
1.0 mM 1.0 mM 1.0 mM 0.4 mM 1.0  mM 
K-Phosphate -Buffer 
concentration 
0.1M  0.1 M 0.1 M 0.1 M 0.1M 
Substrate 
concentration 
 
CEC 
 (3 μM)  
MFC  
(85 μM) 
  
MFC 
 (85 μM) 
 
MAMC  
(15 μM) 
 
BFC  
(10 μM) 
Metabolite  CHC HFC HFC AHMC HFC 
Excitation/Emission 
wavelength (nm) 
405/460  405/535  405/535  390/460  405/535  
Substrates: 7-ethoxy-3-cyanocoumarin (CEC), 7-methoxy-4-trifluoromethylcoumarin (MFC), 7-methoxy-4-
(aminomethyl)-coumarin (MAMC), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), Cyano-hydroxycoumarin 
(CHC), 7-hydroxy-4-trifluoromethylcoumarin (HFC), 3-[2-(diethylamino)ethyl]-7-hydroxy-4-methylcoumarin 
(AHMC). 
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2.2.3.1.2 In vivo prediction of HDI from in vitro data 
One of the objectives of this study is to rank the potential risk of HDI according to the US FDA 
guidelines based on the [I]/Ki ratio where [I] is the concentration of the inhibitor (drug or herb) 
an individual is exposed to and Ki is the inhibition constant. The predicted percentage of 
inhibition of a specific CYP in vivo was calculated using the estimated Ki values and the 
estimated [I] as explained in sub-section 1.3.2.  
 
With both the estimated Ki and [I] values, the I/Ki inhibitory ratio was used to rank the herbs 
with respect to risk for HDI based on FDA guidelines where, I/Ki >1.0 is associated with high 
risk for DDI, I/Ki = 0.1-1 is associated with intermediate risk for DDI and I/Ki<0.1 is unlikely to 
result in DDI (Huang et al., 2008; Prueksaritanont et al., 2013). 
 
2.2.3.1.3 Comparative inhibition of CYP3A4 in recombinant CYP and HLM 
The methanol extracts showed stronger inhibitory effect on human recombinant CYP3A4 than 
the aqueous extracts. To examine whether the inhibition profile of the methanol extracts 
observed in recombinant CYP3A4 is devoid of overestimated or underestimated, comparative 
studies in both recombinant CYP3A4 and HLM were done to re-evaluate the inhibition profile of 
the methanol extracts and fractions. The inclusion of fractions prepared from different solvents 
serves as a guide to determine the appropriate solvent for isolation of the active phytochemicals 
in future experiments.  
6β-hydroxytestosterone formation was used as a marker reaction for the activity of CYP3A4. 
Based on the protocol provided by the manufacturer, the incubation mixture contained human 
liver microsomes (HLMs; 0.6 mg/mL protein) or recombinant CYP3A4 (with protein 
concentration of 0.04 mg/mL leading to activity identical to that of HLMs incubations) in 0.1M 
potassium phosphate buffer (pH 7.4). The methanol herbal extracts and fractions (25 – 100 
μg/mL) were added to the enzyme mixture and pre-warmed for 10 mins. NADPH regeneration 
solution B (1.0 mM) was added to the mixture and incubated for 30 mins at 37
o
C. The reaction 
was terminated by addition of ice-cold acetonitrile containing 5μL corticosterone as an internal 
standard. The mixture was centrifuged at 13,000 x g for 5 mins and the supernatant transferred 
into vials for HPLC analysis.   
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2.2.3.1.4 HPLC analysis 
Testosterone samples were analyzed using a Waters 2695 separation module C18 column (3.9 x 
150 mm, 5µm), with an isocratic elution and UV detection (254 nm) according to the methods 
described by Sonderfan et al. (1987). The HPLC mobile phase consisted of 30% water / 69.9% 
ACN (A) and 99.9% ACN (B) both containing 0.1% formic acid at a flow rate of 1.0 mL/min. 
Each run was followed by 5 min wash with 100% ACN and equilibration period of 10 min. The 
peak area ratio between 6β-hydorxytestosterone and the internal standard were used to determine 
the percent remaining activity. The chrotograms indicated retention times of 6.976 mins, 8.322 
mins and 10.842 mins for 6β-hydorxytestosterone, corticosterone and testosterone, respectively. 
Figure 2.3 demonstrates a typical chromatogram obtained from the HPLC analysis. 
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Figure 2.3 Typical chromatograms of testosterone (TST) in the absence and presence of ketoconazole (KTZ), Kalanchoe crenata 
(KC) and Moringa oleifera (MO). The three peaks represent 6β-hydroxytestosterone (A), corticosterone (B) and testosterone (C). 
Details of the chromatographic conditions are provided in the text. 
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2.2.3.1.5 Assessment of reversible IC50s using a cocktail substrate approach with 
recombinant human CYPs 
As described in the conventional IC50 determination (sub-section 2.2.3.1.1), 3 μL of methanol 
crude extract and fractions of final concentration 100 μg/mL in 150 μL reaction mixture 
consisting of phosphate buffer (0.1 M), glucose 6-phosphate dehydrogenase (0.6 units/mL in 5 
mM sodium citrate buffer 7.5), control protein (0.15 mg/mL) and cofactors (0.14 mM NADP
+
, 
7.2 mM MgCl2, 7.2 mM glucose 6-phosphate) was serially diluted in Costar 96-well black plates. 
The plates were pre-warmed for 10 mins. 100 μL of enzymes/substrates reaction mixture of 25 
pmol CYP3A4/10 μM BFC, 25 pmol CYP2C19/3 μM CEC, 30 pmol CYP2D6/ 15 μM AMMC 
and 2.5 pmol CYP1A2/ 3 μM CEC mixture in phosphate buffer (0.1 M) was added to each well 
except for the blank wells and incubated for 30 mins at 37
o
C. The reaction was terminated by 
addition of ice-cold 20% Tris base/80% ACN. Activity of the enzymes was monitored by 
measuring the formation of fluorescent metabolites at specific emission and excitation 
wavelengths. 
 
2.2.3.1.6 Inhibition of CYP1A2 and CYP3A4 by herbs after absorption through PAMPA 
The initial screening of herbs prepared using the hot aqueous extraction as practiced by the THPs 
implicated CYP1A2 and CYP3A4 as the most affected enzymes. Hence, the inhibitory effect of 
the hot aqueous extracts on CYP1A2 and CYP3A4 after permeation through PAMPA was 
investigated. This could give an indication of the inhibitory potential of each extracts when 
consumed orally if only passive transport is considered. 
The pre-coated PAMPA plate system was warmed at 25 
o
C for 30 mins. 200 µL of phosphate-
buffered saline (PBS) was added to the acceptor compartment. 300 µL of PBS containing 2 
mg/mL of aqueous herbal extracts were introduced to the respective wells in the donor 
compartment (Awortwe et al., 2014b). 200 µM of caffeine and cimetidine were used as positive 
and negative controls, respectively. The plate was incubated at 25 
o
C for 5 hours. Concentrations 
of the controls in both acceptor and donor compartments were measured using UV spectroscopy 
and effective permeability (Pe) determined. 0.2 mg/mL of herbal extracts were collected from the 
acceptor compartment and tested on CYPs (1A2 and 3A4) as described in the screening assays 
(sub-section 2.2.3.1.1). 
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The integrity of the PAMPA plate system was assessed using the Pe of both positive and negative 
controls according to the equation (2.1), permeability (in unit of cm/s): 
Pe=
-In 1-CA t Cequilibrium  
A* 1 VD
  1 VA
  *t
                                                             Equation 2.1 
C equilibrium=  CD t *VD CA t *VA  VD VA   
Where: 
CD (t) = compound concentration in donor well at time t, CA (t) = compound concentration in 
acceptor well at time t, VD = donor well volume (0.3 mL) and VA = acceptor well volume (0.2 
mL), A = filter area (0.3 cm
2
), t = incubation time (18000 s). 
2.2.3.2 Time-dependent inhibition (TDI) of CYP 
2.2.3.2.1 TDI IC50 shift fold 
Three microliters (3 μL) of crude methanol extract and fractions of herbal medicines of final 
concentration of 100 μg/mL in 150 μL enzyme/phosphate buffer reaction mixture consisting of 
phosphate buffer (0.1 M), glucose 6-phosphate dehydrogenase (0.6 units/mL in 5 mM sodium 
citrate buffer 7.5), control protein (0.15 mg/mL) and cofactors (0.14 mM NADP
+
, 7.2 mM 
MgCl2, 7.2 mM glucose 6-phosphate) was serially diluted as described in sub-section 2.2.3.1.1. 
The concentrations of CYPs were similar to that used in the reversible IC50 assay. The plates 
were pre-incubated for 30 mins followed by addition of 100 μL of substrate reaction mixture of 
10 μM BFC or 3 μM CEC for CYP3A4 and CYP2C19, respectively, in phosphate buffer (0.1 M) 
to each well except for the blank wells and incubated for additional 30 mins. The reaction was 
terminated using ice-cold 20% Tris base/80% ACN and the activity of the enzymes was 
monitored by measuring the formation of fluorescent metabolites at similar condition to that of 
reversible IC50. The fold shift in IC50 was determined for each herbal extracts and fractions. 
 
2.2.3.2.2 Application of normalized ratio for TDI screening 
TDI screening was conducted using a protocol described by Yamamoto et al., (2002) with slight 
modification. In brief, a two- step incubation consisting of an inactivation and activity assay 
were performed. In the inactivation assay, 100 μL of aqueous herbal extracts (0.2 and 2.0 
mg/mL) and methanol herbal extract (50 and 100 µg/mL), positive control, troleandomycin (1 
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and 20 μM) and negative control, ketoconazole (0.1 and 1 μM) were incubated with recombinant 
CYPs and 0.1 M phosphate buffer, pH 7.4 in the absence and presence of NADPH for 30 mins at 
37 
o
C. The activity assay consisted of aliquots (100 uL) of the inactivation assay to which an 
appropriate substrate was added and the reaction done for another 30 mins.  The mixture was 
stopped with cold-ice 20% Tris base/80% ACN after incubation and the fluorescent detected 
immediately. 
The time dependent inhibitory effect of each herbal extract on the activity of CYPs was 
expressed as the normalized ratio as demonstrated in the equation (2.2) below:  
Normalized ratio = 
 R 1NADPH  R-1NADPH  
 R 1noNADPH  R-1noNADPH  
                              Equation 2.2 
Where R 1NADPH is the rate of reaction when incubation was performed in the presence of both 
inhibitor and NADPH; R-1NADPH is the rate of reaction when incubation was performed in the 
presence of NADPH but in the absence of inhibitor; R 1noNADPH is the rate of reaction when 
incubation was done in the presence of inhibitor without an NADPH; and R-1noNADPH is the rate 
of reaction when incubation was performed in the absence of both inhibitor and NADPH. The 
normalized ratio was used to classify each test compound as follows: below 0.7 (clear TDI), 
between 0.7 and 0.9 (intermediate zone with undefined TDI), and above 0.9 (non-TDI) as 
described by Atkinson et al., (2005). 
 
2.2.3.2.3 Single point NADPH and TDI 
Methanol extracts and fractions with potential TDI selected based on the IC50 fold shift were 
preincubated (50 μg/mL) with 250 pmol CYP3A4 or CYP2C19/well reaction mixture in the 
absence and presence of NADPH for 30 mins at 37
o
C. The single point NADPH dependent 
inhibition was repeated for 10 and 20 mins preincubation. For TDI, the primary incubate was 
preincubated for 0, 5, 10 and 20 mins. At the end of each preincubation time point, 10 μL aliquot 
of the primary incubates was added to 90 μL of substrate mixture in appropriate wells for 
respective CYPs and incubated for additional 30 mins. The reaction was terminated using an ice-
cold 20% Tris base/80% ACN and the activity of the enzymes monitored by measuring the 
formation of fluorescent metabolites.  
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2.2.3.2.4 Kinetics of CYP3A4 inactivation 
Herbal extracts with strong TDI based on the normalized ratio, the single point NADPH- and the 
time dependent screening were selected for the TDI kinetics. With reference to the initial TDI 
screening assays, the test samples demonstrated stronger NADPH-, time- and concentration 
dependent inhibitory effects on CYP3A4 compared to that of CYP2C19; hence CYP3A4 was 
focused for the inactivation experiment. The two-step incubation method was used to 
characterize the time- and concentration-dependent inhibition of CYP3A4 by the active methanol 
extracts and fractions of K. crenata and M. oleifera. In the inactivation assay, varying 
concentrations of the methanol extracts and fractions (1 – 100 μg/mL) were incubated with 
CYP3A4 (250 pmol/well), cofactor, control protein, and 0.1 M phosphate buffer, pH 7.4. At 0, 5, 
10, 20 and 30 mins preincubation time points, an aliquot of the preincubation mixture (1:10 
dilution) was taken and added to the activity assay (similar to the TDI assay), and a further 30 
mins incubation was carried out at 37°C. The reaction was terminated by addition of ice-cold 
20% Tris base/80% ACN solution, and activity was followed by measuring the formation of 
HFC. To determine kobs values, the decrease in natural logarithm of the remaining activity of 
CYP3A4 (%) against time was plotted for each inactivator concentration, and the kobs values 
were described as negative slopes of the lines. Inactivation kinetic parameters were evaluated 
applying the nonlinear regression of the data to the following expression: 
      
          
      
                                                                            Equation 2.3 
Where [I] represents the conentrations of the inactivators in the preincubation mixture; kobs or λ 
represents the negatives values of the slopes for the natural logarithm of the percentage 
remaining activity of CYP3A4; kinact is the limit maximum inactivation rate constant measured in 
the absence of the inactivator and KI is the inactivator concentration which yields half of kinact. 
 
2.2.3.2.5 In vivo prediction of CYP3A4 inactivation from in vitro data 
Quantitative prediction of mechanism-based DDI in vivo based on in vitro data is very 
challenging even though several mathematical models have been presented.  The US FDA draft 
guidelines for DDI studies published in 2012 recommended the calculation of R-value to assess 
the in vivo DDI risk of potential MBIs. The R-value is mathematically expressed as: 
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                                                              Equation 2.4 
Where kdeg is the rate constant for enzyme degradation in vivo and λ is equivalent to kobs.  
Compounds with R-value >1.1 (or 11 for CYP3A4 inhibition in the gut) are considered possible 
CYP inhibitor in vivo which warrant further investigation in vivo. However, such approach fails 
to predict the magnitude of in vivo DDI risk. In this study, in vivo categorisation of DDI risk of 
MBIs based on λ/kdeg was adapted. According to this approach, the likelihood that a drug will 
cause in vivo interactions was classified as; likely (λ/kdeg >1), intermediate (1>λ/kdeg >0.1) and 
remote (0.1>λ/kdeg) (Fujioka et al., 2012).  
2.2.4 Effects of herbal extracts on metabolic clearance of testosterone in human  
          hepatocytes and HLM 
2.2.4.1 Incubation procedure 
Cryopreserved hepatocytes were thawed and the cells were suspended in HepatoZYME media 
(BD Gentest). The cell viability was monitored at the beginning and the end of the incubation in 
the presence and absence of methanol extracts of herbal medicines with the use of Bio-Rad TC20 
automated cell counter following the instructions provided by the supplier. The cell density was 
adjusted with HepatoZYME media to 0.5 x10
6
 viable cells/mL. For HLMs assays, final protein 
concentration of 0.6 mg/mL in NADPH/MgCl2/phosphate buffer mixture was used for the 
metabolic clearance of testosterone (TST). 100 μM of TST and 100 μg/mL of each herbal extract 
were co-incubated with 1 mL hepatocyte mixture at 37
o
C under humidified atmosphere of 95% 
air and 5% CO2 in Heraeus incubator. Aliquots of the hepatocytes incubation mixture were taken 
at 0, 0.5, 1, 2, 4, and 6 hours of incubation. Samples were stored in eppendorf tubes at -80
o
C for 
24 hours to break the cell walls. In the HLMs assay, an aliquot of the incubation mixture was 
taken for 0, 3, 7, 10, 20 and 30 mins. Each sample was stored at -20
o
C for a maximum of 5 
hours. Both hepocytes and HLM samples were centrifuged at 13000 x g and 200 µL of the 
supernatant stored in HPLC vials for analysis. The metabolic reaction was stopped by the 
addition of ACN containing 5 μL of corticosterone as an internal standard. Samples were kept at 
-80
o
C for at least 4 hours before analysis. 
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2.2.4.2 Clearance calculations 
The half-life (t1/2) and the elimination rate constants of TST in hepatocytes and HLMs incubation 
mixture were determined using log linear regression of TST concentration profile against 
incubation time. The intrinsic clearance in vitro was calculated from the half-life and the cell 
density and scaling of intrinsic clearance in vitro to intrinsic clearance in vivo was made by 
employing the human liver mass (25.7 g/kg body mass), hepatocellularity (number of 
hepatocytes per gram of liver = 99.0 million cells/kg liver) and HLM protein concentration used 
as illustrated in the equations below (Emoto et al., 2006): 
  
  
                                                                          Equation 2.5 
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      Equation 2.7 
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                                  Equation 2.9 
Based on CLint in vivo and the hepatic blood flow [Q (20.7 ml/min)/kg body mass], the hepatic 
metabolic clearance (CLh,b) was predicted using the well-stirred model: 
      
                 
               
                                                                                                     Equation 2.10 
The free fractions in vitro or in vivo were assumed to be identical; hence no corrections were 
made as reported by Davies and Morris, (1993).     
Influence of each herbal extract on plasma concentration of TST in both HLM and hepatocytes 
was determined applying:  
    
   
 
  
   
                                                                                                                 Equation 2.11 
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AUC and AUCi represent plasma concentration area of TST under the curve in the absence and 
presence of herbal extract. CL and CLi represent intrinsic clearance of testosterone in the absence 
and presence of testosterone. The AUC ratios were used to classified the interaction of each 
extract with testosterone as; strong (AUC ratio >5), intermediate (2 ≤ AUC ratio ≤ 5), weak (1.25 
≤ AUC ratio <2) and no interaction (AUC ratio < 1.25) as recommended by FDA guidance for 
drug-drug interaction studies (2012). 
 
2.2.5 Echinacea-mediated activation of PXR in co-transfected HepG2 cell lines 
2.2.5.1 Cell viability 
 
Cell viability was examined using the methyl thiazolyl tetrazolium (MTT) cell proliferation 
assay kit (Life technologies, Grand Island, New York, USA). HepG2 cells were seeded at 1.0 x 
10
4
 cell/100µL/well and cultured in DMEM/F12 medium containing 10% fetal calf serum, 2mM 
glutamine, 100 IU/mL penicillin, and 100 µg/mL streptomycin. Cells were grown to 70-80% 
confluence and placed in serum-free media for 24 hours. The cells were treated with 25, 50 and 
100 µg/mL of test samples for 24 hours. After the treatment period, the media was aspirated and 
the cell viability was immediately assessed by first incubating the cells in MTT solution for two 
hours, followed by measurement of absorbance at 570 nm after removal of untreated dye and 
addition of 200 µL of DMSO. Cell viability was calculated in comparison to untreated control 
In prinicple, the MTT compound is bioreduced by cells into a coloured formazan product via 
NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells (Berridge 
and Tan, 1993). The quantity of formazan product as measured by absorbance at 570 nm is 
directly proportional to the number of living cells in culture. 
 
2.2.5.2 Transient transfection and Luciferase gene reporter assays  
HepG2 cells (10 x 10
6
 cells) transfected with a luciferase reporter construct (0.4 mg/well) and 
expression plasmid encoding pSG5-PXR (50 ng/well) by electroporation at 180V, 1 pulse for 70 
msec, were seeded into 96-well plate at a density of 5 x 10
4
 per well. The cells were subse-
Stellenbosch University  https://scholar.sun.ac.za
71 
 
quently maintained in a medium supplemented with 10% fetal calf serum  containing 2.4 g/L so-
dium bicarbonate, 100 U/ml penicillin-G, and 100 μg/ml streptomycin for 24 hours. Test samples 
and rifampicin (positive control drug) were added to co-transfected cells at different concentra-
tions and further incubated for 24 hrs. The media was aspirated from the cells and 40 μL of 
luciferase reagent (Promega Corporation, Madison, WI, USA) added to each well and lumines-
cence was measured using Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, 
USA). 
 
 For time dependent induction, the above protocol was repeated. The luminescence activity was 
determined after 24 and 48 hours incubation with different concentrations of test samples. 
Luminescence of test samples was determined as background that was subtracted in the final 
calculation from luminescence of cell samples transiently transfected with reporter plasmids 
containing response elements of tested genes. The fold induction of each sample was calculated 
as a ratio between the luminescence of test samples to that of the vehicle treated cells.   
 
 
2.2.5.3 Real-Time -PCR analysis of CYP3A4, CYP1A2 and P-gp mRNA 
 
HepG2 cells (1.5 x10
5
 per well) transfected with PXR expression plasmid (400 ng/well) were 
seeded into 96-well plate and cultivated for 24 h and appropriate transfected cells were exposed 
to different concentrations of test samples for 48 h. The cells were washed with PBS and total 
RNA was extracted using the Quick-start protocol (Qiagen® Texas, USA). The following 
primers were used for:  
CYP3A4, forward (5’-TTCAGCAAGAAGAACAAGGACAA-3’) and, reverse  
(5’-GGTTGAAGAAGTCCTCCTAAGC-3’) primers; CYP1A2, forward (5-AAC-AAG-GGA-
CAC-AAC-GCT-GAA-T-3) and reverse (5’-GGA-AGA-GAA-ACA-AGG-GCT-GAG-T-3’) 
primers; MDR1, forward (5’-TGCTCAGACAGGATGTGAGTTG-3’) and reverse (5’-
AATTACAGCAAGCCTGGAACC-3) primers; and housekeeping genes HPRT (hypoxanthine-
guanine phosphoribosyl transferase), forward ( 5’-CTGGAAAGAATGTCTTGATTGTGG-3’), 
reverse (5’-TTTGGATTATACTGCCTGACCAAG-3’) primers.  
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cDNA was prepared from 1 μg of total RNA with iScript MMLV-RT (RNaseH+) from Bio rad 
using oligo (dT) random primers and porcine RNase inhibitor. Real-time quantitative polymerase 
chain reaction (RT-qPCR) was performed in a 96-well plate employing an iCycler iQ™ Real 
time PCR detector system (Bio-Rad).  cDNA (40 ng of reverse transcribed RNA) was amplified 
with hot-start iTaq DNA polymerase (QIAGEN, Valencia, CA) under the following conditions: 3 
mM MgCl2, 0.2 mM deoxynucleoside-5-triphosphate, 0.3 μM each primer, 0.025 U/l 
polymerase, SYBR Green I in 1:100,000 dilution, and fluorescein (10 nM).  The thermal cycler 
was programmed on the real-time PCR instrument using the following experimental conditions: 
3 min of polymerase activation and denaturation at 95
o
C, DNA amplification consisting of 10-15 
sec denaturation at 95
o
C and 30-60 sec anneling/extension with plate reading at optimized 
temperature (55-60
o
C), cycles at 35-40 min and melt curve analysis between 2-5 sec at 55-95
o
C. 
Test samples were run in triplicate with negative controls. The processing of real-time 
amplification curves was performed on iCycler software version 4.6 (Bio-Rad). Pfaffl’s method 
was applied for relative quantification of gene expression normalized to endogenous control 
(housekeeping) gene (Pfaffl, 2001). Results were presented as the means of at least three 
experiments. Fold induction was expressed as the ratio between the mRNA expression of treated 
samples and that of the untreated sample. 
 
2.2.5.4 Measurement of CYP3A4 enzymatic activity 
 
Transfected HepG2 cells as described in subsection 2.2.5.2 were plated in 96-well plates, 
incubated overnight and  and treated with capsules and fractions of Echinacea (1 - 100 μg/mL) 
for 48 h. CYP3A4 and CYP1A2 enzymatic activities were measured using fluorescent probe 
substrates kits (BD Gentest) according to the instructions provided by the manufacturer. In brief, 
100 μL of cofactors mixture, control protein (0.05 mg of protein/mL), and glucose-6-phosphate 
dehydrogenase were added to each well. Initial readings were taken to record any 
autofluorescence and the plates were incubated at 37◦C for 30 min after addition of 3 µM 7-
ethoxy-3-cyanocoumarin (CYP1A2 substrates) or 10 µM 7-benzyloxy-4-
trifluoromethylcoumarin (CYP3A4 substrate) to respective wells. The reaction was terminated 
by the addition of 50 μL of ice cold ACN/0.5M Trisbase (80:20). Fluorescence was measured on 
Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) at specified excitation 
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and emission wavelengths for CYP1A2 (405/460 nm) and CYP3A4 (405/535 nm). The 
concentration of crude herbal extracts that gives 50% of maximum response of the 
enzyme/transporter activity (EC50) for each fraction was determined by plotting the fold 
induction against log concentrations of the test samples and the curve fitted by employing non-
linear regression using GraphPad Prism.  
 
2.2.6 P-glycoprotein assay 
2.2.6.1 Calcein-AM uptake 
A previously described protocol was followed with some modifications to assess the effect of E. 
purpurea, M. oleifera, K. crenata and K. integra on P-glycoprotein (Shiraki et al., 2002). Briefly, 
MDCKII/MDR1 and MDCKII/WT cells at 80–90% confluency were trypsinized, seeded into 96-
well plates at a cell density of 7.0 x 10
4
 cells/well. The medium was changed 24 h after seeding, 
and the assay was performed 48 h later. On the day of the study, the medium was aspirated, and 
monolayers were washed twice with transport buffer. Herbal extracts were added to monolayers 
in 50 μL of transport buffer containing 1% MeOH. Graded concentrations of each herbal extract 
(0.1–100 μg/mL, n =5) were used. The concentration ranges of 0.1–100 μM were used for 
verapamil as positive control. MeOH concentration (1%) was constant in test and control wells 
(each n = 2). Plates were pre-incubated at 37°C for 10 min. Calcein-AM was added, and the 
plates were immediately placed in a SpectraMax Gemini cytofluorimeter (Molecular Devices) 
for 60 min and read at 15 min intervals at excitation and emission wavelengths of 485 and 530 
nm, respectively. Calcein-AM uptake and Pgp inhibition were immediately quantified. 
 
2.2.6.2 P-gp inhibition by 
3
H-digoxin uptake in hMDR1-MDCK-II cells 
The experimental protocol described earlier by Rautio et al., (2006) was adopted with slight 
modifications. In brief, the cells were seeded at a density of 120,000 cells/well in 12-well 
transwell plates and cultured for 3 days. The TEER values were in the range of 500–800 Ω cm2. 
Cells were washed with warm HBSS buffer (composition: 8.0 g NaCl, 0.4 g KCl, 0.14 g CaCl2, 
0.1 g MgSO4, 0.06 g Na2HPO4.2H2O, 0.06 g MgCl2.6H2O, 0.06 g KH2PO4, 1.0 g glucose and 
0.35 g NAHCO3 to 1000 mL of H2O) supplemented with 10mM HEPES (pH7.4) and pre-
incubated with 0.5 mL of buffer containing test samples on the apical side and 1.5mL of buffer 
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on the basolateral side for 30 min (37
o
C, 5%CO2, and 95% relative humidity). After  incubation, 
buffer was removed from the basolateral side and replaced with 1.5mL of buffer containing 
3
H-
digoxin (40 nM), test samples or standard drugs (25 μM), and incubated further for 2h. Aliquots 
of 25 μL were taken out from the apical side, mixed with100 μL of scintillant (MicroscintTM-40, 
PerkinElmer) and radioactive counts were measured on a Top Count microplate scintillation 
counter(PerkinElmer,Waltham, MA, USA) in CPM mode.The monolayer integrity was 
monitored by measuring the permeability of Ly (afluorescent marker of passive paracellular 
diffusion) as described earlier (Manda et al., 2013). The inhibition of the basolateral to apical 
(B−A) transport of digoxin by test samples was calculated and compared to that of the vehicle 
control. The IC50 value, defined as the concentration that caused an inhibition of 50% in digoxin 
transport, was obtained from dose curves generated by plotting % inhibition versus log 
concentration using GraphPadPrism. 
 
2.2.7 Statistical analysis 
All values in the inhibition assays have been expressed as Mean ± SEM from two independent 
experiments. The percent activity remaining of TST in HLM and recombinant human CYPs were 
compared using unpaired t test with P<0.05 considered as significance. The unpaired t test was 
also used to determine the significance of enzyme activity in the presence and absence of 
NADPH. 
For the induction experiment, one-way analysis of variance (ANOVA) was used to determine the 
significance of difference between untreated group and the treated groups. The Benferroni multi-
comparison test was used for group comparisons. Statistical significance was accepted for p-
values <0.05. 
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CHAPTER THREE 
 
3. RESULTS AND DISCUSSIONS 
PART ONE 
 
3.1 Inhibition of CYPs by herbal extracts and fractions 
The selected herbal medicines used by HIV/AIDS patients in sub-Saharan Africa were 
investigated for their tendency to inhibit the five major drug metabolizing enzymes namely, 
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Initially, reversible and irreversible 
screening of inhibition potency of each herbal medicine on specific isoform of CYP was 
conducted in recombinant human CYPs. Due to the importance of CYP3A4 in the metabolism of 
most drugs, extensive studies on metabolic clearance of testosterone, substrate for CYP3A4 in 
HLM and human hepatocytes were conducted.    
 
3.1.1 Reversible inhibition assays 
3.1.1.1 Two point screening of herbal extracts 
In the preliminarily screening, two different concentrations of the aqueous (0.2 and 2.0 mg/mL) 
and methanol (1.10 µg/mL and 100µg/mL) herbal extracts were tested. The residual activities 
were expressed as percentages of the negative controls for respective CYPs. Aqueous herbal 
extracts of H. hemerocallidea powdered leaves (T30) and capsules (T41); E. purpurea capsules 
(T60) and L. frutescens tablets (T50) generally inhibited the five CYPs more than 50% at the 
highest concentration. The results indicated that, the aqueous herbal extracts of M. oleifera (T80) 
inhibited the CYP1A2, CYP2C9 and CYP3A4 in a concentration dependent manner (Figure 
3.1A). Some herbal extracts showed an apparent activation on the activity of CYPs (2D6 and 
3A4). The methanol extracts inhibited CYPs in the order of CYP3A4>CYP2C9>CYP2C19 
which were also concentration dependent (Figure 3.1B). With the exception of E. purpurea 
capsule (2660), none of the methanol extracts inhibited CYP1A2 and CYP2D6 activities. The 
IC50 values of herbal extracts which inhibited more than 20% of the residual activity indicated 
for the negative control samples were determined. 
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Figure 3.1A Two point screening of aqueous herbal medicines where 0.2 and 2.0 mg/ml of each 
herbal extract was evaluated for inhibitory effects on each of the five CYPs, 1A2, 2C9, 2C19, 
2D6 and 3A4. For each of these CYPs, a positive control diagnostic inhibitor was used, alpha-
nathoflavone (ANF, 0.01 and 0.10 μM) for CYP1A2, sulfaphenazole (SPZ, 1.0 and 10.0 μM) for 
CYPs 2C9 and 2C19, quinidine (QND, 0.01 and 0.1 μM) for CYP2D6 and ketoconazole (KTZ, 
0.01 and 0.1 μM) for CYP3A4. H. hemerocallidea capsule (T41) and powdered leaves (T30), L. 
frutescens tablets (T50) and tea cut (T79), T. officinale root (T66), E. purpurea capsules (T60), 
K. crenata (T61), K. integra (T65) and M. oleifera powdered leaves (T80). 
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Figure 3.1B: Two point screening of methanol herbal extracts where 1.1 and 100.0 µg/mL of 
each herbal extract was evaluated for inhibitory effects on each of the CYPs; 2C9, 2C19 and 
3A4. H. hemerocallidea capsule (HHC) and powdered leaves (HHL), L. frutescens tablets (LFT) 
and tea cut (LFC), T. officinale root (TO), E. purpurea capsules (2660), M. oleifera powdered 
leaves (MO), Kalanchoe crenata (KC) and Kalanchoe integra whole plant (KI). 
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3.1.1.2 The IC50 determination 
The IC50 values were determined for only herbal extracts which indicated inhibitory effect 
greater than 20% on specific CYPs when compared to the negative controls. H. hemerocallidea 
(T30) and E. purpurea (T60) inhibited CYP1A2 with IC50 values of 0.63 μg/mL and 20 μg/mL, 
respectively. L. frutescens inhibited CYP2C9 with an IC50 value of 174 μg/mL. The result also 
showed T. officinale as an inhibitor of CYP2C19 with an IC50 value of 43.52 μg/mL. Like 
CYP1A2, H. hemerocallidea (T30) and T. officinale (T60) inhibited CYP3A4 with an IC50 
values of 58 μg/mL and 12 μg/mL, respectively as demonstrated in Figure 3.2A.  
The methanol extracts showed an inhibitory effect less than 20% on CYP1A2 and CYP2D6 
compared to the negative controls; hence the IC50 values for the herbs on these two CYPs were 
not determined. All the methanol extracts indicated strong inhibition on CYP2C9, CYP2C19 and 
CYP3A4 with IC50 values within the concentrations of 1.04 – 50.87 μg/mL. However, only the 
methanol extract of E. purpurea capsule (2660) exhibited mild inhibition on CYP1A2 with IC50 
value of 56.02 μg/mL. The sigmoidal dose response curves from which the IC50 plots for each 
herbal extract was determined are shown in Figure 3.2A (aqueous extracts) and Figure 3.2B 
(methanol extracts). The inhibition reaction was performed at a substrate concentration 
equivalent to the Km. The IC50 values for the diagnostic inhibitors; 0.008 μM (CYP1A2: α- 
naphtoflavone), 1.351 μM and 0.191 μM (CYP2C9 and CYP2C19, respectively: 
sulfaphenazole), 0.011 μM (CYP2D6: quindine) and 0.021 μM (CYP3A4: ketoconazole) were in 
agreement with the values reported in literature (Helsby et al., 1998; Sai et al., 2000). Table 3.1 
shows the IC50 values of the herbal extracts on various recombinant CYPs. 
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Figure 3.2A Dose-response curves from which the IC50 values were determined. Data are 
expressed as Mean ± SEM, n=2. The IC50 value is the concentration of inhibitor bringing about a 
50 % reduction in enzyme activity. 
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Figure 3.2B: Dose-response curves from which the IC50 values were determined for the 
methanol extracts. Data are expressed as Mean ± SEM, n=2. The IC50 value is the concentration 
of inhibitor bringing about a 50 % reduction in enzyme activity. 
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Table 3.1: IC50 values of herbal extracts on various recombinant CYPs 
Herbal medicines Aqueous extract Methanol extract 
 IC50 µg/mL IC50 µg/mL 
Hypoxis capsule 
CYP1A2 
CYP2C9 
CYP2C19 
CY2D6 
CYP3A4 
 
162.00 ± 3.87 
383.36 ± 11.06 
-
a
 
870.60 ± 23.54 
-
a
 
 
-
 a
 
17.56 ± 1.24 
48.96 ± 3.21 
-
 a
 
38.88 ± 4.61 
Hypoxis leaves 
CYP1A2 
CYP2C9 
CYP2C19 
CYP2D6 
CYP3A4 
 
0.63 ± 0.02 
-
a
 
-
a
 
446.00 ± 10.89 
58.00 ± 5.65 
 
-
 a
 
-
a
 
-
a
 
-
 a
 
30.42 ± 2.54 
Lesertia tablet 
CYP1A2 
CYP2C9 
CYP2C19 
CYP2D6 
CYP3A4 
 
-
 a
 
174.00 ± 9.54 
-
 a
 
-
 a 
-
 a
 
 
 
-
 a
 
25.48 ± 4.16 
20.10 ± 1.89 
30.62 ± 0.78 
-
 a
 
 
Lessertia tea cut 
CYP1A2 
CYP2C9 
CYP2C19 
 
-
a
 
-
 a
 
-
 a
 
 
-
a
 
10.68 ± 2.10 
13.04 ± 1.04 
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CYP2D6 
CYP3A4 
198.00 ± 6.24 
740 ± 5.20 
-
 a
 
28.41 ± 2.10 
Moringa leaves 
CYP1A2 
CYP2C9 
CYP2C19 
CYP2D6 
CYP3A4 
 
37.00 ± 1.89 
-
 a
 
-
 a
 
-
a
 
300.00 ± 18.21 
 
-
 a
 
20.60 ± 1.45 
10.60 ± 0.60 
-
a
 
31.48 ± 1.70 
 
Taraxacum root 
CYP1A2 
CYP2C9 
CYP2C19 
CYP2D6 
CYP3A4 
 
520.00 ± 21.70 
-
a
 
43.52 ± 4.24 
-
a 
-a
 
 
-
 a
 
-
 a
 
-
 a 
-
a 
-
a
 
Echinacea capsule 
CYP1A2 
CYP2C9 
CYP2D6 
CYP2C19 
CYP3A4 
 
Kalanchoe crenata 
CYP1A2 
CYP2C9 
CYP2C19 
CYP2D6 
 
20.20 ± 0.90 
-
 a
 
-
a
 
-
 a
 
12.00 ± 0.53 
 
 
-
a
 
-
a
 
-
a
 
-
a 
 
52.20 ± 2.10 
29.60 ± 0.79 
-
a
 
1.04 ± 0.04 
22.32 ± 1.60 
 
 
-
a
 
-
a
 
38.21 ± 4.10 
-
a
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CYP3A4 
 
Kalanchoe integra 
CYP1A2 
CYP2C9 
CYP2C19 
CYP2D6 
CYP3A4 
-a
 
 
 
-
a
 
-
a
 
-
a
 
-
a
 
-
a
 
36.78 ± 1.51 
 
 
62.37 ± 6.72 
36.44 ± 2.57 
50.87 ± 8.34 
-
a 
36.48 ± 5.10 
-
 a
 No inhibition at the concentration tested 
 
3.1.1.3 In vivo prediction of HDI from in vitro data 
Based on FDA guidelines for in vivo prediction of DDI from in vitro data, certain assumptions 
were made for both inhibitor concentration individual is exposed to in the GIT [I] or the 
maximum hepatic input concentration [I]in. and the inhibitor constant (Ki). These parameters are 
difficult to estimate for herbal medicines. The commonly used working concentration is 
therefore based on the highly unlikely assumption that the whole soluble extract prepared 
employing the 250 mL GIT fluid is available to interact with intestinal CYPs and P-
glycoprotiens. The concentrations of herbal extracts in the GIT were therefore estimated as 
extract per dose used in human divided by the GIT fluid volume (250 mL) as shown in Appendix 
4. For soluble extract that interact with liver CYPs and drug transporters, the maximum hepatic 
input concentration [I]in was determined based on the assumption that there was complete 
absorption of herbal extracts from the GIT into the portal vein (Fa = 1.0). The values of 
absorption rate constant (ka), hepatic blood flow rate (Qh) were also assumed to be 0.1 min
-1
 and 
1610 ml/min (Kanamitsu et al., 2000) based on the equation 3.1: 
[I]in = [I]gut + kaFaD/Qh                                                                      Equation 3.1 
Secondly, the Ki which is an inhibitory constant characteristic of the interaction of a pure 
compound with an enzyme is difficult to determine for herbal extracts for which we do not know 
the chemical constituents. For the use of the inhibition index proposed by FDA, a number of 
Stellenbosch University  https://scholar.sun.ac.za
84 
 
assumptions are necessary, including that the IC50 observed is due to unique chemical constituent 
in the herbal extract. Furthermore, based on the design of the in vitro assay for the determination 
of IC50 with substrate concentration at Km, M-M kinetic derivations allow one to estimate Ki 
from IC50, where for competitive inhibition, Ki =IC50/2 and for non-competitive inhibition, Ki = 
IC50. For determining the safety of herbal extracts, the assumption of competitive inhibition 
would result in a higher inhibition index than non-competitive inhibition. Again, most 
documented modes of CYP inhibition are competitive and not non-competitive inhibition. 
Therefore, the assumption of competitive inhibition will be employed to estimate the Ki. 
 
Based on the above assumptions, the estimation of HDI will be based on the following FDA 
guidelines: [I]/Ki > 1 (likely), 1 > [I] /Ki > 0.1 (possibly) and 0.1 > [I] /Ki (remote) as presented 
in Table 3.2 for each test compound on respective CYPs. The IC50 values for herbal extracts 
which inhibited CYPs less than 20% based on preliminary screening were not investigated. The 
predicted likelihood of in vivo CYP inhibition by the herbal extracts is indicated in Table 3.2. 
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Table 3.2 Prediction of in vivo herb-drug interactions from in vitro data 
Herbal 
medicines 
 Aqueous extract   Methanol extract  
 [I]gut 
(µg/mL) 
[I]in Ki (IC50/2) 
 (µg/mL) 
GIT  
[I]gut/Ki 
Hepatic 
[I]in/Ki 
[I]gut 
(µg/mL) 
[I]in Ki (IC50/2) 
 (µg/mL) 
GIT 
[I]gut/Ki 
Hepatic 
[I]in/Ki 
Hypoxis 
capsule 
CYP1A2 
CYP2C9 
CYP2C19 
CYP2D6 
CY3A4 
1400.00 
 
 
1422.00  
 
81.00 
191.65 
_a 
435.30 
_a 
 
 
 
17.00 
7.30 
_a 
3.20 
_a 
 
 
17.60 
7.40 
 
3.30 
242.00 
 
 
 
 
 
264.00  
 
_a 
8.78 
24.48 
_a 
19.44 
 
 
_a 
27.59 
9.89 
_a 
12.46 
 
 
 
30.07 
10.78 
 
13.58 
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Hypoxis 
leaves  
CYP1A2 
CYP2D6 
CY3A4 
321.84 
 
342.70  
 
0.32 
223.00 
29.00 
 
 
510.0 
1.44 
11.00 
 
 
1087.90 
1.50 
11.80 
378.00 
 
380.00  
 
_a 
 
15.21 
 
 
_a 
 
24.85 
 
 
 
 
26.30 
Lessertia 
tablets 
CYP2C9 
CYP2C19 
CY3A4 
1200.00 
 
1218.60  
 
87.00 
_a 
_a 
 
 
13.80 
_a 
_a 
 
 
14.00 
192.00 
 
229.20  
 
12.74 
10.05 
15.31 
 
 
15.07 
19.10 
12.54 
 
 
17.99 
22.8 
14.97 
Lessertia 
tea cuts 
CYP1A2 
CYP2C9 
CYP2C19 
131.00 
 
149.60  
 
_a 
_a 
_a 
 
 
_a 
_a 
_a 
 
 
 
 
 
146.40 
 
165.00  
 
_a 
5.34 
6.70 
 
 
_a 
27.42 
21.85 
 
 
 
30.90 
24.63 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
87 
 
CYP2D6 
CY3A4 
99.00 
370.00 
 
1.30 
0.35 
1.50 
0.001 
_a 
14.21 
_a 
10.30 
 
11.60 
Moringa 
leaves 
CYP1A2 
CYP2C9 
CYP2C19 
CY3A4 
1600.00 
 
1615.50  
 
18.50 
_a 
_a 
150.00 
 
 
86.50 
_a 
_a 
10.70 
 
 
87.30 
 
 
10.77 
224.00 
 
239.50  
 
_a 
10.30 
5.31 
15.74 
 
 
_a 
21.75 
42.18 
14.23 
 
 
 
23.25 
45.10 
15.21 
Taraxacum 
roots 
CYP2C9 
CYP2C19 
1192.16 
 
 
 
1238.70  
 
260.05 
21.76 
 
 
4.60 
59.61 
 
 
4.76 
56.92 
   
 
_a 
_a 
 
 
_a 
_a 
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Echinacea 
capsules 
CYP1A2 
CYP2C9 
CYP2C19 
CY3A4 
1280.00 
 
1298.60  
 
10.00 
_a 
_a 
6.00 
 
 
128.00 
_a 
_a 
213.00 
 
 
129.86 
 
 
216.43 
238.08 
 
 
256.7  
 
28.10 
14.80 
0.52 
11.16 
 
 
8.47 
16.08 
475.8 
21.33 
 
 
9.13 
17.34 
493.6 
23.00 
_a
No inhibition at the concentration tested, intra-hepatic concentration ([I]in) = Cmax + kaFaD/Qh.  
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3.1.1.4 Comparative inhibition of CYP3A4 in recombinant CYP and HLM  
The methanol extracts exhibited high risk of HDI based on the in vivo prediction from the 
reversible IC50 values. Fractions of the various methanol extracts which showed high risk of HDI 
were prepared and comparative inhibition profile investigation in both HLMs and recombinant 
human CYP3A4 was conducted. HPLC was used to monitor the inhibitory effects of various 
crude methanol extracts and fractions of herbal medicines on CYP3A4-catalyzed 6β-
hydroxylation of TST in HLMs and recombinant human CYP3A4. The concentration of TST 
used as a probe substrate in both HLMs and recombinant human CYP3A4 in this assay was 
approximately the Km. As shown in Figure 3.3A, the crude KC (K. crenata) weakly inhibited 
CYP3A4 yielding remaining enzyme activity of 85% (HLM) and 101% (rCYP3A). The fraction 
45D significantly reduced (P = 0.006) the activity of CYP3A4 in HLM compared to that of rCYP 
at 50 μg/mL.  Conversely, the activity of CYP3A4 was reduced significantly (P = 0.02) in rCYP 
compared to that in HLM by fraction 45D at 100 μg/mL. The fraction 45B indicated significant 
reduction in CYP3A4 activity in rCYP compared to that of HLM at all the three different 
concentrations tested. Crude methanol extract (39KC) and fraction 45A showed no significant 
differences in the activity of CYP3A4 when tested in both HLM and rCYP.   
Both crude and fractions of M. oleifera exhibited strong inhibition in both HLM and rCYP 
though activity in the latter was stronger than those observed in the HLM. For example, 
inhibition of 60% (HLM) and 84% (rCYP3A4) were observed for the crude methanol extract. 
The fraction 50B showed a strong inhibition of 84 % in rCYP and mild inhibition of 40% in 
HLM. Additionally, fraction 50A indicated strong inhibition of 45% and weak inhibition of 20% 
in rCYP3A4 and HLM, respectively as depicted in Figure 3.3B. 
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Figure 3.3A Inhibitory effect of crude K. crenata (39KC) and fractions 45A, 45B and 45D (25 - 
100 μg/mL) on CYP3A4-catalyzed 6β-hydroxytestosterone formation in HLMs and recombinant 
human CYP3A4. Data expressed as Mean ± SEM of duplicate determinations. 
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Figure 3.3B: Inhibitory effect of crude M. oleifera (MO) and fractions 50A, 50B and 50C (25 - 
100 μg/mL) on CYP3A4-catalyzed 6β- hydroxytestosterone formation in HLMs and 
recombinant human CYP3A4. Data expressed as Mean ± SEM of duplicate determinations. 
 
3.1.1.5 Comparative evaluation of conventional and cocktail IC50s using fluorescent 
substrate in rCYPs  
The IC50 values of crude methanol and fractions of M. oleifera and K. crenata were re-evaluated 
using cocktail enzyme/substrate for the five major recombinant human CYPs.  A fold decrease or 
increase in the inhibitory potency of each extract or fraction was determined as a ratio of the 
cocktail to the conventional IC50 values as shown in Table 3.3. Crude methanol extract of K. 
crenata, fractions 45B and 45D showed a 3.32-, 2.55- and 4.8-fold decrease in inhibition 
potencies, respectively on CYP3A4. A 1.18- and 1.63-fold decrease in inhibition potency of M. 
oleifera fractions 50A and 50B, respectively on CYP3A4 was observed. Crude methanol extract 
of M. oleifera indicated an increase in inhibition potency (0.38-fold) on CYP3A4. For 
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CYP2C19, there was no difference in the inhibitory effect of 39KC, 45B, 50A and 5B, whereas 
fraction 45D of K. crenata and crude methanol extract of M. oleifera (80) showed a reduction in 
inhibition potency of 4.36 and 43.55, respectively. 
 
Table 3.3 Comparison of inhibitory potency of test samples in cocktail and single rCYPs 
Fraction Conventional IC50  
(μg/mL) 
Cocktail IC50 
(μg/mL) 
Fold decrease or increase in 
inhibitory potency 
CYP3A4    
39 KC 38.21 127 3.32
b
 
45B 5.33 13.6 2.55
 b
 
45D 15.76 75.72 4.80
 b
 
80 46.30 18.10 0.39
c
 
50A 17.69 20.96 1.18
 b
 
50B 7.66 12.51 1.63
 b
 
CYP2C19    
39KC 36.78 _a _a 
45B 10.30 _a _a 
45D 32.18 140.4 4.36
 b
 
80 5.91 257.40 43.55
 b
 
50A 7.90 _a _a 
50B 5.91 _a _a 
_a
 No inhibition at the concentration tested, 
b
 fold decrease in inhibition potency and 
c
 fold increase in inhibition 
potency. 
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3.1.1.6 Integration of PAMPA screening into rCYP assays  
To monitor the inhibitory effect of various herbal medicines used in this study after permeation 
through absorption membrane, the PAMPA model was used. The hot aqueous herbal extract 
prepared similar to the method used by the THPs was employed for the PAMPA screening. The 
integrity of the PAMPA was intact as the effective permeability (Pe) values for the positive 
control (caffeine = 27.8 x 10
-6
 cm/s) and the negative control (cimetidine = 1.3 x 10
-6 
cm/s) were 
within the ranges reported for high and low permeability compound, respectively by BD Gentest. 
The inhibitory effect of most herbal extracts on CYPs (1A2 and 3A4) before and after PAMPA 
was similar especially for L. frutescens tablets (T50) and tea cut (T79), H. hemerocallidea 
capsule (T41) and M. oleifera powdered leaves (T80). However, the inhibitory effect of E. 
purpurea capsules (T60) and H. hemerocallidea powdered leaves (T30) on CYP1A2 was 
reduced by almost three fold after PAMPA compared to that of before PAMPA as depicted in 
Figure 3.4.  
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Inhibitory effects of herbal medicines on CYPs (1A2 and 3A4) after and before 
PAMPA. Positive control of: CYP1A2 – ANF (0.01µM), CYP3A4 – KTZ (0.01 µM) were used. 
Data are expressed as Mean ± SEM, n=2. 
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DISCUSSION 
 
Reversible inhibition of CYPs 
The screening of new chemical entities for metabolism based DDI is standard practice in 
medicines development. Scientists from the pharmaceutical industry and FDA have published 
opinion documents and guidelines on how such studies should be done (Zhang et al., 2009; 
Prueksaritanont et al., 2013). Knowledge and systems for evaluating DDI involving CYP 
inhibition and induction are well established compared to other enzymes and drug transporters 
(Crespi et al., 1997). As the use of herbal medicines either as nutritional supplements or 
complementary and alternative medicines is on the increase and well established in developing 
countries, concerns about the risk of HDIs have resulted to an increase number of studies on 
inhibitory effects on CYPs based on published guidelines. Such studies have indeed resulted to 
drug label revisions such as indinavir and postmarket withdrawal of mibefradil (Riley et al., 
2002; Clauson et al., 2008). In this study, we evaluated the inhibitory effects of 7 herbal 
medicines used by HIV/AIDS patients to treat HIV or related co-morbidities and control disease 
symptoms. Many of the herbs were shown to potently inhibit the 5 major CYPs (1A2, 2C9, 
2C19, 2D6 and 3A4) at levels predicted to result to significant in vivo HDI if co-administered 
with drugs which are substrates of these enzymes. These herbal medicines are being used in 
populations which are also receiving ARVs under national treatment roll out programs, thus 
present a real healthcare risk for HDIs with ARVs which are metabolized by CYPs such as the 
NNRTI (nevirapine and efavirenz, metabolized by CYP3A4 and 2B6) and protease inhibitors 
(metabolized by CYP3A4). 
The initial screening assay using two concentrations showed that generally the aqueous herbal 
extracts inhibited CYPs in the order CYP1A2 > CYP3A4 > CYP2D6 > CYP2C9 > CYP2C19 in 
a concentration dependent manner. Aqueous extracts of T30 (H. hemerocallidea powdered 
leaves), T41 (H. hemerocallidea capsule), T60 (E. purpurea capsules) and T50 (L. frutescens 
capsules) at a concentration of 2.0 mg/mL inhibited the five major CYPs more than 50%. The 
methanol extracts of Lessertia tablets and tea cuts, K. integra and E. purpurea capsule at a 
concentration of 100 µg/mL exhibited inhibition on CYP3A4, CYP2C9 and CYP2C19 activities 
by at least 50%. Taraxacum officinale methanol extracts weakly (20%) inhibited CYP2C9. 
Stellenbosch University  https://scholar.sun.ac.za
95 
 
Comparing the inhibition profile of aqueous extracts to that of methanol indicated a stronger 
effect by phytochemicals in the latter. This can be attributed to the recovering higher amounts of 
phytochemicals from the plant matrix using methanol as solvent for the extraction process. The 
herbal extracts prepared employing the hot aqueous decoction showed weak inhibition on CYPs; 
CYP3A4, CYP2C9 and CYP2D6.  Thus extraction procedures which do not take into account 
the indigenous mode of preparation (hot aqueous decoction) of these herbal medicines can yield 
different phytoconstituents with varying inhibitory effects on CYPs and other drug metabolizing 
enzymes. Nevertheless, as a form of scientific investigation, several solvents of different polarity 
were employed in this study to improve the recovery of phytochemicals and to flag the potential 
of herbal medicines likely to cause HDI.   
 The aqueous herbal extract of T. officinale showed an apparent activation on the activity of 
CYPs (2D6 and 3A4). An increase in activity of more than 20% compared with the control 
activity was considered to be an apparent activation. The apparent activation needs to be 
interpreted with caution as this has been shown to be a typical in vitro artifact of the fluorimetric 
assays especially when dealing with compound (herbal extracts in this case) with high florescent 
activity. To further study such cases, different assay platforms using HLM and other standard 
CYP marker reactions with HPLC-UV or LC-MS/MS analysis need to be used (Masimirembwa 
et al., 1999).  
Although the recombinant human CYPs are used as an HTS model, the HLM are preferred as an 
ideal in vitro tool for evaluation of the inhibitory activity of new drug candidates by employing 
specific substrates. In comparing the inhibitory effects of crude methanol extracts and fractions 
of the two potent inhibitors of CYP3A4; M. oleifera and K. crenata, CYP3A4 activity in HLMs 
and recombinant CYP3A4 was examined using TST as probe substrate. The results showed a 
general weak inhibition profile of the test samples in HLMs. This could be attributed to some 
phytochemical compounds of the test samples acting as substrates, therefore metabolized via 
other pathways than CYP3A4. A study by Patki et al, (2003) comparing inhibitory potency of 
known CYP3A4 inhibitors employing both HLMs and recombinant CYPs indicated higher IC50 
values in the former. The weak potencies of inhibitors in HLMs were attributed to compounds 
acting as substrates for other isozymes, and therefore metabolized to less active forms which 
weakly inhibit CYP3A4. However, in a situation where metabolites with strong inhibitory effect 
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are generated due to the activities of other isozymes in HLMs, lower IC50 values may be 
observed (Nomeir
 
et al., 2001). In this study, although weaker inhibition activity was observed in 
HLMs assay, the difference was marginal when compared with that of recombinant human CYP. 
The results of this study agree with the findings by Bapiro et al., (2001) and Bell et al., (2008) 
which demonstrated positive correlation between compounds screened with both HLMs and 
recombinant human CYP for their inhibition effects. However, strong inhibition was observed in 
recombinant human CYP compared to HLMs for fraction 45B. This indicates the possibility of 
underestimation of potential inhibitor when HLMs are used as the sole in vitro model for the 
prediction of drug candidates’ potential for DDI or HDI. Conversely, the use of recombinant 
human CYP might also lead to an overestimation of inhibitory effect of such compounds on 
CYPs; hence a combination of these models should be employed in screening herbs purported to 
have potential risk for HDI to avoid loss of important information. Crude K. crenata exhibited a 
strong inhibition profile in HLMs compared to rCYP3A4. Such activity could be due to 
production of metabolites by other enzymes present in HLMs and these metabolites later acting 
as inactivators of CYP3A4.  
The IC50 profile screening indicated CYP1A2 and CYP3A4 as the most sensitive to the aqueous 
herbal extracts whilst the methanol extracts strongly inhibited CYP3A4, CYP2C9 and 
CYP2C19. The aqueous herbal extract of H. hemerocallidea (T30) inhibited CYP1A2 the 
strongest, with an IC50 value of 0.64 ± 0.02 µg/mL, although the methanol did not show any 
effect. The methanol extracts of H. hemerocallidea capsules (HHC) and leaves (HHL) indicated 
strong inhibition on CYP2C9 with IC50 of 17.56 µg/mL and 10.68 µg/mL, respectively. Such 
finding contrasts those of Fasinu et al., (2013) who reported the crude methanol as weak 
inhibitor of CYP2C9 (IC50 = 156 µg/mL) in HLMs. This could be due to the differences in 
phytoconstituents of H. hemerocallidea used for the two independent studies. Additionally, 
whilst recombinant human CYPs contain a single isoform of enzyme, HLMs have several 
enzymes. The phytochemicals in H. hemerocallidea might serve as substrates to other enzymes 
which could account for the weak inhibitory activity reported earlier. Thus for mechanistic 
purposes, the methanol extract of H. hemerocallidea is considered a strong inhibitor of CYP2C9 
in rCYPs even though the same preparation is weak in HLMs and could therefore cause HDI 
upon concurrent administration with substrates of CYP2C9 such as NSAIDS, S-warfarin and 
tolbutamide. The aqueous extract of H. hemerocallidea capsule indicated no effect on CYP3A4. 
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This finding agrees with an in vivo study conducted by Gwaza et al., (2013) in health volunteers 
to evaluate the influence of another subspecies of Hypoxis (H. obtusa) on pharmacokinetics of 
lopinavir/ritonavir.  
The hot aqueous extract of L. frutescens tea cut exhibited weak inhibition on CYP3A4 with IC50 
of 740 ± 5.2 µg/mL whilst both the methanol extracts of the tea cut and tablets inhibited the same 
enzyme with IC50 values of 28.42 ± 2.1 µg/mL and 30.62 ± 0.78 µg/mL, respectively. The strong 
inhibitory effects of methanol extracts of L. frutescens observed in this study agree with the 
findings by Fasinu et al., (2012). However, the weak inhibitory effects of the hot aqueous 
extracts of L. frutescens show that the degree of HDI depends on the nature of solvent used for 
the extraction of the herbal medicine (Pan et al., 2012).   
Both aqueous and methanol extracts of E. purpurea indicated strong inhibition on CYP3A4, 
CYP2C9 and CYP2C19. The aqueous extracts of EP exhibited strongest effects on CYP1A2 
(IC50 = 20.20 ± 0.9 µg/mL) and CYP3A4 (IC50 = 12.0 ± 0.53 µg/mL). A similar trend was 
observed for the methanol extract yielding IC50 values of 15.6 ± 0.79 µg/mL, 1.04 ± 0.01 µg/mL 
and 22.32 ± 1.6 µg/mL for CYP2C9, CYP2C19 and CYP3A4, respectively. Studies conducted 
by Modarai et al., (2010) and Hansen and Nilsen (2008) reported E. purpurea as a weak inhibitor 
of CYP3A4 supersomes (IC50 = 364 - 1812 µg/mL) which contradicts with the findings of this 
study. Such discrepancies between the current results and that of the Modarai et al., (2010) and 
Hansen and Nilsen (2008) can be attributed to the differences in developmental stages, season of 
collection, postharvest preservation and extraction procedures (Bolling et al., 2010). Also the 
type of substrate and the source of enzyme (HLM or rCYP) used could be responsible for the 
differences in the inhibition profile observed especially for CYP3A4. In this study, BFC was 
used as substrate for CYP3A4 which has been shown to have high affinity for the enzyme 
compared to other substrates such as TST, midazolam and nifedipine (Fowler et al., 2002). 
Moringa oleifera, a popular herbal medicine consumed for treatments and management of 
cardiovascular and gastrointestinal complications in HIV/AIDS patients on ARVs also indicated 
strong inhibition of CYPs. The methanol extracts exhibited strong inhibition with IC50 values of 
20.60 ± 1.45 µg/mL, 10.62 ± 0.60 µg/mL and 31.48 ± 1.7 µg/mL for CYP2C9, CYP2C19 and 
CYP3A4, respectively. The strong inhibition of M. oleifera on CYP3A4, agrees with the 
previous findings by Monera et al., (2008). Although the methanol extracts was ineffective on 
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CYP1A2, strong inhibition was observed for the aqueous extracts of M. oleifera with IC50 value 
of 37.00 ± 1.89 µg/mL while weak effect was indicated for CYP3A4 ( IC50 = 300.00 ± 18.21 
µg/mL).  
As a method of confirming the inhibition effects of the crude methanol extract and fractions of 
M. oleifera and K. crenata in the presence of other isozymes, the cocktail approach was adopted. 
A general decrease in inhibition profile was observed as the IC50 values for the cocktail were 
higher compared to the single CYPs. In an attempt to establish differences between potencies of 
known inhibitors using conventional HLMs or recombinant human CYPs against the cocktail 
approach, Dierks et al., (2001) reported a strong correlation between the two models. For 
example, comparable IC50 values of ketoconazole, quinidine, sulfaphenazole and 
tranylcypromine were observed for their respective CYPs in both conventional single CYP and 
the cocktail approach. However, for herbal extracts or fractions with multi-phytochemicals, there 
is a high probability of at least a constituent acting as a substrate to other isozymes or binding to 
other CYP protein(s). Such effects might be responsible for the general weak inhibitory effects 
observed in the cocktail approach. Surprisingly, the crude methanol extract of M. oleifera 
indicated strong inhibition of CYP3A4 using the cocktail approach compared to the conventional 
assay. Generally, the outcome of the cocktail approach confirms the presence of other isozymes 
in HLMs contributing to the reduction of inhibition activity of test samples as opposed to the 
single CYPs.   
 
Prediction of in vivo HDI 
Prediction of HDI based on IC50 values without inclusion of the concentration of herbal extracts 
reaching the liver and interacting with the enzyme could lead to false positive or negative 
estimations. Unlike pure compounds or new candidate drugs, no guidelines for the conduct of 
HDI studies are available. Most research laboratories have adopted the protocol for the conduct 
of DDI by US FDA and/or PhARMA (Bjorsonn et al., 2003).  The adoption of current industry 
and FDA guidelines for prediction of DDI to estimate the degree of HDIs comes with a number 
of important caveats. Firstly, in industry, pure compounds are evaluated whereas for herbs 
mixtures of unknown chemical composition are used making it impossible to know the identity 
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or the concentration of the inhibiting components. The use of the total GIT concentration of the 
herbal extract (μg/mL) as the assumed soluble extract available to interacts with the intestinal 
CYPs and P-glycoprotein is therefore a gross exaggeration. Secondly, the IC50 and estimations of 
Ki from this value using specific M-M kinetic conditions is also difficult to do with herbal 
extracts for the same reason indicated above. The IC50 and Ki used for herbal extracts are 
therefore based on the assumption that at least one pure constituent of the herbal extract is 
responsible for the inhibitory effect observed on the CYPs. Additionally, the substrate 
concentration used for the in vitro assay is equivalent to the Km, hence the speculated 
phytoconstituent is expected to demonstrate competitive inhibition. The Ki value is therefore half 
of the IC50 based on competitive inhibition. Thirdly, industry uses the metabolism-based DDI 
studies to both guide the molecular design of NCE devoid of potential DDI risks during the early 
hit and lead identification and lead optimization stages. At candidate drug selection stage, the 
DDI data is used to select compounds devoid of such DDI risk or the design of in vivo DDI 
studies to determine the extent of the risk of DDI in candidate drugs which still bear the CYP 
inhibitory effects. For herbal extracts already in use, the HDI studies are therefore mainly to 
assess risk, guide the design of in vivo HDI studies and possibly revise product labels to 
highlight the risk of co-administering some herbs with certain conventional drugs. The 
mechanistic approach of using in vitro systems adopted in this study allows for rapid evaluation 
of many herbal medicines and for general or class label recommendations with respect to HDI 
which can guide patients and clinicians in avoiding drug-herb combinations likely to result in 
HDI. 
Despite the study design and results limitations such evaluations allow to identify herbal extracts 
with likely risk for HDI for which more detailed biochemical studies (identification of possible 
components in the extract causing the observed inhibition) and clinical studies (identifying herbs 
for which in vivo evaluation can be conducted) might be required. So for the 7 herbal extracts 
evaluated in this study, a number of outcomes can be highlighted with respect to their possible 
clinical risk to cause HDI. 
A preliminary risk evaluation from in vitro data to in vivo using the FDA guidelines predicted 
that most of the herbal medicines are likely to pose high risk for CYP metabolism-based HDIs. 
The Ki values for aqueous extracts; T41 (H. hemerocallidea capsules), T30 (H. hemerocallidea 
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powdered leaves), T60 (E. purpurea capsules), and T80 (M. oleifera powdered leaves) obtained 
with recombinant CYP1A2, CYP2D6 and CYP3A4 were far below the estimated gut and intra-
hepatic concentrations of the respective herbal medicines. These herbal medicines were therefore 
predicted to inhibit the three CYPs in vivo to a major extent with potential high risk for HDI as 
the estimated Cmax/Ki is greater than 1.0. For most methanol extracts, the Ki values were almost 
10-fold greater than the estimated gut and intra-hepatic concentrations for CYP2C9, CYP2C19 
and CYP3A4. Based on these findings, it is speculated that inadequate concentration of the 
methanol extract is likely to reach the liver to interact with CYPs to cause inhibition and possible 
HDI. Thus, although the methanol extracts were estimated to have high risk to cause HDI based 
on Cmax/Ki, such prediction can be false positive. Incorporation of maximum hepatic input into 
the prediction of HDI indicated severe consequences compared to that of GIT estimation. 
However, due to the several assumptions considered in such estimation, it is inappropriate to 
conclude that hepatic estimation superceeds gut prediction since herbal products consist of 
polyphytochemical with some components unlikely to be completely absorbed. To confirm the 
inhibitory effects of these extracts, in vivo studies in animal models or human is recommended. 
Other models for characterization of absorption parameters can be employed to evaluate the 
probability of specific phytochemicals in herbal extracts to actively or passively traverse the 
intestinal barrier. In this study, a specific absorption model, PAMPA, was introduced to monitor 
the inhibitory effect of the aqueous herbal extracts which showed high risk of HDI based on the 
in vivo prediction. 
 
Inhibition of CYP1A2 and CYP3A4 by herbs after absorption through PAMPA 
The intensity of HDI of orally administered medications depends on transport of the 
phytochemical constituents via the intestinal transmembrane barrier to the enterocytes and 
through the portal vein to the hepatocytes. Herbal medicines consist of multi-phytochemical 
constituents with different physicochemical properties. Certain constituents in herbs are 
impermeable to the intestinal transmembrane barrier. Influx drug transporters can also 
concentrate herbal constituents in hepatocytes with the result that the actual concentration in the 
liver far exceeds that in plasma. It is therefore important to incorporate models that mimic 
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intestinal absorption of drugs in the conduct of in vitro HDI. This will reduce the overestimation 
and underestimation of HDI. The PAMPA plate system which is frequently used for screening 
permeability of new chemical entities was employed in this assay to assess the transcellular 
permeability of the investigated herbal preparations. The plate system employed has triple lipid-
oil-lipid layers which mimic the exterior and interior biological membrane of the intestinal 
barrier (Faller, 2008). The membrane is attached to the basal component of the acceptor plate, 
acting as a barrier between the acceptor (AC) and donor (DC) compartments. Initially, once test 
sample is introduced to the donor compartment in phosphate buffer, passive transport occurs 
unilaterally from the DC to AC. After 5 hours of incubation, the system equilibrates; 
bidirectional transport of test sample from AC to DC and DC to AC occurs, thus parallel 
movement is observed.  
In this study, the inhibitory effects of most herbal medicines on CYPs (1A2 and 3A4) before and 
after PAMPA were similar, indicating that significant amount of phytochemical constituents in 
the herbal medicines evaluated in this study permeated through the lipid- oil- lipid tri-layer. The 
inhibitory effect of T30 (H. hemerocallidea powdered leaves) and T60 (E. purpurea capsules) on 
CYP1A2 was significantly reduced after passive transport through PAMPA compared to the 
observation for CYP3A4. The active site of CYP1A2 has a planar shape which favours 
chemicals with aromatic rings such as polyphenols predominantly found in herbal extracts. 
CYP3A4 however, has different binding pocket and the degree of inhibition depends on the 
affinity of a specific inhibitor for a given active site (Ohkura et al., 2009).    
First-line treatment of most HIV-infected patients in both developing and developed countries 
includes NNRTIs (nevirapine and efavirenz) and PIs (ritonavir and atazanavir) as a therapy 
(Shubber et al., 2013). These NNRTIs are metabolized by intestinal and hepatic CYP3A4. 
Consequently, co-administration of nevirapine and efavirenz with the investigated herbal 
preparations, especially T30 (H. hemerocallidea powdered leaves) and T79 (L. frutescens tea 
cut), has the potential to cause HDI. The inhibitory effect of these herbal preparations on 
CYP3A4 may increase plasma concentrations of NNRTIs and PIs generating possible systemic 
toxicity. 
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PART TWO 
3.2 Time-dependent inhibition of CYP 
3.2.1 TDI IC50 shift fold 
The IC50-shift assay with single substrate for CYP2C19 and CYP3A4 was used to evaluate the 
TDI potencies of the crude methanol extracts and fractions. An inhibition curve (shift IC50 value 
for TDI) obtained in the presence of NADPH was compared with inhibition curve (reversible 
IC50 value) obtained in the absence of NADPH to determine the TDI potency of individual 
fractions as shown in Figures 3.6, 3.7 and 3.8, respectively. Fold shift in IC50 as a ratio of the 
reversible and TDI IC50s was employed to determine the potencies of each fraction by 
categorizing samples as positive TDI or negative TDI (Figure 3.5). Herbal extracts and fractions 
prepared based on the Figure 2.2A to 2.2D were used for TDI screening assays. Test samples 
with fold shift in IC50 ≥1.5 were classified as positive TDI. The fractions 45A and 45D of K. 
crenata showed TDI potencies with fold shift in IC50 of 2.26 and 1.50 for CYP3A4 and, 2.36 and 
5.07 for CYP2C19, respectively. The crude methanol extract of K. crenata (39KC) and the 
fraction 45B were observed as positive TDI of CYP3A4 with fold shift of 3.29 and 1.91, 
respectively. However, both 39KC and 45B indicated a non-TDI effect on CYP2C19 with fold 
shift of 1.30 and 1.20. The crude methanol extract of L. frutescens and fraction 43.10 exhibited 
TDI potential with IC50 shift fold of 3.0 and 2.12, respectively on CYP3A4, whilst the pure 
compounds were non-TDI. However, Sutherlandioside D and, fractions 43D and 43C exhibited 
TDI potential with IC50 shift fold of 1.85, 4.73 and 2.06, respectively on CYP2C19. Fractions 
50A, 50B, and 50C of M. oleifera demonstrated TDI activity with IC50 shift fold of 8.31, 7.16 
and 3.92, respectively on CYP3A4. However, the crude methanol extract and fractions of M. 
oleifera showed non-TDI activity on CYP2C19. Troleandomycin and ketoconazole produced a 
fold shift of 3.29 and 0.67, respectively which were in agreement with previous study by Berry et 
al., (2008). The positive and negative controls of CYP2C19, ticlopidine (TPD) and 
tranylcypromine (TCP) yielded a fold shift of 2.10 and 0.55, respectively. 
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Figure 3.5 Determination of TDI based on IC50 shift fold. Bars represent the ratio of IC50 values 
from the no preincubation (-) assays to the 30 min preincubation (+) assays for the test samples 
listed. Data are the mean ± SEM (n＝2). Positive control (PC) and negative control (NC) used 
for the various CYPs were; troleandomycine and ketoconazole (CYP3A4), ticlopidine and 
tranylcypromine (CYP2C19) and Tienilic acid and sulphenazole (CYP2C9). 
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Figure 3.6A IC50 shift curves for rCYP3A4 in the presence of Crude (39KC) and fractions 45A, 
45B and 45D of K. crenata in recombinant CYP3A4.  
Values represent the average of duplicate experiments. Inhibition percentages for no 
preincubation (closed circles) and 30 min preincubation (close triangle) are shown. 39KC (crude 
methanol extract), 45A (CHCl3: 100%), 45B (CHCl3/MeOH: 90/10%), 45D (CHCl3/MeOH/H2O: 
67/28/5%) and 45E (MeOH: 100%). 
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Figure 3.6B: IC50 shift curves for rCYP2C19 in the presence of Crude (39KC) and fractions 
45A, 45B and 45D of K. crenata.  
Values represent the average of duplicate experiments. Inhibition percentages for no 
preincubation (closed circles) and 30 min preincubation (close triangle) are shown. 39KC (crude 
methanol extract), 45A (CHCl3: 100%), 45B (CHCl3/MeOH: 90/10%), 45D (CHCl3/MeOH/H2O: 
67/28/5%) and 45E (MeOH: 100%). 
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Figure 3.7A IC50 shift curves for rCYP3A4 in the presence of L. frutescens crude (2678), 
fractions 43A, 43B, 43C, 43D and 43F and pure compounds (sutherlandioside A-D and 
sutherlandin A-D). The values represent the average of duplicate experiments. Inhibition 
percentages for no preincubation (closed circles) and 30 min preincubation (close triangle) are 
shown. 2678 (crude methanol extract), 43A (CHCl3: 100%), 43B (CHCl3/MeOH: 90/10%), 43C-
E (CHCl3/MeOH/H2O: 67/28/5%) and 43F (MeOH: 100%). 
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Figure 3.7A continued:  
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Figure 3.7B: IC50 shift curves for rCYP2C19 in the presence of L. frutescens crude (2678), 
fractions 43A, 43B, 43C, 43D and 43F and pure compounds (sutherlandioside D).  
Values represent the average of duplicate experiments. Inhibition percentages for no 
preincubation (closed circles) and 30 min preincubation (close triangle) are shown. 
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Figure 3.8A IC50 shift curves for rCYP3A4 in the presence of crude (MO) and fractions 50A, 
50B, 50C and 50E of M. oleifera.  
Values represent the average of duplicate experiments. Inhibition percentages for no 
preincubation (closed circles) and 30 min preincubation (close triangle) are shown. MO (crude 
methanol extract), 50A (CHCl3: 100%), 50B (CHCl3/MeOH: 90/10%), 50C (CHCl3/MeOH/H2O: 
64/16/20%) and 50E (MeOH: 100%). 
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Figure 3.8B: IC50 shift curves for rCYP2C19 in the presence of crude (MO) and fractions 50A, 
50B, 50C and 50E of M. oleifera.  
Values represent the average of duplicate experiments. Inhibition percentages for no 
preincubation (closed circles) and 30 min preincubation (close triangle) are shown. 
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3.2.2 Application of normalized ratio for TDI screening 
The aqueous and methanol extracts of the various herbal medicines were categorized into clear 
(≤0.70), intermediate TDI (0.7 – 0.9) or non-TDI (>0.9) applying the normalized ratio. Aqueous 
herbal extracts of L. frutescens tablets (T50) and H. hemerocallidea capsule (T41) showed 
concentration dependent TDI on CYP3A4. Although H. hemerocallidea powdered leaves (T30) 
showed a clear TDI, the effect was a non-concentration dependent. The aqueous extracts of T. 
officinale and M. oleifera exhibited non-TDI effect (Figure 3.9A). All methanol extracts of 
herbal medicines tested except M. oleifera indicated clear TDI at 100 µg/mL. M. oleifera showed 
an intermediate TDI at 100 µg/mL and as a non-TDI at 25 µg/mL (Figure 3.9B). The 
troleandomycin (TAO) and KTZ demonstrated clear TDI (<0.7) and non-TDI (>0.9), 
respectively with values which agreed with those reported by Atkinson et al., (2005). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9A TDI classification of aqueous herbal extracts based on normalized ratio. Known 
TDI compound, troleandomycin (TAO, 1 and 20 μM) and non-TDI compound, ketoconazole 
(KTZ, 0.1 and 1 μM) were used as positive and negative controls. High and low concentrations 
of herbal extracts 0.2 and 2.0 mg/mL were used. The normalized ratio was calculated as 
described under Materials and Methods. Data expressed as Mean ± SEM, n= 2. 
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Figure 3.9B: TDI classification of methanol herbal extracts based on normalized ratio. Known 
TDI compound, troleandomycin (TAO, 1 and 20 μM) and non-TDI compound, ketoconazole 
(KTZ, 0.1 and 1 μM) were used as positive and negative controls. High and low concentrations 
of herbal extracts 25.0 and 100.0 µg/mL were used. The normalized ratio was calculated as 
described under Materials and Methods. Data expressed as Mean ± SEM, n = 2. 
 
3.2.3 Time-, concentration- and NADPH- dependent inhibition 
The crude extract and fractions of K. crenata indicated varying degree of inhibitory effect on 
CYP2C19 and CYP3A4 in the presence and absence of NAPDH. The fractions 45A, 45B and 
45D showed an NADPH dependent inhibitory effect on both CYP2C19 and CYP3A4. However, 
the crude extract indicated NADPH dependent inhibition on CYP3A4 and non-NADPH 
dependent inhibition potential on CYP2C19 (Figure 3.10A). M. oleifera crude extract and the 
fractions indicated non-NADPH dependent inhibitory effect on CYP3A4. The fractions 50B, 
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50E and crude methanol of M. oleifera inhibited CYP2C19 significantly in NADPH-dependent 
manner as shown in Figure 3.10B. 
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 Figure 3.10A Inhibitory effects of crude and fractions of K. crenata (50 μg/mL) on CYP3A4 
and CY2C19 preincubated for 30 mins in the presence or absence of NADPH. The percent 
residual activities were plotted against respective fractions.  Two tailed unpaired t-test were used 
to compare the percent activity remaining for each fraction with P < 0.05 considered significant. 
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Figure 3.10B: Inhibitory effects of crude and fractions of M. oleifera (50 μg/mL) on CYP3A4 
and CY2C19 preincubated for 30 mins in the presence or absence of NADPH. The percent 
residual activities were plotted against respective fractions.  A two-tailed unpaired t-test was 
used to compare the percent activity remaining for each fraction, with P < 0.05 considered 
significant. 
Preincubation of crude methanol and fractions of K. crenata and M. oleifera for 0, 10, 20 and 30 
mins indicated time-dependent inactivation of CYP3A4 as the degree of inhibition increased 
with time (Figures 3.11A-B). However, 39KC did not show TDI following preincubation with 
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CYP2C19 in the presence of NADPH. The fractions 45A, 45B and 45D however indicated TDI 
on CYP2C19 as shown in Figure 3.11A. The large SEM indicated on residual activity of fraction 
45A in the absence of NADPH could be due to artifact. Crude M. oleifera and fractions were 
inactive on CYP2C19 after preincubation at specific durations. 
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Figure 3.11A Time-dependent inhibition of K. crenata on CYP3A4 and CYP2C19. 50 μg/mL of 
39KC, 45B or 45D were preincubated for 0, 10, 20 and 30 min. The percent remaining activity 
was plotted against respective time point through connecting lines. Each point represents the 
Mean ± SEM of duplicate determinations. 
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Figure 3.11B: Time-dependent inhibition of M. oleifera on CYP3A4. 50 μg/mL of MO and 50B 
were preincubated for 0, 10, 20 and 30 min. The percent remaining activity was plotted against 
respective time point through connecting lines. Each point represents the Mean ± SEM of 
duplicate determinations. 
 
Inactivation of CYP3A4 by 39KC, 45B and 50B followed a time- and concentration-dependent 
pattern. Crude methanol extract of M. oleifera had a concentration-dependent and not a time-
dependent effect on CYP3A4. However, inactivation of CYP2C19 by 39KC and 45D did not 
indicate time- and concentration dependency, as the inhibition profile became weaker with 
increase in both time and concentration of the respective extract or fractions applied to the 
incubation mixture (Figure 3.12A). 
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Figure 3.12A Concentration- and time-dependent inhibition of CYP3A4 and CYP2C19 by 
39KC, 45B and 45D preincubation for 0, 10, 20 and 30 min. The percent remaining activity was 
plotted against respective time point through connecting lines. Each point represents the Mean ± 
SEM of duplicate determinations. 
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Figure 3.12B: Concentration- and time-dependent inhibition of CYP3A4 by MO and 50B 
preincubation for 0, 10, 20 and 30 min. The percent remaining activity was plotted against 
respective time point through connecting lines. Each point represents the Mean ± SEM of 
duplicate determinations. 
 
3.2.4 Kinetics of CYP3A4 inactivation 
CYP3A4 HFC activity was inactivated by K. crenata preparations (39KC and 45B) and M. 
oleifera preparations (MO and 50B) in a time- and concentration- dependent manner in the 
presence of NADPH regeneration system. The loss of activity followed pseudo-first-order 
kinetics. Linear regression analysis of the time course data was used to determine the kobs values 
at various concentrations (Figure 3.13A-B). The KI and kinact values were determined from 
double reciprocal plots of kobs values and inactivator concentrations. The KI and kinact values for 
39KC were 1.77μg/mL and 0.091 min-1 while that of 45B were 6.45 μg/mL and 0.024 min-1, 
respectively. The crude M. oleifera and fraction 50B yielded KI of 25.3 and 47.85 μg/mL, 
respectively while their individual Kinact values were 0.018 and 0.044 min
-1
. 
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Figure 3.13A Inactivation kinetics of CYP3A4 by 39KC and 45B. Concentrations of fractions 
are shown on the right of the plots (A). Double-reciprocal plots of kobs and inhibitor 
concentrations were plotted on linear graph to determine inactivation parameters KI and Kinact in 
plot (B). Each point represents the mean of duplicate determinations. 
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Figure 3.13B: Inactivation kinetics of CYP3A4 by MO and 50B. Concentrations of fractions are 
shown on the right of the plots (A). Double-reciprocal plots of kobs and inhibitor concentrations 
were plotted on linear graph to determine inactivation parameters KI and Kinact in plot (B). Each 
point represents the mean of duplicate determinations. 
 
3.2.5 In vivo prediction of CYP3A4 inactivation 
The likely in vivo effects of crude extracts of K. crenata and M. oleifera on both enteric and 
hepatic CYP3A4 were evaluated by applying the λ/kdeg approach of classification. The [I] of 
each herbal extracts was derived from the daily dosage for normal adult. Also, the rate constants 
of enzyme degradation (kdeg) 0.000321/min and 0.000481/min were used for enteric and hepatic 
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CYP3A4 (Obach et al., 2006), respectively. Crude extracts of M. oleifera and K. crenata 
demonstrated the potential to inactivate both enteric and hepatic CYP3A4 as shown in Table 3.4. 
Table 3.4 in vivo prediction of CYP3A4 inactivation 
Parameters K. crenata M. oleifera 
Concentration (µg/mL) 60 244 
Kinact (min
-1
) 0.024 0.018 
KI (µg/mL) 6.45 2.53 
  
            
      
 (min
-1
) 0.022 0.018 
Gut (λ/kdeg) 68.53 56.07 
Hepatic (λ/kdeg) 45.73 37.42 
HDI risk Likely Likely  
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DISCUSSION  
Usually, novel compounds are evaluated for their potential to cause CYP-mediated drug 
interaction based on single concentration screening while allowing for later detailed 
characterization involving IC50 and Ki determinations for reversible inhibition. Additionally, 
evaluation of compounds as time-dependent or mechanism-based inhibitors following reversible 
inhibition has become necessary, as the consequences are more detrimental. However, due to the 
complexity of mechanism-based inhibition, pharmaceutical industry and FDA have developed 
approaches to evaluate the potential of time-dependent inactivation by funneling compounds 
through single concentration, single time point experiments, and determining IC50 shift to avoid 
waste of time, labour and money on compounds that are weak CYP inactivators (Obach et al., 
2007). The choice of in vitro models for the conduct of mechanism-based screening of 
compounds is important, because false positive or negative predictions can result to 
inappropriate compound progression or de-selection. The HLM or recombinant human CYPs are 
routinely applied for the conduct of such studies (Preuksaritanont et al., 2013). As preliminary 
studies to evaluate the TDI potential of K. crenata and M. oleifera to cause HDIs, several 
screening  approaches were adopted to de-select and select the appropriate test samples in which 
inactivation kinetics will be required.   
Limited information is currently available regarding the interactions of K. crenata and M. 
oleifera with clinically prescribed medications. This is an issue of potential safety concern as 
these herbal products are consumed by geriatrics and patients with chronic diseases such as 
diabetes, HIV/AIDS and asthma. Drugs commonly used by these patients include analgesics 
(diclofenac, ibuprofen, celecoxib - CYP2C9 substrates), protein pump inhibitors like omeprazole 
(CYP2C19 substrate), antiasthmatics (theophylline –CYP1A2 substrate) and nevirapine 
(CYP3A4); some of these have narrow therapeutic indices and high tendencies for DDI. 
Furthermore, such patients are prone to co-morbidities and infections, which might require the 
use of medications like the sulphonylureas (tolbutamide and glipizide), antituberculosis 
(isoniazid, rifampicin), and macrolide antibiotics (e.g., erythromycin, clarithromycin) 
metabolized by CYPs. Hence, there exists a high potential risk for interaction when any of these 
medications are consumed concurrently with K. crenata or M. oleifera which contain multiple 
phyto-constituents.    
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Recently, the US Pharmaceutical Research and Manufacturers Association recommended the use 
of IC50-shift approach as the first step for TDI assays (Bjornsson et al., 2003). This method 
involves the application of HLMs or recombinant human CYPs to evaluate whether the potency 
of the NCE to inhibit CYP increases when the drug candidate is preincubated in the presence of 
NADPH. The IC50 shift approach was subsequently used by Obach et al., (2007) to evaluate the 
TDI potential and demonstrated a progressive flow strategy in which NCEs are selected for 
detailed TDI kinetics estimations. Therefore, this study used the IC50 shift approach to examine 
the TDI potency of crude and fractions of K. crenata, L. frutescens and M. oleifera. The test 
samples were preincubated with single recombinant human CYPs in the presence of NADPH as 
a primary incubate. An aliquot of the primary incubate was taken at predetermined time points 
and added to the secondary incubate containing the probe substrate to make a 10-fold dilution 
prior to 30 mins incubation. Such approach showed a leftward shift in the inhibition curves after 
preincubation compared to the curves without preincubation. Although many institutions are 
adopting the IC50 shift approach for screening of TDI potential compounds, there is currently no 
definitive criterion for classification of compounds as negative or positive TDI. Many 
pharmaceutical companies have been using the fold-shift criterion of 1.2 to 1.3-fold whilst Berry 
et al., (2008) also concluded that an IC50-shift decrease of >1.5 indicated significant potency. In 
these studies, the Berry et al criterion was adopted whereby compounds with a fold shift ≥1.5 
were tagged as potential TDI candidates. The crude methanol extract of K. crenata (39KC) and 
L. frutescens together with fractions 43.10, 45A, 45B and 45D tested had TDI effects. Although 
crude methanol extract of M. oleifera exhibited a non-TDI effect, the fractions 50A, 50B and 
50C showed TDI potencies with IC50 shift of 8.31, 7.16 and 3.92, respectively on CYP3A4. TDI 
potencies of 3.29 and 0.67 was observed for troleandomycin and ketoconazole, known TDI and 
non-TDI compounds for CYP3A4 which were in agreement with the results reported by 
Sekiguchi et al., (2009). The K. crenata fractions 45A and 45D also exhibited positive TDI on 
CYP2C19 with fold shift of 2.36 and 5.07, respectively. However, the crude methanol extract 
(39KC) and 45B indicated non-TDI effects, with respective fold decreases of 1.30 and 1.20.  
Sutherlandioside D, a saponin isolated from L. frutescens exhibited positive TDI with shift fold 
of 1.85 while those of the fractions 43D and 43C were 4.73 and 2.06 on CYP2C19.   
To confirm the positive TDI of fractions evaluated in this assay, the normalized ratio was used as 
described by Atkinson et al., (2005). The aqueous extracts; T41 (H. hemerocallidea capsule) and 
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T30 (H. hemerocallidea powdered leaves) showed clear TDI effect on CYP3A4. These herbal 
products could therefore reversibly and irreversibly inhibit CYP3A4; hence caution must be 
exercised in administering such medications to ARV-treated HIV patients. Interestingly, clear 
TDI was observed for T50 (L. frutescens tablets) which did not show significant reversible 
inhibition on CYP3A4 during early screening. Thus, although acute use of T50 (L. frutescens 
tablets) may not pose any danger to patients, chronic use of such products can generate enough 
intermediary metabolites which are deleterious to consumers concomitantly taking other 
conventional medications. Clear TDI was observed for all the methanol extract except M. 
oleifera which exhibited intermediate TDI at 100 µg/mL. Thus methanol extract of these herbal 
medicines can be fatal to the health of perpetual consumers on conventional medications such as 
efavirenz and nevirapine which are substrates of CYP3A4. 
Inactivators of CYPs are known to be time- and concentration dependent, hence the effects of 
such parameters on K. crenata and M. oleifera crude and fractions were tested. The results 
showed that none of the fractions of K. crenata was a time-dependent inactivator of CYP2C19, 
as the inhibition profile weakened after incubation. Such a phenomenon can be due to recovery 
of enzyme activity, since the inhibition potency of the phytoconstituents weakens with time 
regardless of the concentration applied. However, crude methanol extract of K. crenata and 
fraction 45B as well as that of M. oleifera (MO and 50B) exhibited time- and concentration- 
dependent inhibition as their inhibition profile increased on CYP3A4. Thus, MO, 50B, 39KC 
and 45B were identified as TDIs of CYP3A4 based on the observations that their inhibitory 
effects on CYP3A4 activity were dependent on: 1) the preincubation, 2) concentration, and 3) 
NADPH. Next, the inactivation kinetics parameters of these four samples (MO, 50B, 39KC and 
45B) were determined in recombinant human CYP3A4. The kinetic parameters for the 
inactivation of CYP3A4 by 39KC and 45B were: KI, 1.77 and 6.45 μg/mL; Kinact, 0.019 and 0.02 
min
-1
, respectively. The crude M. oleifera and fraction 50B also demonstrated strong inhibitory 
kinetics on CYP3A4. Prediction of Kinact based on reversible and irreversible inhibition IC50 
yielded values of 0.015 and 0.04 min
-1
 for 39KC and 45B, respectively which were closer to the 
results obtained from the dilution method. Thus, shift IC50 values can be used to predict 
inactivation constant of time-dependent inhibition of herbal medicines as recommended earlier 
by Sekiguchi et al., (2009). Categorization of MBIs based on λ/kdeg confirmed that both MO and 
KC are potential inactivators of both enteric and hepatic CYP3A4. 
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PART THREE 
3.3 RESULTS 
3.3.1 Metabolic clearance of testosterone 
The viability of hepatocytes (percentage viable cell relative to total cells) reduced from 78.10% 
at time zero to 52.3% without the herbal extracts and to 50.5% with the extracts. Hence, the cell 
degradation is not attributable to the presence of the herbal extracts. The TST was also stable in 
the HepatoZYME media.  
The intrinsic clearance of TST in the presence and absence of herbal extracts was monitored in 
both HLM and human hepatocytes (Figure 3.14). Previous study conducted in our laboratory 
extensively investigated the metabolic clearance of L. frutescens and H. hemerocallidea in 
hepatocytes. This study therefore investigated the influence of the other four herbs (M. oleifera, 
E. purpurea, K. crenata and K. integra) that showed strong inhibitory effects in recombinant 
CYPs. Estimation of hepatic blood clearance was done using the well-stirred liver model. The 
intrinsic clearance of TST was reduced by K. crenata; 8.5% (HLM) and 14.1% (hepatocytes), M. 
oleifera; 59.2% (HLM) and 52.7% (Hepatocytes), E. purpurea; 63.1% (HLM) and 62.3% 
(hepatocytes) in vivo (Table 3.4 and Appendix 3). Clearance of TST by respective herbal extracts 
taken into account the hepatic blood flow were K. integra; 74.38% (HLM) and 22.00% 
(hepatocytes), M. oleifera; 49.20% (HLM) and 52.89% (hepatocytes), E. purpurea; 58.96 (HLM) 
and 56.78% (hepatocytes) and K. crenata; 12.6% (HLM) and 6.69% (hepatocytes) as shown in 
Figure 3.14. 
Prediction of the degree of interaction of the herbal extracts with TST indicated that K. integra 
interacts intermediately (AUC ratio = 4.30) and weakly (AUC ratio = 1.39) in HLM and 
hepatocytes, respectively. Moringa oleifera demonstrated weak (AUC ratio = 1.47) and 
intermediate (AUC ratio = 2.46) interactions, respectively in HLM and hepatocytes. Echinacea 
purpurea indicated intermediate interaction in both systems whilst K. Crenata exhibited no 
interaction in both HLM and hepatocytes (Table 3.5).  
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Figure 3.14A: Time course showing the influence of crude methanol extract of M. oleifera (MO) and K. integra (KI) on clearance of 
TST in HLM and human hepatocytes (HEP). 
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Figure 3.14B: Time course showing the influence of crude methanol extract of E. purpurea (EP) and K. crenata (KC) on clearance of 
TST in HLM and human hepatocytes (HEP). 
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Table 3.5: Comparative evaluation of metabolic clearance of TST in HLM and hepatocyte  
Test samples CLint in vitro (mL/min/kg) CLint in vivo (mL/min/kg) AUCi/AUC 
 HLM Hepatocyte HLM Heaptocyte HLM Hepatocyte 
TST 2.64 2.45 3.05 6.24 - - 
TST+ KI 0.61 1.77 0.71 4.50 4.30
 _b
 1.39
 _c
 
TST + MO 1.25 1.00 1.44 2.54 1.47
_c
 2.46
_b
 
TST + EP 1.00 0.90 1.15 2.30 2.65
_b
 2.71
_b
 
TST + KC 2.26 2.24 2.62 5.71 1.16
_d
 1.09
_d
 
AUC ratio of interactions: 
_a 
Strong (AUC ratio >5) 
_b Intermediate (2 ≤ AUC ratio ≤ 5) 
_c
 Weak (1.25 ≤ AUC ratio <2) 
_d
No interaction (AUC ratio < 1.25) 
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DISCUSSION 
During development of new candidate drugs at early drug discovery stage, the in vitro metabolic 
stability is often examined in a high-throughput manner. The conduct of in vitro metabolic 
stability studies of new drugs enhances the prediction of in vivo clearance in humans. The 
knowledge of in vivo clearance of a new drug is critical for the determination of plasma 
concentration of specific drug, allowing the prediction of the appropriate dosage regimen for 
specific patient populations. For herbal medicines which are mostly consumed orally, it is 
imperative to examine their influence on drug metabolism by using appropriate in vitro systems 
with specific probe substrates. The outcome of such investigation shows the impact of herbal 
extracts on intrinsic clearance of specific drug, attempting to envisage the likely magnitude of 
HDI to occur in humans.   
Traditionally, the HLMs are commonly used as an in vitro system for the prediction of metabolic 
clearance of new drugs. However, the use of this system has resulted in an underestimation of 
intrinsic clearance of drugs during in vivo extrapolations (Hewitt et al., 2007).  Alternatively, in 
vitro systems such as pooled human hepatocytes are envisaged as a potentially more accurate 
model because of the complete availability of both phase I and phase II metabolizing enzymes, 
drug transporters and NADPH cofactors  resulting to drug concentration in the hepatocytes 
closer to the concentration within the liver of humans. This study used both pooled human liver 
microsomes and pooled human hepatocytes to predict the influence of crude methanol extracts of 
the herbal extracts; M. oleifera, K. integra, K. crenata and E. purpurea on the metabolic 
clearance of TST. 
The in vitro prediction showed an equivalent intrinsic clearance of TST in both HLM and 
hepatocytes systems. Thus differences in intrinsic clearance observed in the subsequent 
evaluations are primarily due to the influence of herbal extracts applied. However, to avoid 
under- and over-estimation of intrinsic clearance of TST, the biological scaling factors such as 
microsomal content (HLM), hepatocellularity (hepatocytes), adult liver mass and rate of hepatic 
blood flow were employed to extrapolate the in vitro data to in vivo (Hallifax et al., 2005; Ito and 
Houston, 2005).  The estimation of TST clearance based on the biological scaling factors showed 
2-fold increase in intrinsic clearance of TST in human hepatocytes compared to that of HLM. 
Thus, prediction of intrinsic clearance of TST in vitro without application of biological scaling 
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factors to estimate clearance in vivo could lead to under-prediction in human hepatocytes and/or 
over-prediction in HLM. 
Kalanchoe integra demonstrated intermediate interaction with TST in HLM whilst weak 
interaction was observed in hepatocytes. Considering hepatocytes as an intact cell with constant 
influx and efflux of compounds, the degree of interaction depends on the free extracellular-
intracellular gradient and the concentration of herbal extract available at the enzyme active site. 
For herbal extract rapidly metabolized by CYPs and further conjugated by the phase II enzymes, 
its clearance will be facilitated to reduce interaction as observed in the case of K. integra in the 
hepatocyte. However, for HLM, the metabolism of K. integra is primarily mediated by the 
CYPs. Hence, accumulation of metabolites of K. integra with potential inactivation effect on 
CYP3A4 could be presumably attributed to the high AUC ratio observed compared to the 
hepatocytes. Conversely, Moringa oleifera demonstrated weak and intermediate interactions 
with TST in HLM and hepatocytes, respectively. In this case, it is speculated that the 
phytochemicals of M. oleifera are metabolized by other CYPs in addition to CYP3A4 to generate 
inactivators that intensify the inactivation of CYP3A4, hence the intermediate interaction 
between the herbal and TST observed in hepatocytes compared to HLM. The intrinsic clearance 
of TST in the presence of E. purpurea and K. crenata were equal in both hepatocytes and HLM. 
The equivalent interaction indicates non-significant influence of phase II, membrane barrier, 
transporters and other factors relevant to hepatocyte which might affect the disposition of the 
herbal drugs. Thus, the influence of herbal extract on metabolic clearance of specific drug will 
depend on the nature of the phytochemicals and the free concentration reaching the active site of 
the CYP3A4. 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
131 
 
PART FOUR 
3.4 RESULTS 
3.4.1 Assesment of cytotoxic effect of herbal medicines 
HepG2 cell preparations were exposed to 100, 50 and 25 µg/mL methanol extracts of Echinacea 
purpurea plant material, capsules and fractions to assess the effect on HepG2 cell mitochrondrial 
activity applying MTT assay. Echinacea demonstrated non-cytotoxic effect on HepG2 at the 
concentrations tested as shown in Figure 3.15. Other herbal medicines demonstrated non-toxic 
effect on HepG2 (data no shown). 
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Figure 3.15: Effect of Echinacea on HepG2 cell viability. 
HepG2 cells were treated for 24 h with Echinacea (100, 50, 25μg/mL) or rifampicin or 
doxorubicin (30, 10, 1μM). At the end of this period, cell viability was measured as described 
under Materials and Methods. The figure shows the mean of duplicate treatments expressed as a 
percentage of the value in MeOH-treated cells, with the SEM indicated by the vertical bars. 
Cytostatic agent, doxorubicin (DOX) was used as positive control, rifampicin (RIF), Echinacea 
capsule (2660), Echiancea plant material (EP) and Echinacea fractions (48A and 48B). 
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3.4.2 Reporter gene assay 
3.4.2.1 Initial screening of herbs for PXR activation 
Initial screening of herbal extracts implicated methanol extract of E. purpurea as significant 
inducer of CYP3A4 comparable to rifampicin (Figure 3.16A). Influence of the herbal extracts on 
rifampicin-mediated PXR activation indicated Hypoxis powdered leaves (HHL) and K. integra as 
non-concentration dependent competitive inhibitors. Other herbal extracts had no significant 
effect on rifampicin-mediated PXR activation as demonstrated in Figure 3.16B. The subsequent 
investigation therefore focused on E. purpurea crude methanol and fractions. Echinacea capsule 
(2660) activated hPXR with fold induction of 1.9 compared to the vehicle control (Figure 
3.16C).  
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Figure 3.16A Effect of herbal medicines on activation of PXR in co-transfected HepG2 cells. 
The fold induction relative to vehicle (methanol) was determined. One-way ANOVA was used to 
compare the mean value between the vehicle and the treatment groups and Benferroni multiple 
comparison was conducted for multiple comparison between the treatment groups when the P < 
0.05. Results are expressed as Mean ± SEM. **P=0.01 and ***P = 0.001. 
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Figure 13.16B: Influence of herbal medicines on rifampicin-induced activation of PXR. 
The data are represented as Mean ± SEM of triplicate measurements in two independent 
experiments. Ketoconazole (KET), Lessertia tablets (LFT), Lessertia tea cut (LFC), Hypoxis 
capsule (HHC), Hypoxis powder (HHL), Echinacea capsule (2660), Moringa powdered leaves 
(MO), Taraxacum root (TO), Kalanchoe crenata (KC) and Kalanchoe integra whole plant (KI). 
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Figure 3.16C: Effect of Echinacea purpurea on activation of PXR. 
HepG2 cells were transiently transfected with p3A4-luc reporter construct containing the basal 
promoter (-362/-53) with proximal PXR response element and the distal xenobiotic responsive 
enhancer module (-7836/-7208) of CYP3A4 (0.4 μg/well) and pSG5-PXR expression vector (50 
ng) using the manufacturer’s instructions. Transfected HepG2 cells were maintained in medium 
containing Echinacea purpurea at the indicated concentrations for 24 h. Luciferase activities are 
normalized to protein concentration and expressed as -fold activation of non-treated cells 
transfected with p3A4-luc. Results are expressed as Mean ± SEM. One-way ANOVA was used 
to compare the mean value between the vehicle and the treatment groups and Benferroni multiple 
comparison was conducted for multiple comparison between the treatment groups when the P < 
0.05. ***P = 0.001. 
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3.4.2.2 Concentration- dependent PXR activation      
 
To identify the appropriate solvent(s) for extraction of active constituents responsible for 
activation of hPXR, Echinacea fractions of different polarity were prepared from the methanol 
extract of whole E. purpurea. Echinacea plant material (EP), and fractions; 48A and 48B 
strongly activated hPXR with fold increase in luciferase activity of 4, 5.5 and 3.5, respectively 
compared to the vehicle control at 50 μg/mL. At 16.67 μg/mL, 48B caused strong activation of 
hPXR with luciferase activity of 3.8- fold increase while EP and 48B mildly activated hPXR 
with 2-fold increase in luciferase activity compare to the vehicle. However, 48C, 48D and 48E 
showed no activation of hPXR (Figure 3.17). 
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Figure 3.17 Concentration-dependent effect of Echinacea on PXR activation.  
HepG2 cell line transfected with PXR was exposed to fractions of Echinacea purpurea at 
different concentrations for 24 hours. The fold induction relative to vehicle (methanol) was 
determined. Results are expressed as Mean ± SEM. 
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3.4.2.3 Time- dependent PXR activation  
Unlike inhibition, the onset of PXR-mediated induction of DME or drug transporter genes is 
relatively slow and it may take days or even weeks for the full effects to manifest. The effects of 
various fractions on hPXR activation after 24 and 48 h treatment in HepG2 cells were analyzed.  
EP and 48A showed 8-10% increase in hPXR activation at 48 h compared to 24 h at 
concentrations ranging 1.85 – 50 μg/mL. No difference was noticed for 48B and 48C at 24 and 
48 h (Figure 3.18A). One-tailed t test showed no significant effect of time on activation of hPXR 
by fractions except EP tested at 50 μg/mL and 16.65 μg/mL with P value of 0.047.     
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Figure 3.18: Time-dependent effect of Echinacea on PXR activation. 
 HepG2 cell line transfected with PXR was exposed to fractions E. purpurea at different 
concentrations for 24 and 48 hours to determine concentration and time dependent effect of test 
samples on induction in PXR. The fold induction relative to vehicle (methanol) was determined. 
Results are expressed as Mean ± SEM. One-tailed t test was performed to compare the PXR 
activation for 24 and 48 h, respectively. *P = 0.047 was noted for EP. 
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3.4.2.4 Regulation of CYP1A2, CYP3A4 and P-gp mRNA expression 
 
Crude extracts and fractions of E. purpurea were tested for their potential to activate mRNA 
expression of CYP1A2, CYP3A4 and P-gp in HepG2 cells transfected with hPXR. The 
expression of mRNA was used to differentiate CYP or P-gp inducers and non-inducers based on 
the normalized ratio of the housekeeping gene after 48 h exposure of hPXR transfected HepG2 
cells to the test samples using RT-qPCR (Figure 3.19). Test samples with mRNA expression ≥2-
fold of the non-treated group were classified as inducers whilst others with mRNA expression 
cut-off <2-fold of non-treated group were tagged as non-inducers. Crude extract of Echinacea 
and fraction 48B indicated a non-inducing effect on CYP1A2 mRNA expression in PXR. 
However, crude extract of Echinacea capsule and active fraction 48A exhibited an induction 
effect on CYP1A2 mRNA expression at 50 µg/mL. The crude extracts of Echinacea plant 
material and the capsule demonstrated strong induction effect on CYP3A4 and P-gp mRNA 
expression in PXR. Additionally, a similar effect was observed for the active fraction 48A on 
both CYP3A4 and P-gp mRNA expressions.  
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Figure 3.19: Analysis of Echinacea-mediated up-regulation of CYP3A4, CYP1A2 and P-gp 
mRNAs. HepG2 cells were transfected with pSG5-PXR expression plasmids (400 ng/well) using 
the manufacturer’s instructions and exposed to different concentrations of Echinacea (5.6 – 50 
μg/mL) for 48 h. mRNA expression of tested genes was determined using real-time RT-PCR and 
normalized to HPRT housekeeping gene. The effect of Echinacea on CYP1A2 (A), CYP3A4 (B) 
and MDR1 (C) mRNA expression is presented as -fold increase to HPRT. Test samples with 
mRNA expression ≥2-fold of untreated were considered as an inducer. OMP and DEX refer to 
omeprazole and dextromethorphan, respectively. 
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3.4.2.5 Measurement of CYP1A2 enzymatic activity 
To examine the effect of the test samples on CYP1A2 and CYP3A4, the activities of the 
enzymes were tested in PXR-transfected HepG2 cells; omeprazole and rifampicin were used as 
inducers for CYP1A2 and CYP3A4, respectively using specific fluorescent substrates. 
Significant induction of CYP1A2 by Fraction 48A (EC50 = 41.01 μg/mL) and crude extract, 2660 
(EC50 = 83.04 μg/mL) were observed (Figure 3.20). None of the fractions of Echinacea showed 
positive activity on CYP3A4 (data not shown). 
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Figure 3.20 Determination of CYP1A2 activity in Echinacea-mediated activated PXR.           
Log transformations of test sample concentrations against % CYP1A2 activity after 30 mins 
incubation with CEC in hPXR-tranfected HepG2 cells was fitted using non-linear regression and 
EC50 determined.  
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3.4.2.6 In vivo prediction of HDI from in vitro data 
One of the objectives of the present study is to rank the potential risk of HDI according to the US 
FDA guidelines based on the [I]/EC50 ratio where [I] is the gut or intra-hepatic concentration of 
the inducer (drug or herb) an individual is exposed to and EC50 is the half of the maximum 
inducer concentration.  In the absence of knowledge of the chemical constituents in the herbs or 
how much would be absorbed to finally reach the liver and interact with the CYP, the worst case 
assumption that all herbal extract administered would be absorbed was made. The gut 
concentration was therefore estimated by dividing the administered dose by the estimated GIT 
volume of 250 mL. The intra-hepatic concentration of herbal extract was determined using 
equation 3.1. The estimated concentration for each herb is shown in Table 3.6A.  
With both the estimated EC50 and [I] values, the [I]/EC50 induction ratio was used to rank the 
herbs with respect to risk for HDI based on FDA guidelines where, I/EC50 >1.0 is associated 
with high risk for DDI, I/EC50 = 0.1-1 is associated with intermediate risk for DDI and I/EC50 
<0.1 is unlikely to result in DDI (Table 3.6B) 
 
(Hewitt et al., 2007).  
 
Table 3.6A: Calculation of herbal medicine concentration in the gut 
Fraction  Yield 
(%W/W) 
Estimated 
extract per dose 
(mg/mL) 
GIT concentration 
(μg/mL) 
Intra-hepatic concentration 
(μg/mL) 
EP 58.38 186.80 747.2 767.07 
2660 23.17 74.14 296.58 316.45 
48A 4.19 13.41 53.63 73.50 
Usual human dose for Echinacea capsule (320 mg single dose) 
Table 3.6B: in vivo prediction of HDI from in vitro data 
Test sample EC50 
(μg/mL) 
Induction potency 
[I]gut/EC50 
Induction potency 
[I]in/EC50 
Risk for HDI 
2660 83.04 3.57 3.81 Likely  
48A 41.01 1.3 1.79 Likely  
Induction potency of EP not determined, intra-hepatic concentration ([I]in) = Cmax + kaFaD/Qh and kaFaD/Qh = 19.87 
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DISCUSSION 
 
Evaluation of the potential of a new drug candidate to cause drug-drug or herb-drug interactions 
has become an integral part of drug development and regulatory review prior to market approval. 
Although drug interactions can be evaluated using specific clinical studies in healthy subjects or 
patients, in vitro approaches are now adopted as a critical first step in the assessment of drug 
interaction potential through specific pathways. Results obtained from in vitro studies can be 
employed to predict in vivo interaction and guide the need for further in vivo studies. The 
application of luciferase reporter genes for investigation of mechanisms underlying the induction 
potential of drugs or xenobiotics has become a routine practice.  
Human PXR-transfected HepG2 cells have been utilized as an in vitro tool to evaluate the 
potential of new drug candidates to cause clinically significant induction of DME or transporter 
proteins (Chu et al., 2009). As the use of herbal medicines either as nutritional supplements or 
medication is on the increase and well established in developing and developed countries, 
concerns on the risk of herb-mediated induction of CYPs and drug transporters studies have 
increased. St. John’s wort (SJW) and garlic are examples of herbal products that have drawn a lot 
of attention because of HDI. Previous studies have demonstrated that concurrent use of SJW and 
garlic can significantly reduce plasma concentration of unboosted protease inhibitors (Piscitelli 
et al., 2000a; Piscitelli et al., 2000b). PXR was identified as a key mediator in SJW interaction 
with conventional drugs (Mannel, 2004). Other herbal products such as Ginkgo biloba, Tian 
Xian and Coleus forskohlii have been reported as herbs that activate PXR (Ding and Staudinger, 
2005; Li et al., 2009). In recent times, E. purpurea has become a popular herbal supplement used 
as immunostimulant in HIV/AIDS patients. Although in vitro studies have reported E. purpurea 
ability to induce CYP3A4 and P-gp employing different models, the underlying mechanism is 
unknown. In this study, we showed that E. purpurea up-regulates the CYP1A2, CYP3A4 and 
MDR1 (P-gp) gene expression via activation of PXR nuclear receptor.  
Echinacea purpurea demonstrated a non-cytotoxic effect on HepG2 cell. Additionally, it was 
found in this study that 0.8% methanol had no significant effect on PXR activation. This makes 
methanol a good solvent to dissolve E. purpurea capsule and fractions.  The final concentration 
did not exceed 0.8% in the experiments. Hence subsequent outcomes observed in the assays were 
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presumably due to activation or induction effect of Echinacea on PXR. Initial screening of the 
methanolic extract of E. purpurea (EP) plant material and capsule indicated significant activation 
of PXR with 3.5- and 2.0-fold increase in luciferase activities, respectively (Figure 3.16C). Any 
herbal supplement showing ≥2 fold increase in luciferase activity is considered to be an activator 
of PXR with the potential to cause HDI (Shimizu, 2010). However, unlike conventional 
medications, herbal supplements consist of several phytochemical compositions which may 
differ depending on the place of collection, the season and extraction process. Profiling the 
chemicals in an herbal supplement is therefore a critical step in understanding the mechanism for 
HDI. In this study, silica gel fractionation was used to collect six different fractions of increasing 
polarity. Each fraction was evaluated for its potential to activate PXR. The non-polar fractions; 
48A and 48B were the most potent activators of PXR with fold increase in luciferase activity of 
5 and 3.5, respectively. The activation effects of 48A and 48B on PXR were significant at 16.67 
μg/mL and 50 μg/mL although dose-dependent activation was observed. However, the activation 
of PXR by 48C, 48D and 48E2 were non-significant when compared with the control vehicle. 
The fractions 48A and 48B of E. purpurea root showed evidence of alkamides as the principal 
phytochemicals in a chromatographic scanning (Bauer and Remiger, 1989). Chloroform is the 
best solvent for the extraction of alkamide, even though both methanol and ethanol can be used. 
It is therefore not surprising that chloroform fraction 48A showed the strongest activation of 
PXR.  
The activation of CYP and drug transporter is time- and concentration- dependent. Therefore the 
effect of time on the activation of PXR by the fractions of Echinacea was investigated. The 
results showed 30-50% increase in PXR activation at 48 hours compared to 24 hours by EP, 
Fractions 48A and 48B at 50 μg/mL and 16.67 μg/mL. Comparison of PXR activation between 
24 and 48 h indicated significant difference at 50 μg/mL for the crude EP. The observed 
significant time-dependent activation of PXR by the crude EP is an indication of its potential to 
cause HDI during chronic administration.  
To analyze the effect of E. purpurea on expression of CYP1A2, CYP3A4 and P-gp genes, 
primers of respective DME and transporter were introduced into PXR co-transfected HepG2 cell 
model using the protocol supplied by the manufacturer. In this study, it was observed that, 
Echinacea significantly potentiates up-regulation of CYP1A2, CYP3A4 and MDR1 (P-gp) in 
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PXR co-transfected HepG2 cell model. The outcome of this study agrees with that of Naspinski 
et al., (2008) who reported that PXR up-regulates the expression of CYP1A2 and CYP3A4. 
However, in their study, the expression of MDR1 (P-gp) was down-regulated by PXR co-
transfected HepG2. Thus the current study speculate that up-regulation of CYP1A2, CYP3A4 
and MDR1 mRNA genes to be presumably the underlying mechanism of Echinacea-mediated 
induction reported in humans and other in vitro studies (Gorski et al., 2004; Gurley et al., 2004; 
Yale and Glurich, 2005; Penzak et al., 2010). However, the observed differences in the 
activation of CYP1A2 genes by the Echinacea capsule compared to the EP authenticated plant 
material warrants further investigation to ascertain a complete phytochemical profile. Cases of 
capsules and tablets of herbal supplements surreptitious with conventional drugs such as 
benzodiazepine, fluoxetine and furosemide as weight loss products have been reported (de 
Carvalho et al., 2011).  
The adoption of current industry and FDA guidelines for classification of herbal supplements’ 
potential to cause drug interactions comes with a number of challenges. Firstly, in drug 
development, pure compounds are evaluated whereas for herbal supplements, mixtures of 
unknown chemical composition are used, making it impossible to know the identity or the 
concentration of the inducing or activating components. The use of the total GIT concentration 
of the herbal extract (μg/mL) as the assumed absorbed amount and also responsible for 
interacting with the CYPs is therefore a gross exaggeration of the likely concentration of inducer 
or activator components to interact with CYPs. Accounting for plasma protein binding is also not 
possible with herbal extracts. Secondly, the EC50 used for herbal extracts is an apparent value 
associated with complex mixtures of chemicals hence likely to also be a gross exaggeration of 
these kinetic parameters. Thirdly, industry uses the metabolism based DDI studies to both guide 
the molecular design of NCE devoid of potential DDI risks during the early hit and lead 
identification and lead optimization stages. At candidate drug selection stage, the DDI data is 
used to select compounds devoid of such DDI risk or the design of in vivo DDI studies to 
determine the extent of the risk of DDI in compounds which still bear the CYP induction effects. 
For herbal extracts already in use, the HDI studies are therefore mainly to assess risk, guide the 
design of in vivo HDI studies and possibly revise product labels to highlight the risk of co-
administering some herbs with certain conventional drugs. The effect of SJW on the protease 
inhibitor, indinavir is a good example of the likely use of results from this study through the 
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observations done in reverse, that is, observations of pharmacokinetic interactions in vivo 
(Piscitelli et al., 2001) and working backwards to in vitro studies to understand the underlying 
mechanism, and eventually have product label recommendation to avoid such HDI (Clauson et 
al., 2008). The mechanistic approach of using in vitro systems used in this study allows rapid 
evaluation of many herbal medicines and re-labelling of products with respect to HDI which can 
guide patients and clinicians in avoiding drug-herb combinations likely to result in HDI 
(Awortwe et al., 2014b).  
Several approaches based on results from the PXR reported gene assay can be used to risk rank 
the potential of fractions tested to cause HDI. The I/EC50 induction ratio was used to rank the 
herbs with respect to risk for HDI based on FDA guidelines where, I/EC50 >1.0 is associated 
with high risk for DDI, I/EC50 = 0.1-1 is associated with intermediate risk for DDI and I/EC50 
<0.1 is unlikely to result in DDI on CYP1A2. The inclusion of inducer or activator concentration 
in both the gut and the intra-hepatic systems for the risk ranking of compounds reduces the 
tendency of false positive or false negative estimation. Echinacea capsule (2660) and 48A was 
ranked with high risk to cause HDI with a ratio of 3.57 and 1.3 in the gut and 3.81 and 1.79 in 
the intra-hepatic systems, respectively for CYP1A2. The risk ranking correlated with the earlier 
prediction observed when mRNA expression of CYP1A2 based on positive control.  
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PART FIVE 
3.5 RESULTS 
3.5.1 Time-dependent Calcein-AM uptake 
Evaluation of the influence of herbal extracts (100 µg/mL) on P-gp employing calcein-AM 
uptake demonstrated that TO, KC, EP and LFT are time-dependent inhibitors of the transporter 
protein in co-transfected MDCKII with fluorescence of >2-fold above the untreated cells. 
However, these herbs were mild inhibitors of P-gp compared to verapamil at 60 minutes as 
shown in Figure 3.21. Methanol extracts of HHC and MO had calcein fluorescence units below 
the untreated cells. 
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Figure 3.21 Influence of the methanol extracts of various herbal medicines on P-gp inhibition in 
hMDR1-MDCKII cell lines determined based on calcein fluorescence. Data expressed as Mean 
± SEM of duplicate determinations. 
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3.5.2 Concentration-dependent Calcein-AM uptake 
The herbal extracts were screened for their ability to increase calcein-AM uptake expressed as a 
percentage of the wild type of MDCKII. All the herbal extracts except HHC exhibited at least 
110% increased uptake of Calcein-AM at a given concentration within the range of 1-100 μg/mL 
after 1 hour preincubation. Nevertheless, none of these herbal extract indicated concentration-
dependent uptake of calcein-AM in MDCKII (Figure 3.22).   
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Figure 3.22 Concentration-dependent uptake of Calcein-AM in hMDR1-MDCKII cell lines used 
as an index of inhibitory effect of various herbal extracts on P-gp. Data expressed as Mean of 
duplicate determinations. 
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However, verapamil (positive control) demonstrated a dose-dependent effect on calcein-AM 
uptake in MDCKII cell lines with EC50 value of 23.0 ± 2.4 (Figure 3.22).  
0.1 1 10 100 1000
0
100
200
300
400
500
EC50 = 23.07  2.4
Concentration (M)
%
 i
n
c
re
a
s
e
 i
n
 C
a
lc
e
in
-A
M
 u
p
ta
k
e
 
Figure 3.23 Dose-response curves of P-gp inhibition by Verapamil determined by calculating 
the per cent uptake of calcein AM into hMDR1-MDCKII cells. Equations used in evaluating 
EC50 and % increase in uptake of calcein-AM were described in materials and methods section. 
The data are represented as mean ± SEM of 2 independent experiments (n=2 in each 
experiment). 
 
3.5.3 P-gp inhibition by 
3
H-digoxin uptake in hMDR1-MDCK-II cells 
 
The herbal medicines demonstrated varying degrees of inhibition on transport of 
3
H-digoxin 
from basolateral to apical in hMDR1-MDCKII cell monolayer. K. integra and E. purpurea 
indicated strong inhibiton on 
3
H-digoxin transport with IC50 values of 18.24 ± 2.52 µg/mL and 
24.47 ± 4.97 µg/mL, respectively. M. oleifera exhibited moderate inhibitory effect on 
3
H-digoxin 
transport in hMDR1-MDCKII with IC50 value of 35.45 ± 3.91 µg/mL. However, K. integra 
indicated a weak inhibition on transport of 
3
H-digoxin in MDR1-MDCKII cells as shown in 
Figure 3.24.   
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Figure 3.24: Dose-response curve of P-gp inhibiton by selected herbal medicines determined by 
calculating the basolateral to apical transport (%) of 
3
H-digoxin across hMDR1-MDCKII cell 
monolayer. The data are represented as Mean ± SEM of 2 independent experiments. (n=1 for 
each experiment).  
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DISCUSSION 
P-glycoprotein is considered as the most critical ABC transporter involved in intestinal 
absorption, biliary and urinary excretion and brain distribution of drugs. Thus, drug interactions 
mediated by P-gp may cause significant pharmacokinetic changes in systemic drug exposure or 
tissue specific distribution. Recently, the international transporter consortium released a white 
paper containing the decision tree for evaluation of clinically relevant P-gp mediated DDI 
studies. This white paper reported the relevance of using more than single substrates for P-gp 
mediated DDI evaluation presumably due to the multiple binding sites within the transporter 
protein (Giacomini et al., 2010). In evaluating the potential of the various herbal extracts used in 
this study to inhibit P-gp, the calcein acetoxymethyl ester (Calcein-AM) fluorescent probe 
substrate and digoxin radiolabelled substrates were used. 
Calcein is a fluorescent dye designed for intracellular quantification of Ca
2+
 and the 
acetoxymethyl ester moiety is transported by MDR1 hence it was proposed to be a useful probe 
substrate for P-gp mediated inhibition evaluation. Calcein-AM is P-gp transporter substrate with 
high permeability through cell membranes. Within the cell, it is rapidly cleaved to free calcein, a 
low permeable fluorescent molecule which is non-substrate of P-gp. Thus, cells expressing P-gp 
accumulate low amounts of free calcein, whilst increased fluorescent is an indication of P-gp 
blockade (Szerémy et al., 2011). 
Screening of the herbal extracts using the calcein-AM implicated MO and HHC as non-inhibitors 
of P-gp with calcein fluorescent units below that of the untreated MDR1 cells. Conversely, 
extracts; KC, LFT, EP and TO exhibited moderate inhibitory effects on P-gp with calcein 
fluorescent units between verapamil (positive control) and the untreated MDR1 (negative 
control). However, the inhibitory effect of these herbal extracts were non-concentration 
dependent as illustrated in Figure 3.22. Verapamil demonstrated strong inhibition on P-gp with 
EC50 value of 23.07 ± 2.4 µg/mL.   
E. purpurea and K. crenata demonstrated strong inhibition on P-gp by reducing transport of 
digoxin in hMDR1-MDCKII cell monolayer. Additionally, M. oleifera and K. integra were 
observed as intermediate and weak inhibitor of digoxin transport across basolateral to apical in 
hMDR1-MDCKII. Digoxin is considered as a sensitive marker for P-gp due to its narrow 
therapeutic index (Giacomini et al., 2010). However, most drugs possess wider therapeutic index 
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and thus less likely to interact with other medications or herbal medicines which are P-gp 
modulators. Hence, the inhibition profile of various herbal extracts exhibited on transport of 
digoxin across hMDR1-MDCKII cell monolayer should be interpreted with caution to avoid 
false prediction. 
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CHAPTER FOUR 
 
4. CONCLUSIONS, STUDY LIMITATIONS AND RECOMMENDATIONS 
4.1 Conclusions 
The objectives of this thesis were to: 1) investigate inhibition of CYPs and P-glycoprotein by 
herbal medicines namely; Moringa oleifera, Kalanchoe integra, Kalanchoe crenata, Echinacea 
purpurea, Lessertia frutescens, Hypoxis hemercallidea and Taraxacum officinale in recombinant 
CYPs, HLM, hepatocytes and MDCKII-MDR1 cells, 2) rank the potential risk of each herbs to 
cause HDI employing FDA guideline for DDI (2012), 3) investigate the degree of inhibition of 
CYP by the above mentioned herbal medicines after permeation through PAMPA and 4) 
investigate the modulation of PXR and regulation of CYP3A4, CYP1A2 and P-gp genes in 
activated PXR by the selected herbal medicines. 
 
Based on the findings of the study, the following conclusions can be drawn: 
1. The inhibition potential of herbal medicines on CYPs depends on the type of solvent and 
method used for the preparation of the herbal extract, and the kind of in vitro drug 
metabolism model applied. According to this study, preparation of plant material 
employing the hot aqueous extract method as practiced by the THPs presented mild 
inhibitory effect on the activity of CYPs in recombinant. The use of different organic 
solvents like methanol and chloroform enhanced inhibitory activity of herbal extracts on 
CYPs due to high recovery of phytochemicals. The prediction of in vivo HDI from in 
vitro data in methanol extracts confirmed over-estimation when compared with the 
aqueous extracts. Examination of the likelihood of herbal extracts to inhibit CYP in HLM 
indicated weak inhibition compared to the outcome observed in recombinant CYPs which 
may be attributed to presence of other phase I enzymes in HLM. Confirmatory tests using 
the cocktail approach also indicated reduced HDI compared to the conventional assays. 
However, the herbal extracts screened in this assay especially M. oleifera, L. frutescens 
and E. purpurea are reversible inhibitors of CYP3A4, CYP2C19 and CYP1A2 regardless 
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of the solvents and in vitro system applied. Thus these three herbal medicines have high 
risk to cause HDI in patients on other medications metabolized by CYP3A4, CYP2C19 
and CYP1A2.  
2. The introduction of absorption model, PAMPA, into the screening of herbal medicines 
for their potential to inhibit CYPs has shown the tendency for reduction in HDI 
prediction when an absorption model is introduced during the conduct of in vitro HDI 
studies. Such false negative predictions observed can be attributed to the inclusion of 
impermeable phytochemicals in the conventional in vitro assays which does not reflect in 
vivo scenario.  
3. The inhibitory effect of most herbal medicines becomes pronounced after prolonged 
exposure to patients. Long term exposure of herbal medicines; M. oleifera and K. crenata 
has demonstrated high risk of CYP3A4 inactivation. Lessertia frutescens tea cut has 
indicated that although some herbal medications might be safe for acute usage, prolonged 
intake of such medication might affect the metabolic activity of CYP negatively later in 
life. 
4. Prediction of metabolic clearance in HLM and Hepatocytes has shown the strong 
inhibitory effect of M. oleifera and E. purpurea on CYP3A4 activity when these herbal 
medicines are consumed concurrently with conventional drugs that are metabolized by 
the enzyme. The significant inhibition of CYP3A4 in hepatocytes by these two herbal 
medications observed is an indicative of their high risk to cause HDI in humans. 
5. The PXR co-transfected HepG2 cell activation study has demonstrated that E. purpurea 
up-regulates expression CYP1A2, CYP3A4 and MDR1 genes in activated PXR. Hence 
caution must be exercised in patients concurrently taking orthodox medications and E. 
purpurea.  
6. Echinacea purpurea and Kalanchoe crenata are strong inhibitors of P-gp whilst Moringa 
oleifera and Kalanchoe integra have shown mild inhibition on P-gp transport of digoxin. 
Thus these four herbal preparations have the potential to reduce plasma concentration of 
P-gp substrates when administered concurrently. 
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Figure 4.1 provides an overview of the work carried out in this study. The study has 
demonstrated the overlap between the various in vitro models used. Design of study in this 
manner offers a comprehensive examination of HDI potential of herbal medicine, avoiding the 
possibility of missing vital information. Such process has been used in many pharmaceutical 
companies at early drug discovery and development to screen new candidate drugs and proven to 
be beneficial. The outcome of studies involving herbal medications design using this approach 
will form basis for justification for possible studies in health subjects. 
 
 Herbal medicines  
 
 
 
 
Assays         Enzyme inhibition ADME Enzyme induction 
 
 
 
In vitro                                                                             hPXR 
systems 
 
Figure 4.1 Summary of in vitro assays carried out in this study 
 
 
 
 
 
HLM 
rCYP 
PAMPA, P-gp 
Hepatocytes 
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4.2 Study limitations 
Traditionally, different extraction conditions (temperature, duration and solvent) are applied for 
the preparation of herbal medicines. The variations in the extraction procedures culminate to 
consumption of different amount and phytoconstituents of plant extract by the patients. However, 
the methodologies employed in the laboratory to process the herbal extracts are different from 
the non-standardized methods used by the THPs. As a consequence, the magnitude of interaction 
of the herbal extracts with intestinal CYPs and transporters determined in vitro might be difficult 
to compare with that obtained in humans. 
With the exception of Lessertia frutescens, the effects of herbal medicines on the CYPs and the 
P-glycoprotein were evaluated on crude extracts and fractions only. Due to logistical constraints, 
the inhibition and/or induction effect(s) of pure compounds of the other herbal extracts on CYPs 
and transportes could not be investigated.    
 
The use of healthy human subjects is considered as the ideal approach to generate clinically 
significant pharmacokinetic HDI information on specific herbal medicines. However, due to the 
risk associated with such studies in humans and the rigorous ethical and regulatory requirements, 
the use of in vitro models has become the best alternative. In this study, human recombinant 
CYPs, human liver microsomes, cryopreserved hepatocytes and transfected mammalian cell lines 
were used under different experimental conditions. In all these in vitro systems, the herbal 
extracts are in direct contact with the enzymes/transporters and their respective substrates. This 
deviates from the in vivo system where intestinal pH and membrane barriers, non-specific plasma 
protein binding, organ perfusion and blood circulation affect the concentration and the 
phytoconstituents of the herbal extracts that enters the enzyme/transporter sites for effective 
interactions to occur. Additionally, in an attempt to predict in vivo HDI from in vitro data 
adopting the FDA guidelines, several assumptions were deduced to make the data meaningful. 
The soluble herbal extracts in the GIT consisted of polyphtoconstituents with different 
permeability coefficients. A reasonable proportion of these constituents may be impermeable via 
the intestinal membrane, and therefore complete bioavailability of the contents of the soluble 
herbal extracts is likely impossible. Thus although information from in vitro HDI studies provide 
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the basis for the need to conduct in vivo studies, studies in healthy human subjects are the 
definitive evidence for clinically significant HDI.   
 
4.3 Recommendations 
The use of in vitro liver-based models for screening of new candidate drugs and herbal medi-
cines is considered as gold standard for drug interaction studies. However, due to the increase 
consumption of herbal medicines among HIV/AIDS patients, in vivo studies in healthy human 
subjects is recommended to provide better insight with respect to HDI potential of the selected 
herbal medicines used in this study. Studies of such nature provide the relevance of the observed 
inhibition of drug metabolizing enzymes and transporter clinically employing sophisticated 
mathematical models such as physiologically based pharmacokinetic (PBPK) modelling. Fur-
thermore, there is the need for identification and isolation of active phytoconstituents based on 
the bioassay guided fractions documented in this study. This will be beneficial for structure elu-
cidation and the possibility of drug discovery. The outcome of such studies will be important in 
understanding the safety and toxicity of phytoconstituents.    
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APPENDIX 1: Abstracts of papers published from this thesis 
Appendix 1.1:  In vitro evaluation of reversible and time-dependent inhibitory effects of Kalanchoe crenata on CYP2C19 and 
CYP3A4 activities 
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APPENDIX 1.2 Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 genes expression by activation of pregnane X 
receptor pathway 
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APPENDIX 1.3 Application of Caco-2 cell line in herb-drug interaction studies 
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APPENDIX 1.4 Inhibition of Major drug metabolising CYPs by common herbal medicines used by HIV/AIDS patients in Africa- 
Implication for herb-drug interactions 
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APPENDIX 1.5 Prediction of reversible and TDI potential of CYP3A4 by L. frutescens 
Planta Med 2014; 80 - PU8 
DOI: 10.1055/s-0034-1382758 
Prediction of reversible and time-dependent inhibition potential of CYP3A4 by Lessertia frutescens fractions and possibility of 
herb-drug interactions with anti-HIV drugs 
C Awortwe 1, V Manda 2, S Khan 2, L Walker 2, PJ Bouic 3, B Rosenkranz 1 
1Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa                            
2National Center for Natural Products Research, School of Pharmacy, University of Mississippi, USA.                                                                       
3Synexa Life Sciences, Montague Gardens, Cape Town, South Africa and Division of Medical Microbiology, Faculty of Medicine and Health Sciences, 
University of Stellenbosch, Cape Town, South Africa 
Congress Abstract 
Lessertia frutescens is a popular medicinal product used in sub-Saharan Africa by patients with HIV-infection, malignancies or other diseases. 
Non-nucleotide reverse transcriptase inhibitors (NNRTIs) (nevirapine and efavirenz) and protease inhibitors (PIs) (ritonavir) are mainly 
biotransformed by CYP3A4. Consequences of CYP3A4 inhibition by Lessertia frutescens could cause inefficacy or systemic toxicity when 
coadministered with NNRTIs or PIs. Six concentrations of each of the tested Lessertia fractions (100 – 1.0µg/mL) were co-incubated or pre-
incubated with 25 pmol/mL of CYP3A4 enzyme and 10µM of 7-benzyloxy-4-trifluoromethylcoumarin (BFC) as a substrate. Based on FDA 
guidelines, the potential risk for herb drug interaction (HDI) in vivo was predicted for the fractions using IC50 values. Time-dependent 
inhibition (TDI) was also assessed using IC50 shift with ≥1.5-fold reduction considered significant. Lessertia frutescens fractions; MeOH 
(100%), CHCl3 (100%), CHCl3:MeOH (90:10%), CHCl3/MeOH/H20 (78.0:19.5:2.5%) inhibited CYP3A4 with IC50 of 26.9 ± 5.2, 12.0 ± 2.4, 6.0 
± 0.8, and 16.0 ± 1.8 respectively. An IC50 shift of 3.6, 1.3, 1.8 and 2.9 fold decrease was observed for MeOH (100%), CHCl3(100%), 
CHCl3:MeOH (90:10%), CHCl3/MeOH/H20 (78.0:19.5:2.5%) respectively, when these fractions were preincubated with the enzyme. Fractions 
of Lessertia frutescens have the potential to cause both reversible and time-dependent inhibition on CYP3A4 and could affect the metabolism 
of NNRTI and PI upon concomitant administration. 
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APPENDIX 1. 6 Integration of Parallel Artificial Membrane Permeability Assays into HTS of 
DME  
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APPENDIX 1.7 Risk assessment of two medicinal herbs used in HIV-infected patients for 
potential inhibition on CYP3A4 
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APPENDIX 2: Ethics approval 
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APPENDIX 3: Metabolic clearance of TST 
 
Appendix 3.1A: Intrinsic clearance of testosterone in the absence and presence of herbal extracts in human hepatocytes 
Test samples t½ (min)
1)
 CLint in vitro 
((µL/min)/million 
cells)
2)
 
CLint in vivo 
((mL/min)/kg body 
mass)
3)
 
CLh,b ((mL/min)/kg 
body mass)
4,5)
 
CLh,b (% hepatic blood 
flow) 
TST 565.3 2.45 6.24 4.79 23.16 
TST+ KI 783.3 1.77 4.50 3.70 17.87 
TST + MO 1,390.8 1.00 2.54 2.26 10.91 
TST + EP 1,532.2 0.90 2.30 2.07 10.01 
TST + KC 618.1 2.24 5.71 4.47 21.61 
 
1) Half-lives were evaluated by linear extrapolation 
2) (ln2/T1/2) /  viable cells x 1000 
3) (CLint / 1000) * (cells / g liver) * (g liver / kg body weight) 
4) CLh = (Qh * CLint, scaled) / (Qh + CLint, scaled), Qh: hepatic blood flow; (well-stirred liver model) 
5) Qh (mL/min/kg body weight): 55 (rat); 30.9 (dog); 43.6 (monkey) ; 20.7 (human)  
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Appendix 3.1B: Intrinsic clearance of testosterone in the absence and presence of herbal extracts in HLM 
Test samples t½ (min)
1)
 CLint in vitro 
((µL/min)/microsom
al protein (mg))
2)
 
CLint in vivo 
((mL/min)/kg 
body mass)
3)
 
CLh,b ((mL/min)/kg 
body mass)
4,5)
 
CLh,b (% hepatic 
blood flow) 
TST 439.7 2.64 3.05 2.66 12.84 
TST+ KI 1,901.2 0.61 0.71 0.68 3.29 
TST + MO 928.0 1.25 1.44 1.35 6.52 
TST + EP 1,164.3 1.00 1.15 1.09 5.27 
TST + KC 512.2 2.26 2.62 2.32 11.22 
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                               APPENDIX 4: Estimation of GIT concentrations of herbal extracts 
                              Appendix 4.1A: Calculation of aqueous herbal extracts concentration in the gut 
Herbal extracts % yield (W/W) Usual human 
dose  
(single; mg) 
Estimated extract 
per dose (mg/mL) 
Putative GIT 
concentration 
(μg/mL) 
T30 22.989 350 80.46 321.84 
T41 N.A 350 350.00 1400 
T66 7.451 4000 298.04 1192.16 
T79 10.917 300 32.75 131 
T50 N.A 300 300.00 1200 
T70 N.A 500 500.00 2000 
T60 N.A 320 320.00 1280 
T80 N.A 400 400.00 1600 
 
                             Appendix 4.1B: Calculation of methaolic herbal extracts concentration in the gut 
Herbal extracts % yield (W/W) Usual human 
dose  
(single; mg) 
Estimated extract 
per dose (mg/mL) 
Putative GIT 
concentration 
(μg/mL) 
HHC 17.3 350 60.55 242.20 
HHL 27.0 350 94.50 378.00 
EP 18.6 320 59.52 238.08 
KI 12.5 NA NA NA 
MO 14.0 400 56.00 224.00 
LFT 16.0 300 48.00 192.00 
LFC 12.2 300 36.60 146.40 
     
                                 Putative GIT concentration [I] = Estimated extract per dose/volume of GIT fluid (250 mL).  
                                 Estimated extract per dose = Yield (W/W %) x single dose of herbal formulation recommended in human. 
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